

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 2018282131 B2

(54) Title
Additive manufacturing using recombinant collagen-containing formulation

(51) International Patent Classification(s)
A61L 27/24 (2006.01) **B33Y 70/00** (2015.01)

(21) Application No: **2018282131** (22) Date of Filing: **2018.06.08**

(87) WIPO No: **WO18/225076**

(30) Priority Data

(31) Number
62/517,179 (32) Date
2017.06.09 (33) Country
US

(43) Publication Date: **2018.12.13**
(44) Accepted Journal Date: **2024.05.09**

(71) Applicant(s)
CollPlant Ltd.

(72) Inventor(s)
SHOSEYOV, Oded;ORR, Nadav;SEROR MAKNOUZ, Jasmine;ZARKA, Revital

(74) Agent / Attorney
FB Rice Pty Ltd, L 33 477 Collins Street, Melbourne, VIC, 3000, AU

(56) Related Art
WO 2015/055656 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2018 (13.12.2018)

(10) International Publication Number
WO 2018/225076 A8

(51) International Patent Classification:
A61L 27/24 (2006.01) *B33Y 70/00* (2015.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:
PCT/IL2018/050627

(22) International Filing Date:
08 June 2018 (08.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/517,179 09 June 2017 (09.06.2017) US

(71) Applicant: **COLLPLANT LTD.** [IL/IL]; 3 Sapir Street, 7403626 Ness Ziona (IL).

(72) Inventors: **SHOSEYOV, Oded**; 10 Bareket Street, 6080410 Shoham (IL). **ORR, Nadav**; 21 Palmach Street, 7680400 Mazkeret Batya (IL). **SEROR MAKNOUZ, Jasmine**; 7 Rakhel Street, 6458407 Tel-Aviv (IL). **ZARKA, Revital**; 8/3 Hershkovitz Street, 7680400 Mazkeret Batya (IL).

(74) Agent: **EHRLICH, Gal** et al.; G. E. Ehrlich (1995) LTD., 11 Menachem Begin Road, 5268104 Ramat Gan (IL).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— of inventorship (Rule 4.17(iv))

(54) Title: ADDITIVE MANUFACTURING USING RECOMBINANT COLLAGEN-CONTAINING FORMULATION




FIG. 3

(57) Abstract: Compositions containing curable recombinant human collagen, and kits comprising same, which are usable in preparing modeling material formulations for additive manufacturing (e.g., 3D bioprinting) of 3D objects are provided. Methods utilizing such modeling material formulations in additive manufacturing of 3D objects having a collagen-based material in at least a portion thereof, are also provided. The formulations feature a desired viscosity at a temperature higher than 10 °C (e.g., room temperature or 37 °C) and allow performing the additive manufacturing without cooling the system or a part thereof.



Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

28 February 2019 (28.02.2019)

(15) Information about Correction:

see Notice of 28 February 2019 (28.02.2019)

ADDITIVE MANUFACTURING USING RECOMBINANT COLLAGEN-CONTAINING FORMULATION

RELATED APPLICATION

5 This application claims the benefit of priority of U.S. Provisional Patent Application No. 62/517,179 filed June 9, 2017, the contents of which are incorporated herein by reference in their entirety.

FIELD AND BACKGROUND OF THE INVENTION

10 The present invention, in some embodiments thereof, relates to additive manufacturing and, more particularly, but not exclusively, to three-dimensional (3D) bioprinting of 3D objects using a collagen-based building material.

15 Collagen comprises the main component of connective tissue and is the most abundant protein in mammals, comprising approximately 30 % of the proteins found in the body. Collagen serves as the predominant component and primary structural-mechanical determinant of most tissue extracellular matrix (ECM) [see, for example, Kadler K. Birth Defects Res C Embryo Today. 2004; 72:1–11; Kadler KE, Baldock C, Bella J, Boot-Handford RP. J Cell Sci. 2007; 120:1955–1958.; Kreger ST. Biopolymers. 2010 93(8): 690–707].

20 Due to its unique characteristics and diverse profile in human body functions, collagen is frequently selected from a variety of biocompatible materials for use in tissue repair to support structural integrity, induce cellular infiltration and promote tissue regeneration. Among the 5 major collagen types, Type I collagen is the most abundant form of in the human body. Collagen's unique properties make it a favorite choice for regenerative medicine products.

25 Additive manufacturing (AM) is generally a process in which a three-dimensional (3D) object is manufactured utilizing a computer model of the objects. The basic operation of any AM system consists of slicing a three-dimensional computer model into thin cross sections, translating the result into two-dimensional position data and feeding the data to control equipment which manufacture a three-dimensional structure in a layerwise manner.

30 Various AM technologies exist, amongst which are stereolithography, digital light processing (DLP), and three-dimensional (3D) printing such as 3D inkjet printing. Such techniques are generally performed by layer by layer deposition and hardening (e.g., solidification) of one or more building materials, which typically include photopolymerizable (photocurable) materials.

35 Stereolithography, for example, is an additive manufacturing process which employs a liquid ultraviolet (UV)-curable building material and a UV laser. In such a process, for each

dispensed layer of the building material, the laser beam traces a cross-section of the part pattern on the surface of the dispensed liquid building material. Exposure to the UV laser light cures and solidifies the pattern traced on the building material and joins it to the layer below. After being built, the formed parts are immersed in a chemical bath in order to be cleaned of excess building material and are subsequently cured in an UV oven.

In three-dimensional printing processes, for example, a building material is dispensed from a dispensing head having a set of nozzles to deposit layers on a supporting structure. Depending on the building material, the layers may then be cured or solidify using a suitable device.

10 The building materials may include modeling material formulation(s) and support material formulation(s), which form, upon hardening, the object and the temporary support constructions supporting the object as it is being built, respectively.

15 The modeling material formulation(s) is/are deposited to produce the desired object and the support material formulation(s) is/are used, with or without modeling material elements, to provide support structures for specific areas of the object during building and assure adequate vertical placement of subsequent object layers, e.g., in cases where objects include overhanging features or shapes such as curved geometries, negative angles, voids, and so on.

20 Both the modeling and support materials are preferably liquid at the working temperature at which they are dispensed, and subsequently hardened, typically upon exposure to hardening or curing condition such as curing energy (e.g., UV curing), to form the required layer shape. After printing completion, support structures, if present, are removed to reveal the final shape of the fabricated 3D object. The hardening (curing) of the dispensed materials typically involves polymerization (e.g., photopolymerization) and/or crosslinking (e.g., photocrosslinking).

25 Additive manufacturing has been first used in biological applications for forming three-dimensional sacrificial resin molds in which 3D scaffolds from biological materials were created.

30 3D bioprinting is an additive manufacturing methodology which uses biological materials, optionally in combination with chemicals and/or cells, that are printed layer-by-layer with a precise positioning and a tight control of functional components placement to create a 3D structure.

Three dimensional (3D) bioprinting is gaining momentum in many medicinal applications, especially in regenerative medicine, to address the need for complex scaffolds, tissues and organs suitable for transplantation.

Inherent to 3D printing in general is that the mechanical properties of the printing media (the dispensed building material) are very different from the post-printed cured (hardened) material.

To allow tight control on the curing (e.g., polymerization) after printing, the building material commonly includes polymerizable (e.g., photopolymerizable) moieties or groups that polymerize (e.g., by chain elongation and/or cross-linking) upon being dispensed, to preserve the geometric shape and provide the necessary physical properties of the final product.

Different technologies have been developed for 3D bioprinting, including 3D Inkjet printing, Extrusion printing, Laser-assisted printing and Projection stereolithography [see, for example, Murphy SV, Atala A, *Nature Biotechnology*. 2014 32(8).; Miller JS, Burdick J. *ACS Biomater. Sci. Eng.* 2016, 2, 1658–1661]. Each technology has its different requirements for the dispensed building material (also referred to herein as printing media), which is derived from the specific application mechanism and the curing/gelation process required to maintain the 3D structure of the scaffold post printing.

For all technologies, the most important parameter determining the accuracy and efficiency of the printing is the static and dynamic physical properties of the dispensed building material, including viscosity, shear thinning and thixotropic properties. The static and dynamic properties of the building material are important not only for the printing technology but also when considering cell-laden printing, i.e. including cells in the building material dispensed during printing. In this case, the shearing forces applied to the building material during printing (dispensing) have a significant effect on the survival of the cells. Therefore, it is desirable to have good control on the specific properties of the printing media over a wide range of conditions, i.e. concentration, temperature, ionic strength and pH.

Type I collagen is considered a perfect candidate for use as a major component of a building material in 3D-bioprinting.

Collagen methacrylate can be used as a rapidly self-assembling type I collagen to form cross-linked hydrogels for tissue engineering [see, for example, Isaacs et al., *Experimental Eye Research* 173, 188–193 (2018)]. It has been used with mesenchymal stem cells [Kathryn E. Drzewiecki et al., *A thermoreversible, photocrosslinkable collagen bio-ink for free-form fabrication of scaffolds for regenerative medicine, TECHNOLOGY* (2017)], fibroblasts, adipose derived stem cells, epithelial cells, and many more. Collagen methacrylate is useful for forming scaffolds with varying degree of stiffness, by altering collagen concentration or the curing conditions (e.g., intensity and duration of irradiation).

Collagen methacrylate extracted from tissues has been extensively characterized for its usefulness in 3D-bioprinting (extrusion, inkjet, and photolithographic [Drzewiecki, K. E. et al. Langmuir 30, 11204–11211 (2014); Gaudet, I. D. & Shreiber, D. I. *Biointerphases* 7, 25 (2012)].

Despite the significant advantages offered by this natural polymer, a number of factors 5 hinder its use for 3D bioprinting. The use of tissue extracted collagen for this purpose is limited due to its sensitivity to temperature and ionic strength, which leads to spontaneous gel formation at temperatures higher than 20 °C, under physiological conditions [see, for example, PureCol, Advanced BioMatrix, Inc.]. The typical temperature-dependent formation of gel of tissue extracted-collagens hampers significantly the precise fluidity during printing. Keeping the 10 printing media at low temperature until application is a possible solution for this phenomena but implies a serious technical limitation. Another solution is the use of gelatin, the denatured form of collagen which does not become gel-like under these conditions. However, gelatin lacks the genuine tissue and cell interactions of native collagen and thus crucial biological functions are lost.

15 The present assignee has developed a technology that allows the purification of naïve human Type I collagen (rhCollagen) by introducing into tobacco plants, five human genes encoding heterotrimeric type I collagen [see, for example, Stein H. (2009) *Biomacromolecules*; 10:2640-5]. The protein is purified to homogeneity through a cost-effective industrial process taking advantage of collagen's unique properties. See also WO 2006/035442, WO 2009/053985, 20 WO 2011/064773, WO 2013/093921, WO 2014/147622, and patents and patent applications deriving therefrom, all of which are incorporated by reference as if fully set forth herein. Additional background art includes U.S. Patent application No. 15/867,783.

SUMMARY OF THE INVENTION

25 According to an aspect of some embodiments of the present invention there is provided a formulation for use, or usable, in additive manufacturing of a three-dimensional object that comprises, in at least a portion thereof, a collagen-based material, the formulation comprising a recombinant human collagen featuring at least one curable group.

30 According to some of any of the embodiments of the present invention, the at least one curable group is a photocurable group.

According to some of any of the embodiments of the present invention, the recombinant human collagen is a recombinant human Type I collagen.

According to some of any of the embodiments of the present invention, the recombinant human collagen is a plant-derived recombinant collagen.

According to some of any of the embodiments of the present invention, the formulation further comprises and an aqueous carrier.

According to some of any of the embodiments of the present invention, the formulation features a pH that ranges from about 6 to about 8.

5 According to some of any of the embodiments of the present invention, the aqueous carrier comprises a phosphate buffer.

According to some of any of the embodiments of the present invention, the aqueous carrier comprises an acid.

10 According to some of any of the embodiments of the present invention, the aqueous carrier comprises a culturing medium.

According to some of any of the embodiments of the present invention, a concentration of the recombinant human collagen in the modeling material formulation ranges from 0.5 mg/mL to 50 mg/mL, or from 0.5 mg/mL to 20 mg/mL.

15 According to some of any of the embodiments of the present invention, the formulation further comprises at least one curable material other than the recombinant human collagen featuring the curable group.

According to some of any of the embodiments of the present invention, a weight ratio of the recombinant human collagen featuring the curable group and the at least one curable material ranges from 10:1 to 1:2, or from 10:1 to 1:1, or from 5:1 to 2:1.

20 According to some of any of the embodiments of the present invention, the formulation further comprises an agent that modifies a mechanical and/or rheological and/or physical property of the formulation and/or of a respective portion of the object.

According to some of any of the embodiments of the present invention, the formulation further comprises a biological material other than the human recombinant collagen.

25 According to some of any of the embodiments of the present invention, the formulation is a shear-thinning formulation.

According to some of any of the embodiments of the present invention, the formulation is a thermal-thinning formulation.

30 According to some of any of the embodiments of the present invention, the formulation features a viscosity of no more than 2,000 centipoises, or no more than 1,500 centipoises, at a zero shear strain rate, at 37 °C, wherein a concentration of the recombinant human collagen featuring a curable group is at least 3 mg/mL.

According to some of any of the embodiments of the present invention, the modeling material formulation features a viscosity of no more than 2000 centipoises, or no more than 1,500

centipoises, at a shear strain rate of 5 1/sec, at room temperature, wherein a concentration of the recombinant human collagen featuring a curable group is at least 3 mg/mL.

According to some of any of the embodiments of the present invention, the formulation features, when hardened, storage modulus (G') of at least 1,000 Pa.

5 According to some of any of the embodiments of the present invention, the formulation features, when hardened, an increase of at least 10-folds of its storage modulus (G').

According to an aspect of some embodiments of the present invention there is provided a process or a method of additive manufacturing of a three-dimensional object featuring, in at least a portion thereof, a collagen-based material, the process comprising dispensing at least one 10 modeling material formulation to sequentially form a plurality of layers in a configured pattern corresponding to a shape of the object, wherein for at least a portion of the layers, the dispensing is of a modeling material formulation that comprises a recombinant human collagen featuring at least one curable group, as described herein in any of the respective embodiments and any combination thereof, thereby manufacturing the three-dimensional object.

15 According to some of any of the embodiments described herein, the process further comprises exposing the portion of the layers to a curing condition suitable for hardening the recombinant human collagen featuring the at least one curable group.

According to some of any of the embodiments described herein, the at least one curable group is a photocurable group.

20 According to some of any of the embodiments described herein, the process further comprises exposing the portion of the layers to irradiation.

According to some of any of the embodiments described herein, the recombinant human collagen is a recombinant human Type I collagen.

25 According to some of any of the embodiments described herein, for at least a portion of the layers, the dispensing is further of a modeling material formulation that comprises at least one curable material other than the recombinant human collagen featuring the curable group.

According to some of any of the embodiments described herein, the dispensing is of a modeling material formulation that comprises the recombinant human collagen featuring the curable group and the at least one curable material.

30 According to some of any of the embodiments described herein, a weight ratio of the recombinant human collagen featuring the curable group and the at least one curable material ranges from 10:1 to 1:2, or from 10:1 to 1:1, or from 5:1 to 2:1.

According to some of any of the embodiments described herein, the at least one curable material comprises a hyaluronic acid featuring at least one curable group.

According to some of any of the embodiments described herein, the modeling material formulation further comprises an agent that modifies a mechanical and/or rheological and/or physical property of the formulation and/or of a respective portion of the object.

According to some of any of the embodiments described herein, for at least a portion of 5 the layers, the dispensing is further of a modeling material formulation that comprises an agent that modifies a mechanical and/or rheological and/or physical property of the formulation and/or of a respective portion of the object.

According to some of any of the embodiments described herein, the agent is a thixotropic agent.

10 According to some of any of the embodiments described herein, the agent is a gel-forming agent.

According to some of any of the embodiments described herein, the modeling material formulation further comprises a biological material other than the human recombinant collagen.

15 According to some of any of the embodiments described herein, for at least a portion of the layers, the dispensing is further of a modeling material formulation that comprises a biological material other than the human recombinant collagen.

According to some of any of the embodiments described herein, the modeling material formulation that comprises the human recombinant collagen further comprises the biological material.

20 According to some of any of the embodiments of the present invention, the dispensing is at a temperature of at least 10 °C, or of at least 20 °C, or of 37 °C.

According to an aspect of some embodiments of the present invention there is provided a three-dimensional biological object obtainable by the process of AM as described herein in any of the respective embodiments and any combination thereof.

25 According to some of any of the embodiments of the present invention, the object further comprises a biological material other than the collagen-based material in or on at least a portion thereof.

According to some of any of the embodiments of the present invention, the object is for use, or is usable in, repairing a damaged tissue.

30 According to some of any of the embodiments of the present invention, the object is an artificial tissue or organ, or is usable, or for use, in constructing an artificial organ or tissue.

According to an aspect of some embodiments of the present invention there is provided a composition comprising a recombinant human collagen featuring at least one curable group, as described herein in any of the respective embodiments and any combination thereof.

According to some of any of the embodiments of the present invention, the composition is for use, or is usable, in preparing a modeling material formulation usable in additive manufacturing of a three-dimensional object that comprises, in at least a portion thereof, a collagen-based material.

5 According to some of any of the embodiments of the present invention, the composition further comprises an aqueous solution of the recombinant human collagen featuring at least one curable group.

0 According to an aspect of some embodiments of the present invention there is provided a kit comprising the composition described herein packaged therein, the kit being identified for use in preparing a modeling material formulation usable in additive manufacturing of a three-dimensional object that comprises, in at least a portion thereof, a collagen-based material.

According to some of any of the embodiments of the present invention, the modeling material formulation further comprises an aqueous carrier, and the kit further comprises the aqueous carrier or instructions to prepare the formulation with the aqueous carrier.

According to an aspect of some embodiments of the present invention there is provided a process of additive manufacturing a three-dimensional object featuring, in at least a portion thereof, a collagen-based material, the process comprising sequentially forming a plurality of layers in a configured pattern corresponding to a shape of the object, wherein at least a portion of said layers are formed of a modeling material formulation that comprises a plant-derived recombinant human Type I collagen featuring at least one photocurable group, at a temperature of at least 20 °C, thereby manufacturing the three-dimensional object.

According to an aspect of some embodiments of the present invention there is provided a formulation for use in additive manufacturing of a three-dimensional object that comprises, in at least a portion thereof, a collagen-based material, the formulation comprising a plant-derived recombinant human Type I collagen featuring at least one photocurable group and an aqueous carrier, the formulation featuring a viscosity of no more than 2000 centipoises, or no more than 1,500 centipoises, at a shear strain rate of 5 1/sec, at room temperature, or at a zero shear strain rate, at 37 °C, wherein a concentration of said plant-derived recombinant human Type I collagen featuring at least one photocurable group is at least 3 mg/mL.

15 Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

Implementation of the method and/or system of embodiments of the invention can involve performing or completing selected tasks manually, automatically, or a combination thereof.

Moreover, according to actual instrumentation and equipment of embodiments of the method and/or system of the invention, several selected tasks could be implemented by hardware, by software or by firmware or by a combination thereof using an operating system.

For example, hardware for performing selected tasks according to embodiments of the invention could be implemented as a chip or a circuit. As software, selected tasks according to embodiments of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In an exemplary embodiment of the invention, one or more tasks according to exemplary embodiments of method and/or system as described herein are performed by a data processor, such as a computing platform for executing a plurality of instructions. Optionally, the data processor includes a volatile memory for storing instructions and/or data and/or a non-volatile storage, for example, a magnetic hard-disk and/or

removable media, for storing instructions and/or data. Optionally, a network connection is provided as well. A display and/or a user input device such as a keyboard or mouse are optionally provided as well.

5 **BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)**

Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the 10 drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

In the drawings:

15 FIG. 1 presents ^1H nuclear magnetic resonance (NMR) spectra of rhCollagen (top) and of rhCollagen methacrylate (bottom), as recorded in quantitative analysis using 500 MHz spectrometer. The signals of the methyl function and acrylic protons of the methacrylate introduced in rhCollagen methacrylate are indicated as (b) and (c), respectively, and the lysine methylene signals of the rhCollagen as indicated as (a).

20 FIG. 2 presents comparative plots showing the viscosity as a function of shear rate, of a solution of 2.7 mg/mL bovine collagen in DPBS (solid line), and of a solution of 2.79 mg/mL rhCollagen in DPBS (dashed line), as measured at 4 °C (blue), and at 37 °C (red).

FIG. 3 presents comparative plots showing the viscosity as a function of shear rate, of a solution of 3.4 mg/mL rhCollagen in FB, as measured at 4 °C (blue), and at 37 °C (red), demonstrating an identical shear thinning behavior at both temperatures.

25 FIG. 4 presents comparative plots showing the viscosity as a function of shear rate, of a solution of 10 mg/mL rhCollagen-MA in DPBS as measured at 4 °C (blue), and at 37 °C (red), demonstrating a shear thinning behavior at both temperatures.

30 FIG. 5 presents comparative plots showing the viscosity as function of temperature increase, of a solution of 10 mg/ml rhCollagen-MA in 20 mM acetic acid (blue) and an equivalent solution of bovine collagen methacrylate ink (bovine type I collagen methacrylate) (red), measured in a rheometer using rotational temperature steps CR mode with shear rate of 5 [1/sec].

FIGs. 6A-B are bar graphs presenting the storage and loss moduli and tan phase shift angle (tan delta) of rhCollagen-MA formulation at different concentrations before (FIG. 6A) and after (FIG. 6B) photocuring.

10 FIG. 7 is a bar graph showing the G' and G'' values of cured objects prepared from various formulations of fibrillar rhCollagen-MA, at 37 °C, recorded in frequency sweep test and plotted at 1 Hz.

5 FIG. 8 presents plots showing G' and complexed viscosity values measured over time of cured objects prepared from a solution of 15 mg/ml rhCollagen-MA in 10 mM HCl, as recorded in a rheometer using Oscillation with 7 % strain and 5 rad/sec angular frequency.

FIG. 9 presents comparative plots showing the viscosity as a function of shear rate of a solution containing rhCollagen-MA, rhCollagen-MA+hyaluronic acid (HA), or rhCollagen-MA and hyaluronic acid-MA (HAMA) in DMEM.

10 FIG. 10 presents comparative plots showing the viscosity as a function of shear rate of a solution of 5 mg/ml rhCollagen-MA (col; black curve), and of solutions of 5 mg/ml rhCollagen-MA and Polyvinyl alcohol methacrylate (PVAMA; green curves), at rhCollagen-MA:PVAMA weight ratio of 5:1 (green solid curve), 2:1 (green dashed curve), or 1:2 (green dotted curve). All solutions are in 0.1M PB + 11.3 mM NaCl, pH 7.4.

15 FIG. 11 presents comparative plots showing the viscosity as a function of shear rate of a solution of 5 mg/ml rhCollagen-MA (col; black curve) and of solutions of 5 mg/ml rhCollagen-MA and HAMA (blue curves) at rhCollagen-MA:HAMA weight ratio of 5:1 (blue solid curve) or 2:1 (blue dashed curve). All solutions are in 0.1MPB + 11.3 mM NaCl pH 7.4.

20 FIG. 12 presents comparative plots showing the viscosity as a function of shear rate of a solution of 5 mg/ml rhCollagen-MA (col; black curve) and of solutions of 5 mg/ml rhCollagen-MA and TiO_2 (red curves) at rhCollagen-MA: TiO_2 weight ratio of 5:1 (red solid curve), 2:1 (red dashed curve), or 1:2 (red dotted curve). All solutions are in 0.1MPB + 11.3 mM NaCl pH 7.4.

25 FIG. 13 presents comparative plots showing the viscosity as a function of shear rate of a solution of 5 mg/ml rhCollagen-MA (col; black curve) and of solutions of 5 mg/ml rhCollagen-MA and oxidized cellulose (orange curves) at rhCollagen-MA: oxidized cellulose weight ratio of 5:1 (orange solid curve), 2:1 (orange dashed curve), or 1:2 (orange dotted curve). All solutions are in 0.1MPB + 11.3 mM NaCl pH 7.4.

FIG. 14 presents photographs of cured objects (scaffolds) obtained from formulations containing rhCollagen-MA and various additives at rhCollagen-MA: additive weight ratio of 2:1.

30 FIG. 15 presents plots showing the viscosity as a function of shear rate of solutions containing 10 mg/ml rhCollagen-MA in phosphate buffer 0.1M/NaCl 0.016M (blue) and in 10 mM HCl (red) solutions before curing, as recorded in the rheometer using Rotational CR mode at R.T., demonstrating a more pronounced shear thinning behavior of the PBS solution.

FIG. 16 is a bar graph showing G' values of objects obtained upon curing solutions containing 10 mg/ml rhCollagen-MA in phosphate buffer 0.1M/NaCl 0.016M and in 10 mM HCl, as recorded in the rheometer using Oscillation CR mode at 37 °C.

FIG. 17 presents a photograph of a scaffold prepared from a solution of rhCollagen-MA integrated into a mouse skin patch (ex-vivo) following illumination with a white LED torch through the skin. The skin patch was illuminated on its external side, while the rhCollagen-MA solution was dispensed in a mold underneath the skin

FIG. 18 is a bar graph showing the proliferation of normal human dermal fibroblasts seeded in scaffolds made of a solution containing rhCollagen-MA and calcium phosphate particles.

DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

The present invention, in some embodiments thereof, relates to additive manufacturing and, more particularly, but not exclusively, to three-dimensional (3D) bioprinting of 3D objects using a collagen-based building material.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

The present inventors have surprisingly uncovered that recombinant human collagen (rhCollagen) is much more tolerant to temperature and ionic strength conditions than tissue extracted-collagen. The present inventors have uncovered that an aqueous solution of rhCollagen does not form gels at temperatures above 20 °C, and even at 37 °C, and that its viscosity is minimally affected at varying conditions, for example, at acidic conditions, or at a salt concentration above 50mM.

Figures 2 and 3 demonstrate the similar viscosity profile at increasing shear rate of an rhCollagen solution at different temperatures, and Figure 2 further demonstrates the different viscosity profile observed at different temperatures for an aqueous solution of a tissue-extracted

collagen, and particularly the substantially higher viscosity of the tissue-extracted collagen solution at low shear rates.

The present inventors have realized that these properties of rhCollagen can be advantageously utilized in additive manufacturing processes (e.g., 3D-bioprinting), by allowing 5 performing such processes at conditions that are compatible with biological additives (e.g., physiological temperature and ionic strength, lower applied shear force), while avoiding the need to cool the additive manufacturing system, and while having a better control on the fluidity of the modeling material formulation.

While reducing the present invention to practice, the present inventors have successfully 10 generated curable groups (e.g., (meth)acrylic groups) as substituents of amino acid residues (e.g., lysine residues) of the rhCollagen, and have shown that more than 80 % of the lysine residues were modified to feature a methacrylamide group instead of amine group in the side chain thereof, as is exemplified in Figure 1 and in Table 1.

The rhCollagen that features one or more, preferably a plurality of, curable groups such 15 as (meth)acrylic groups as described herein is also referred to herein throughout, interchangeably, as “curable rhCollagen” or simply as “curable collagen”.

An aqueous solution of the curable rhCollagen was found to exhibit the same relatively 20 low viscosity at low shear rates, and a similar shear-thinning behavior, as exemplified in Figure 4. Moreover, the curable rhCollagen solution was shown to exhibit a thermal-thinning behavior within a temperature range of working temperatures usable in additive manufacturing processes, and suitable viscosities at this temperature range, as opposed to a thermal-thickening behavior 25 and high viscosities exhibited by a curable tissue-extracted collagen solution, as can be seen in Figure 5.

The curable rhCollagen solution was further shown to exhibit good curability and curing 25 stability, providing a cured material with desired mechanical properties, as shown in Figures 6A-B, 7 and 8.

The advantageous properties of the curable rhCollagen were shown to be maintained also in the presence of variable additives, and when used in different solutions (aqueous carriers), as shown in Figures 10-16.

30 The curable rhCollagen was shown to perform successfully in an *in vitro* model of transdermal application, as shown in Figure 17, and as biocompatible, as shown in Figure 18.

Embodiments of the present invention therefore relate to a composition that comprises a curable recombinant human collagen, to a formulation that comprises a curable recombinant

human collagen, and to additive manufacturing processes utilizing same for manufacturing three-dimensional (3D) objects featuring a collagen-based material.

Additive manufacturing:

According to an aspect of some embodiments of the present invention, there is provided a process (a method) of additive manufacturing (AM) of a three-dimensional object. According to embodiments of this aspect, the method is effected by sequentially forming a plurality of layers in a configured pattern corresponding to the shape of the object, thereby forming the object. According to embodiments of this aspect, formation of each layer is effected by dispensing at least one uncured building material, and exposing the dispensed building material to a curing condition to thereby form a hardened (cured) material.

Herein throughout, the phrase “building material” encompasses the phrases “uncured building material” or “uncured building material formulation” and collectively describes the materials that are dispensed by sequentially forming the layers, as described herein. This phrase encompasses uncured materials which form the final object, namely, one or more uncured modeling material formulation(s), and optionally also uncured materials used to form a support, namely uncured support material formulations. The building material can also include non-curable materials that preferably do not undergo (or are not intended to undergo) any change during the process, for example, biological materials or components (other than a curable collagen as described herein) and/or other agents or additives as described herein.

The building material that is dispensed to sequentially form the layers as described herein is also referred to herein interchangeably as “printing medium” or “bioprinting medium”.

An uncured building material can comprise one or more modeling material formulations, and can be dispensed such that different parts of the object are made upon hardening (e.g., curing) of different modeling formulations, and hence are made of different hardened (e.g., cured) modeling materials or different mixtures of hardened (e.g., cured) modeling materials.

The method of the present embodiments manufactures three-dimensional objects in a layerwise manner by forming a plurality of layers in a configured pattern corresponding to the shape of the object.

Each layer is formed by an additive manufacturing apparatus which scans a two-dimensional surface and patterns it. While scanning, the apparatus visits a plurality of target locations on the two-dimensional layer or surface, and decides, according to a pre-set algorithm, for each target location or a group of target locations, whether or not the target location or group of target locations is to be occupied by a building material, and which type of a building material is to be delivered thereto. The decision is made according to a computer image of the surface.

When the AM is by three-dimensional inkjet printing, an uncured building material, as defined herein, is dispensed from a dispensing head having a set of nozzles to deposit building material in layers on a supporting structure. The AM apparatus thus dispenses building material in target locations which are to be occupied and leaves other target locations void. The apparatus 5 typically includes a plurality of dispensing heads, each of which can be configured to dispense a different building material (for example, different modeling material formulations, each containing a different biological component; or each containing a different curable material; or each containing a different concentration of a curable material, and/or different support material formulations). Thus, different target locations can be occupied by different building materials 10 (e.g., a modeling formulation and/or a support formulation, as defined herein).

The final three-dimensional object is made of the hardened modeling material or a combination of hardened modeling materials or a combination of hardened modeling material/s and support material/s or modification thereof (e.g., following curing). All these operations are well-known to those skilled in the art of additive manufacturing (also known as solid freeform 15 fabrication).

In some exemplary embodiments of the invention an object is manufactured by dispensing a building material that comprises two or more different modeling material formulations, each modeling material formulation from a different dispensing head of the AM apparatus. The modeling material formulations are optionally and preferably deposited in layers 20 during the same pass of the dispensing heads. The modeling material formulations and/or combination of formulations within the layer are selected according to the desired properties of the object.

An exemplary process according to some embodiments of the present invention starts by receiving 3D printing data corresponding to the shape of the object. The data can be received, for 25 example, from a host computer which transmits digital data pertaining to fabrication instructions based on computer object data, *e.g.*, in a form of a Standard Tessellation Language (STL) or a StereoLithography Contour (SLC) format, Virtual Reality Modeling Language (VRML), Additive Manufacturing File (AMF) format, Drawing Exchange Format (DXF), Polygon File Format (PLY), Digital Imaging and Communications in Medicine (DICOM) or any other format 30 suitable for Computer-Aided Design (CAD).

The process continues by dispensing the building material as described herein in layers, on a receiving medium, using one or more dispensing (*e.g.*, printing) heads, according to the printing data.

The dispensing can be in a form of droplets, or a continuous stream, depending on the additive manufacturing methodology employed and the configuration of choice.

The receiving medium can be a tray of a printing system, or a supporting article or medium made of, or coated by, a biocompatible material, such as support media or articles 5 commonly used in bioprinting, or a previously deposited layer.

In some embodiments, the receiving medium comprises a sacrificial hydrogel or other biocompatible material as a mold to embed the printed object, and is thereafter removed by chemical, mechanical or physical (e.g., heating or cooling) means. Such sacrificial hydrogels can be made of, for example, a Pluronic material or of Gelatin.

10 Once the uncured building material is dispensed on the receiving medium according to the 3D data, the method optionally and preferably continues by hardening the dispensed formulation(s). In some embodiments, the process continues by exposing the deposited layers to a curing condition. Preferably, the curing condition is applied to each individual layer following the deposition of the layer and prior to the deposition of the previous layer.

15 As used herein, the term “curing” describes a process in which a formulation is hardened. The hardening of a formulation typically involves an increase in a viscosity of the formulation and/or an increase in a storage modulus of the formulation (G'). In some embodiments, a formulation which is dispensed as a liquid becomes solid or semi-solid (e.g., gel) when hardened. A formulation which is dispensed as a semi-solid (e.g., soft gel) becomes solid or a harder or 20 stronger semi-solid (e.g., strong gel) when hardened.

The term “curing” as used herein encompasses, for example, polymerization of monomeric and/or oligomeric materials and/or cross-linking of polymeric chains (either of a polymer present before curing or of a polymeric material formed in a polymerization of the monomers or oligomers). The product of a curing reaction is therefore typically a polymeric 25 material and/or a cross-linked material. This term, as used herein, encompasses also partial curing, for example, curing of at least 20 % or at least 30 % or at least 40 % or at least 50 % or at least 60 % or at least 70 % of the formulation, as well as 100 % of the formulation.

Herein, the phrase “a condition that affects curing” or “a condition for inducing curing”, which is also referred to herein interchangeably as “curing condition” or “curing inducing 30 condition” describes a condition which, when applied to a formulation that contains a curable material, induces a curing as defined herein. Such a condition can include, for example, application of a curing energy, as described hereinafter to the curable material(s), and/or contacting the curable material(s) with chemically reactive components such as catalysts, co-catalysts, and activators.

When a condition that induces curing comprises application of a curing energy, the phrase “exposing to a curing condition” and grammatical diversions thereof means that the dispensed layers are exposed to the curing energy and the exposure is typically performed by applying a curing energy to the dispensed layers.

5 A “curing energy” typically includes application of radiation or application of heat.

The radiation can be electromagnetic radiation (e.g., ultraviolet or visible light), or electron beam radiation, or ultrasound radiation or microwave radiation, depending on the materials to be cured. The application of radiation (or irradiation) is effected by a suitable radiation source. For example, an ultraviolet or visible or infrared or Xenon or mercury or lamp, 10 or LED source, can be employed, as described herein.

A curable material or system that undergoes curing upon exposure to radiation is referred to herein interchangeably as “photopolymerizable” or “photoactivatable” or “photocurable”.

When the curing energy comprises heat, the curing is also referred to herein and in the art as “thermal curing” and comprises application of thermal energy. Applying thermal energy can 15 be effected, for example, by heating a receiving medium onto which the layers are dispensed or a chamber hosting the receiving medium, as described herein. In some embodiments, the heating is effected using a resistive heater.

In some embodiments, the heating is effected by irradiating the dispensed layers by heat-inducing radiation. Such irradiation can be effected, for example, by means of an IR lamp or 20 Xenon lamp, operated to emit radiation onto the deposited layer.

In some embodiments, heating is effected by infrared radiation applied by a ceramic lamp, for example, a ceramic lamp that produces infrared radiation of from about 3 μm to about 4 μm , *e.g.*, about 3.5 μm .

A curable material or system that undergoes curing upon exposure to heat is referred to 25 herein as “thermally-curable” or “thermally-activatable” or “thermally-polymerizable”.

In some of any of the embodiments described herein, hardening the dispensed formulation(s) comprises exposing the dispensed formulation to a curing condition as described herein in any of the respective embodiments, for example, to irradiation (illumination).

In some embodiments, the exposure to a curing condition is for a short time period, for 30 example, a time period of less than 3 minutes, less than 300 seconds, for example, of from 10 seconds to 240 seconds, or from 10 seconds to 120 seconds, to from 10 seconds to 60 seconds, including an intermediate values and subranges therebetween.

In some of any of the embodiments described herein, the method further comprises exposing the cured modeling material formulation(s) either before or after removal of a support

material formulation, if such has been included in the building material, to a post-treatment condition. The post-treatment condition is typically aimed at further hardening the cured modeling material(s). In some embodiments, the post-treatment hardens a partially-cured formulation to thereby obtain a completely cured formulation.

5 In some embodiments, the post-treatment is effected by exposure to heat or radiation, as described in any of the respective embodiments herein.

Some embodiments contemplate the fabrication of an object by dispensing different formulations from different dispensing heads. These embodiments provide, *inter alia*, the ability to select formulations from a given number of formulations and define desired combinations of 10 the selected formulations and their properties.

According to the present embodiments, the spatial locations of the deposition of each formulation with the layer are defined, either to effect occupation of different three-dimensional spatial locations by different formulations, or to effect occupation of substantially the same three-dimensional location or adjacent three-dimensional locations by two or more different 15 formulations so as to allow post deposition spatial combination of the formulations within the layer.

The present embodiments thus enable the deposition of a broad range of material combinations, and the fabrication of an object which may consist of multiple different combinations of modeling material formulations, in different parts of the object, according to the 20 properties desired to characterize each part of the object.

A system utilized in additive manufacturing may include a receiving medium and one or more dispensing heads. The receiving medium can be, for example, a fabrication tray that may include a horizontal surface to carry the material dispensed from the printing head. In some embodiments, the receiving medium is made of, or coated by, a biocompatible material, as 25 described herein.

The dispensing head may be, for example, a printing head having a plurality of dispensing nozzles arranged in an array of one or more rows along the longitudinal axis of the dispensing head. The dispensing head may be located such that its longitudinal axis is substantially parallel to the indexing direction.

30 The additive manufacturing system may further include a controller, such as a microprocessor to control the AM process, for example, the movement of the dispensing head according to a pre-defined scanning plan (e.g., a CAD configuration converted to a Standard Tessellation Language (STL) format and programmed into the controller). The dispensing head

may include a plurality of jetting nozzles. The jetting nozzles dispense material onto the receiving medium to create the layers representing cross sections of a 3D object.

In addition to the dispensing head, there may be a source of curing energy, for curing the dispensed building material. The curing energy is typically radiation, for example, UV radiation or heat radiation. Alternatively, there may be means for providing a curing condition other than electromagnetic or heat radiation, for example, means for cooling the dispensed building material or for contacting it with a reagent that promotes curing.

Additionally, the AM system may include a leveling device for leveling and/or establishing the height of each layer after deposition and at least partial solidification, prior to the deposition of a subsequent layer.

According to the present embodiments, the additive manufacturing method described herein is for bioprinting a biological object.

As used herein, "bioprinting" means practicing an additive manufacturing process while utilizing one or more bio-ink formulation(s) that comprise(s) biological components, as described herein, via methodology that is compatible with an automated or semi-automated, computer-aided, additive manufacturing system as described herein (e.g., a bioprinter or a bioprinting system).

Herein throughout, the phrase "modeling material formulation", which is also referred to herein interchangeably as "modeling formulation" or "modeling material composition" or "modeling composition", or simply as a "formulation", or a "composition", describes a part or all of the uncured building material (printing medium) which is dispensed so as to form the final object, as described herein. The modeling formulation is an uncured modeling formulation, which, upon exposure to a curing condition, forms the object or a part thereof.

In the context of bioprinting, an uncured building material comprises at least one modeling formulation that comprises one or more biological components or materials (e.g., a curable rhCollagen as described herein), and is also referred to herein and in the art as "bio-ink" or "bio-ink formulation".

In some embodiments, the bioprinting comprises sequential formation of a plurality of layers of the uncured building material in a configured pattern, preferably according to a three-dimensional printing data, as described herein. At least one, and preferably most or all, of the formed layers (before hardening or curing) comprise(s) one or more biological component(s) as described herein (e.g., a curable rhCollagen as described herein). Optionally, at least one of the formed layers (before hardening or curing) comprises one or more non-biological curable materials, and/or non-curable biological or non-biological components, preferably biocompatible

materials which do not interfere (e.g., adversely affect) with the biological and/or structural features of the biological components (e.g., collagen) in the printing medium and/or bio-ink.

In some embodiments, the components in the bio-ink or the printing medium, e.g., non-curable and curable materials, and/or the curing condition applied to effect curing, are selected 5 such that they do not significantly affect structural and/or functional properties of the biological components in the bio-ink or printing medium.

In some of any of the embodiments described herein, the building material (e.g., the printing medium) comprises modeling material formulation(s) (bio-ink) and optionally support material formulation(s), and all are selected to include materials or combination of materials that 10 do not interfere with the biological and/or structural features of the biological components.

In some of any of the embodiments described herein, the bioprinting method is configured to effect formation of the layers under conditions that do not significantly affect structural and/or functional properties of the biological components in the bio-ink.

In some embodiments, a bioprinting system for effecting a bioprinting process/method as 15 described herein is configured so as to allow formation of the layers under conditions that do not significantly affect structural and/or functional properties of the biological components in the bio-ink.

In some of any of the embodiments described herein, the additive manufacturing (e.g., bioprinting) process and system are configured such that the process parameters (e.g., 20 temperature, shear forces, shear strain rate) do not interfere with (do not substantially affect) the functional and/or structural features of the biological components.

In some of any of the embodiments described herein, the additive manufacturing process (the bioprinting) is performed at a temperature of at least 10 °C, or of at least 20 °C, for example, 25 at a temperature that ranges from about 10 to about 40 °C, preferably from about 10 °C to 37 °C, or from about 20 °C to 37 °C, or from about 20 °C to about 30 °C, or from about 20 °C to about 28 °C, or from about 20 °C to about 25 °C, including any intermediate values and subranges therebetween, or at room temperature, or at 37 °C.

In some of any of the embodiments described herein, the above-indicated 30 temperatures/temperature ranges are the temperatures at which the building material (e.g., at least a modeling material formulation that comprises a biological component as described herein) are dispensed, that is, a temperature of a dispensing head in the AM system and/or a temperature at which the modeling material formulation is maintained prior to passing in the dispensing head.

In some of any of the embodiments described herein, the AM process is performed without cooling the AM system (e.g., without cooling the dispensing heads and/or a modeling material formulation), to a temperature below room temperature, e.g., a temperature lower than 20 °C or lower than 10 °C, or lower than 5 °C (e.g., 4 °C).

5 In some of any of the embodiments described herein, the AM system is devoid of means for cooling the system or a part thereof (e.g., means for cooling the dispensing heads and/or the modeling material formulation), to a temperature below room temperature, e.g., a temperature lower than 20 °C or lower than 10 °C, or lower than 5 °C (e.g., 4 °C).

10 In some of any of the embodiments described herein, the additive manufacturing process (bioprinting) is performed while applying a shear force that does adversely affect structural and/or functional properties of biological components (e.g., cells). Applying the shear force can be effected by passing the building material (e.g., at least a modeling material formulation that comprises a biological component as described herein) through the dispensing head, and is to be regarded also as subjecting the building material to shear force.

15 As discussed herein and demonstrated in the Examples section that follow, embodiments of the present invention allow to perform AM bioprinting processes under conditions that do not affect the functional and/or structural features of biological components included in the bio-ink (e.g., at low shear force and room temperature or a physiological temperature), while maintaining the required fluidity (a viscosity that imparts fluidity, e.g., lower than 10,000 centipoises or lower than 5,000 centipoises, or lower than 2,000 centipoises), and while further maintaining the curability of the dispensed building material. The embodiments of the present invention allow a successful operation of bioprinting using any of the known methodology, without being limited to the process parameters required for each such methodology.

25 The following describes exemplary AM bioprinting methodologies that are usable in the context of embodiments of the present invention.

30 A bioprinting method and a corresponding system can be any of the methods and systems known in the art for performing additive manufacturing, and exemplary such systems and methods are described hereinabove. A suitable method and system can be selected upon considering its printing capabilities, which include resolution, deposition speed, scalability, bio-ink compatibility and ease-of-use.

Exemplary suitable bioprinting systems usually contain a dispensing system (either equipped with temperature control module or at ambient temperature), and stage (a receiving medium), and a movement along the x, y and z axes directed by a CAD-CAM software. A curing source (e.g., a light or heat source) which applies a curing energy (e.g., by applying light or heat

radiation) or a curing condition to the deposition area (the receiving medium) so as to promote curing of the formed layers and/or a humidifier, can also be included in the system. There are printers that use multiple dispensing heads to facilitate a serial dispensing of several materials.

Generally, bioprinting can be effected using any of the known techniques for additive 5 manufacturing. The following lists some exemplary additive manufacturing techniques, although any other technique is contemplated.

3D Inkjet printing:

3D Inkjet printing is a common type of 3D printer for both non-biological and biological 10 (bioprinting) applications. Inkjet printers use thermal or acoustic forces to eject drops of liquid onto a substrate, which can support or form part of the final construct. In this technique, controlled volumes of liquid are delivered to predefined locations, and a high-resolution printing with precise control of (1) ink drops position, and (2) ink volume, which is beneficial in cases of 15 microstructure-printing or when small amounts of bioreactive agents or drugs are added, is received. Inkjet printers can be used with several types of ink, for example, comprising multiple types of biological components and/or bioactive agents. Furthermore, the printing is fast and can 20 be applied onto culture plates.

A bioprinting method that utilizes a 3D inkjet printing system can be operated using one or more bio-ink modeling material formulations as described herein, and dispensing droplets of the formulation(s) in layers, on the receiving medium, using one or more inkjet printing head(s), 20 according to the 3D printing data.

Extrusion printing:

This technique uses continuous beads of material rather than liquid droplets. These beads of material are deposited in 2D, the stage (receiving medium) or extrusion head moves along the z axis, and the deposited layer serves as the basis for the next layer. The most common methods 25 for biological materials extrusion for 3D bioprinting applications are pneumatic or mechanical dispensing systems.

Stereolithography (SLA) and Digital Light Processing (DLP):

SLA and DLP are additive manufacturing technologies in which an uncured building 30 material in a bath is converted into hardened material(s), layer by layer, by selective curing using a light source while the uncured material is later separated/washed from the hardened material. SLA is widely used to create models, prototypes, patterns, and production parts for a range of industries including for Bioprinting.

Laser-assisted printing:

5 Laser-assisted printing technique, in the version adopted for 3D bioprinting, and is based on the principle of laser-induced forward transfer (LIFT), which was developed to transfer metals and is now successfully applied to biological material. The device consists of a laser beam, a focusing system, an energy absorbing /converting layer and a biological material layer (e.g., cells and/or hydrogel) and a receiving substrate. A laser assisted printer operates by shooting a laser beam onto the absorbing layer which convert the energy into a mechanical force which drives tiny drops from the biological layer onto the substrate. A light source is then utilized to cure the material on the substrate.

10 Laser assisted printing is compatible with a series of viscosities and can print mammalian cells without affecting cell viability or cell function. Cells can be deposited at a density of up to 10^8 cells/ml with microscale resolution of a single cell per drop.

Electrospinning:

15 Electrospinning is a fiber production technique, which uses electric force to draw charged threads of polymer solutions, or polymer melts.

Recombinant human collagen:

20 The term "collagen" as used herein, refers to a polypeptide having a triple helix structure and containing a repeating Gly-X-Y triplet, where X and Y can be any amino acid but are frequently the imino acids proline and hydroxyproline. According to one embodiment, the collagen is a type I, II, III, V, XI, or biologically active fragments therefrom.

25 A collagen of the present invention also refers to homologs (e.g., polypeptides which are at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, at least 85 %, at least 87 %, at least 89 %, at least 91 %, at least 93 %, at least 95 % or more say 100 % homologous to collagen sequences listed in Table A as determined using BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters). The homolog may also refer to a deletion, insertion, or substitution variant, including an amino acid substitution, thereof and biologically active polypeptide fragments thereof.

30 According to a particular embodiment, the collagen is a human collagen.

35 In another embodiment, the collagen comprises a naturally occurring amino acid sequence of human collagen.

Table A below lists examples of collagen NCBI sequence numbers.

23
Table A

<i>Exemplary procollagen NCBI sequence number</i>	<i>SEQ ID NO:</i>
P02452	1
P08123	2

The annotation of SEQ ID NO: 1 is as follows:

Amino acids 1-22 - signal peptide;

5 Amino acids 23-161 - N-terminal peptide;

Amino acids 162-1218 - collagen alpha-1(I) chain;

Amino acids 1219-1464 - C-terminal peptide;

The annotation of SEQ ID NO: 2 is as follows:

Amino acids 1-22 - signal peptide;

10 Amino acids 23-79 - N-terminal peptide;

Amino acids 80-1119 - collagen alpha-2(I) chain;

Amino acids 1120-1366 - C-terminal peptide.

According to one embodiment, the collagen of the present invention comprises a sufficient portion of its telopeptides such that under suitable conditions it is capable of forming 15 fibrils.

Thus, for example, the collagen may be atelocollagen, a telocollagen or procollagen.

As used herein, the term "atelocollagen" refers to collagen molecules lacking both the N- and C-terminal propeptides typically comprised in procollagen and at least a portion of its 20 telopeptides, but including a sufficient portion of its telopeptides such that under suitable conditions it is capable of forming fibrils.

The term "procollagen" as used herein, refers to a collagen molecule (e.g. human) that comprises either an N-terminal propeptide, a C-terminal propeptide or both. Exemplary human procollagen amino acid sequences are set forth by SEQ ID NOs: 3, 4, 5 and 6.

The term "telocollagen" as used herein, refers to collagen molecules that lack both the N- and C-terminal propeptides typically comprised in procollagen but still contain the telopeptides. The telopeptides of fibrillar collagen are the remnants of the N-and C-terminal propeptides following digestion with native N/C proteinases.

According to another embodiment, the collagen is devoid of its telopeptides and is not capable of undergoing fibrillogenesis.

According to another embodiment, the collagen is a mixture of the types of collagen above.

According to a particular embodiment, the collagen is genetically engineered using recombinant DNA technology (e.g. human collagen).

5 Methods of isolating collagen from animals are known in the art. Dispersal and solubilization of native animal collagen can be achieved using various proteolytic enzymes (such as porcine mucosal pepsin, bromelain, chymopapain, chymotrypsin, collagenase, ficin, papain, peptidase, proteinase A, proteinase K, trypsin, microbial proteases, and, similar enzymes or combinations of such enzymes) which disrupt the intermolecular bonds and remove the
10 immunogenic non-helical telopeptides without affecting the basic, rigid triple-helical structure which imparts the desired characteristics of collagen (see U.S. Pat. Nos. 3,934,852; 3,121,049; 3,131,130; 3,314,861; 3,530,037; 3,949,073; 4,233,360 and 4,488,911 for general methods for preparing purified soluble collagen). The resulting soluble collagen can be subsequently purified by repeated precipitation at low pH and high ionic strength, followed by washing and re-
15 solubilization at low pH.

Plants expressing collagen chains and procollagen are known in the art, see for example, WO06035442A3; Merle et al., FEBS Lett. 2002 Mar 27;515(1-3):114-8. PMID: 11943205; and Ruggiero et al., 2000, FEBS Lett. 2000 Mar 3;469(1):132-6. PMID: 10708770; and U.S. Patent Applications Publication Nos. 2002/098578 and 2002/0142391, as well as U.S. Patent Nos. 20 6,617,431 each of which are incorporated herein by reference.

It will be appreciated that the present invention also contemplates genetically modified forms of collagen/atelocollagen – for example collagenase-resistant collagens and the like [Wu et al., Proc Natl. Acad Sci, Vol. 87, p.5888-5892, 1990].

25 Recombinant procollagen or telocollagen (e.g. human) may be expressed in any non-animal cell, including but not limited to plant cells and other eukaryotic cells such as yeast and fungus.

Plants in which procollagen or telocollagen may be produced (i.e. expressed) may be of lower (e.g. moss and algae) or higher (vascular) plant species, including tissues or isolated cells and extracts thereof (e.g. cell suspensions). Preferred plants are those which are capable of 30 accumulating large amounts of collagen chains, collagen and/or the processing enzymes described herein below. Such plants may also be selected according to their resistance to stress conditions and the ease at which expressed components or assembled collagen can be extracted. Examples of plants in which human procollagen may be expressed include, but are not limited to tobacco, maize, alfalfa, rice, potato, soybean, tomato, wheat, barley, canola, carrot, lettuce and

cotton.

Production of recombinant procollagen is typically effected by stable or transient transformation with an exogenous polynucleotide sequence encoding human procollagen.

Exemplary polynucleotide sequences encoding human procollagen are set forth by SEQ

5 ID NOS: 7, 8, 9 and 10.

Production of human telocollagen is typically effected by stable or transient transformation with an exogenous polynucleotide sequence encoding human procollagen and at least one exogenous polynucleotide sequence encoding the relevant protease. Alternatively, a protease may be added following isolation of the recombinant procollagen.

10 The stability of the triple-helical structure of collagen requires the hydroxylation of prolines by the enzyme prolyl-4-hydroxylase (P4H) to form residues of hydroxyproline within the collagen chain. Although plants are capable of synthesizing hydroxyproline-containing proteins, the prolyl hydroxylase that is responsible for synthesis of hydroxyproline in plant cells exhibits relatively loose substrate sequence specificity as compared with mammalian P4H. Thus, 15 production of collagen containing hydroxyproline only in the Y position of Gly –X–Y triplets requires co-expression of collagen and human or mammalian P4H genes [Olsen et al, *Adv Drug Deliv Rev.* 2003 Nov 28;55(12):1547-67].

Thus, according to one embodiment, the procollagen or telocollagen is expressed in a subcellular compartment of a plant that is devoid of endogenous P4H activity.

20 As used herein, the phrase "subcellular compartment devoid of endogenous P4H activity" refers to any compartmentalized region of the cell which does not include plant P4H or an enzyme having plant-like P4H activity. According to one embodiment, the subcellular compartment is a vacuole, an apoplast or a chloroplast. According to a particular embodiment, the subcellular compartment is a vacuole.

25 According to another embodiment, the subcellular compartment is an apoplast.

Accumulation of the expressed procollagen in a subcellular compartment devoid of endogenous P4H activity can be effected via any one of several approaches.

For example, the expressed procollagen/telocollagen can include a signal sequence for targeting the expressed protein to a subcellular compartment such as the apoplast or an organelle 30 (e.g. chloroplast).

Examples of suitable signal sequences include the chloroplast transit peptide (included in Swiss-Prot entry P07689, amino acids 1-57) and the Mitochondrion transit peptide (included in Swiss-Prot entry P46643, amino acids 1-28). Targeting to the vacuole may be achieved by fusing the polynucleotide sequence encoding the collagen to a vacuolar targeting sequence - for

example using the vacuolar targeting sequence of the thiol protease aleurain precursor (NCBI accession P05167 GI:113603):

MAHARVLLALAVLATAAVAVASSSSFADSNPIRPVTDRAASTLA (SEQ ID NO: 14).

Typically, the polynucleotide sequence encoding the collagen also comprises an ER targeting sequence. In one embodiment, the ER targeting sequence is native to the collagen sequence. In another embodiment, the native ER targeting sequence is removed and a non-native ER targeting sequence is added. The non-native ER targeting sequence may be comprised in the vacuolar targeting sequence. It will be appreciated, for it to traverse the ER and move on to the vacuole, the collagen sequence should be devoid of an ER retention sequence.

10 Alternatively, the sequence of the procollagen can be modified in a way which alters the cellular localization of the procollagen when expressed in plants.

15 The present invention contemplates genetically modified cells co-expressing both human procollagen and a P4H. In one embodiment, the P4H is capable of correctly hydroxylating the procollagen alpha chain(s) [i.e. hydroxylating only the proline (Y) position of the Gly -X-Y triplets]. P4H is an enzyme composed of two subunits, alpha and beta as set forth in Genbank Nos. P07237 and P13674. Both subunits are necessary to form an active enzyme, while the beta subunit also possesses a chaperon function.

20 The P4H expressed by the genetically modified cells of the present invention is preferably a human P4H. An exemplary polynucleotide sequence which encodes human P4H is SEQ ID Nos: 11 and 12. In addition, P4H mutants which exhibit enhanced substrate specificity, or P4H homologues can also be used. A suitable P4H homologue is exemplified by an Arabidopsis oxidoreductase identified by NCBI accession no: NP_179363.

25 Since it is essential that P4H co-accumulates with the expressed procollagen chain, the coding sequence thereof is preferably modified accordingly (e.g. by addition or deletion of signal sequences). Thus, the present invention contemplates using P4H polynucleotide sequences that are fused to vacuole targeting sequences. It will be appreciated that for targeting to the vacuole, when an endogenous ER retention sequence is present, it should be removed prior to expression.

30 In mammalian cells, collagen is also modified by Lysyl hydroxylase, galactosyltransferase and glucosyltransferase. These enzymes sequentially modify lysyl residues in specific positions to hydroxylysyl, galactosylhydroxylysyl and glucosylgalactosyl hydroxylysyl residues at specific positions. A single human enzyme, Lysyl hydroxylase 3 (LH3), as set forth in Genbank No. O60568, can catalyze all three consecutive modifying steps as seen in hydroxylysine-linked carbohydrate formation.

Thus, the genetically modified cells of the present invention may also express mammalian LH3 (optionally fused to vacuole targeting sequences). It will be appreciated that for targeting to the vacuole, the endogenous ER retention sequence is removed prior to expression.

5 An LH3 encoding sequence such as that set forth by SEQ ID NO: 13, can be used for such purposes.

The procollagen(s) and modifying enzymes described above can be expressed from a stably integrated or a transiently expressed nucleic acid construct which includes polynucleotide sequences encoding the procollagen alpha chains and/or modifying enzymes (e.g. P4H and LH3) 10 positioned under the transcriptional control of functional promoters. Such a nucleic acid construct (which is also termed herein as an expression construct) can be configured for expression throughout the whole organism (e.g. plant, defined tissues or defined cells), and/or at defined developmental stages of the organism. Such a construct may also include selection markers (e.g. antibiotic resistance), enhancer elements and an origin of replication for bacterial 15 replication.

There are various methods for introducing nucleic acid constructs into both monocotyledonous and dicotyledonous plants (Potrykus, I., *Annu. Rev. Plant. Physiol., Plant. Mol. Biol.* (1991) 42:205-225; Shimamoto et al., *Nature* (1989) 338:274-276). Such methods rely on either stable integration of the nucleic acid construct or a portion thereof into the genome 20 of the plant, or on transient expression of the nucleic acid construct, in which case these sequences are not inherited by the plant's progeny.

In addition, several methods exist in which a nucleic acid construct can be directly introduced into the DNA of a DNA-containing organelle such as a chloroplast.

There are two principle methods of effecting stable genomic integration of exogenous 25 sequences, such as those included within the nucleic acid constructs of the present invention, into plant genomes:

(i) Agrobacterium-mediated gene transfer: Klee et al. (1987) *Annu. Rev. Plant Physiol.* 38:467-486; Klee and Rogers in *Cell Culture and Somatic Cell Genetics of Plants*, Vol. 6, *Molecular Biology of Plant Nuclear Genes*, eds. Schell, J., and Vasil, L. K., Academic 30 Publishers, San Diego, Calif. (1989) p. 2-25; Gatenby, in *Plant Biotechnology*, eds. Kung, S. and Arntzen, C. J., Butterworth Publishers, Boston, Mass. (1989) p. 93-112.

(ii) Direct DNA uptake: Paszkowski et al., in *Cell Culture and Somatic Cell Genetics of Plants*, Vol. 6, *Molecular Biology of Plant Nuclear Genes* eds. Schell, J., and Vasil, L. K., Academic Publishers, San Diego, Calif. (1989) p. 52-68; including methods for direct uptake of

DNA into protoplasts, Toriyama, K. et al. (1988) *Bio/Technology* 6:1072-1074. DNA uptake induced by brief electric shock of plant cells: Zhang et al. *Plant Cell Rep.* (1988) 7:379-384. Fromm et al. *Nature* (1986) 319:791-793. DNA injection into plant cells or tissues by particle bombardment, Klein et al. *Bio/Technology* (1988) 6:559-563; McCabe et al. *Bio/Technology* 5 (1988) 6:923-926; Sanford, *Physiol. Plant.* (1990) 79:206-209; by the use of micropipette systems: Neuhaus et al., *Theor. Appl. Genet.* (1987) 75:30-36; Neuhaus and Spangenberg, *Physiol. Plant.* (1990) 79:213-217; or by the direct incubation of DNA with germinating pollen, DeWet et al. in *Experimental Manipulation of Ovule Tissue*, eds. Chapman, G. P. and Mantell, S. H. and Daniels, W. Longman, London, (1985) p. 197-209; and Ohta, *Proc. Natl. Acad. Sci. USA* (1986) 83:715-719.

There are various methods of direct DNA transfer into plant cells. In electroporation, protoplasts are briefly exposed to a strong electric field. In microinjection, the DNA is mechanically injected directly into the cells using very small micropipettes. In microparticle bombardment, the DNA is adsorbed on microprojectiles such as magnesium sulfate crystals, 15 tungsten particles or gold particles, and the microprojectiles are physically accelerated into cells or plant tissues.

Regardless of the transformation technique employed, once collagen-expressing progeny are identified, such plants are further cultivated under conditions which maximize expression thereof. Progeny resulting from transformed plants can be selected, by verifying presence of 20 exogenous mRNA and/or polypeptides by using nucleic acid or protein probes (e.g. antibodies). The latter approach enables localization of the expressed polypeptide components (by for example, probing fractionated plants extracts) and thus also verifies the plant's potential for correct processing and assembly of the foreign protein.

Following cultivation of such plants, the telopeptide-comprising collagen is typically 25 harvested. Plant tissues/cells are preferably harvested at maturity, and the procollagen molecules are isolated using extraction approaches. Preferably, the harvesting is effected such that the procollagen remains in a state that it can be cleaved by protease enzymes. According to one embodiment, a crude extract is generated from the transgenic plants of the present invention and subsequently contacted with the protease enzymes.

As mentioned, the propeptide or telopeptide-comprising collagen may be incubated with 30 a protease to generate atelocollagen or collagen prior to solubilization. It will be appreciated that the propeptide or telopeptide-comprising collagen may be purified from the genetically engineered cells prior to incubation with protease, or alternatively may be purified following incubation with the protease. Still alternatively, the propeptide or telopeptide-comprising

collagen may be partially purified prior to protease treatment and then fully purified following protease treatment. Yet alternatively, the propeptide or telopeptide-comprising collagen may be treated with protease concomitant with other extraction/purification procedures.

Exemplary methods of purifying or semi-purifying the telopeptide-comprising collagen 5 of the present invention include, but are not limited to salting out with ammonium sulfate or the like and/or removal of small molecules by ultrafiltration.

According to one embodiment, the protease used for cleaving the recombinant propeptide or telopeptide comprising collagen is not derived from an animal. Exemplary proteases include, but are not limited to certain plant derived proteases e.g. ficin (EC 3.4.22.3) and certain bacterial 10 derived proteases e.g. subtilisin (EC 3.4.21.62), neurase. The present inventors also contemplate the use of recombinant enzymes such as rhTrypsin and rhPepsin. Several such enzymes are commercially available e.g. Ficin from Fig tree latex (Sigma, catalog #F4125 and Europe Biochem), Subtilisin from *Bacillus licheniformis* (Sigma, catalog #P5459) Neutraser from bacterium *Bacillus amyloliquefaciens* (Novozymes, catalog # PW201041) and TrypZeanTM, a 15 recombinant human trypsin expressed in corn (Sigma catalog #T3449).

In some of any of the embodiments described herein, the recombinant human collagen is a recombinant human type I collagen.

In some of any of the embodiments described herein, the recombinant human collagen is a plant-derived recombinant human collagen and in some embodiments the plant is tobacco.

20 In some of any of the embodiments described herein, the recombinant human collagen is a recombinant human type I collagen comprising two $\alpha 1$ units having the amino acid sequence which is at least 90 % homologous, at least 91 % homologous, 92 % homologous, at least 93 % homologous, at least 94 % homologous, at least 95 % homologous, at least 96 % homologous, at least 97 % homologous, at least 98 % homologous, at least 99 % homologous or 100 % homologous to the sequence as set forth in SEQ ID NO:15 as determined using BlastP software 25 of the National Center of Biotechnology Information (NCBI) using default parameters), and one $\alpha 2$ unit having the amino acid sequence which is at least 90 % homologous, at least 91 % homologous, 92 % homologous, at least 93 % homologous, at least 94 % homologous, at least 95 % homologous, at least 96 % homologous, at least 97 % homologous, at least 98 % homologous, 30 at least 99 % homologous or 100 % homologous to the sequence as set forth in SEQ ID NO:6. According to a particular embodiment, the type I collagen consists of two $\alpha 1$ units which consists of the sequence as set forth in SEQ ID NO: 15 and one $\alpha 2$ unit consisting of the sequence as set forth in SEQ ID NO:6, as determined using BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters).

In some of any of the embodiments described herein, the $\alpha 1$ unit is encoded by a polynucleotide sequence being at least which is at least about 80 %, at least about 81 %, at least about 82 %, at least about 83 %, at least about 84 %, at least about 85 %, at least about 86 %, at least about 87 %, at least about 88 %, at least about 89 %, at least about 90 %, at least about 91 %, at least about 92 %, at least about 93 %, at least about 93 %, at least about 94 %, at least about 95 %, at least about 96 %, at least about 97 %, at least about 98 %, at least about 99 %, e.g., 100 % identical to the nucleic acid sequence as set forth in SEQ ID NO: 16. The $\alpha 2$ unit is encoded by a polynucleotide sequence being at least which is at least about 80 %, at least about 81 %, at least about 82 %, at least about 83 %, at least about 84 %, at least about 85 %, at least about 86 %, at least about 87 %, at least about 88 %, at least about 89 %, at least about 90 %, at least about 91 %, at least about 92 %, at least about 93 %, at least about 93 %, at least about 94 %, at least about 95 %, at least about 96 %, at least about 97 %, at least about 98 %, at least about 99 %, e.g., 100 % identical to the nucleic acid sequence as set forth in SEQ ID NO: 10.

Identity (e.g., percent homology) can be determined using any homology comparison software, including for example, the BlastN software of the National Center of Biotechnology Information (NCBI) such as by using default parameters.

In some of any of the embodiments described herein, the human recombinant collagen (rhCollagen) as described herein in any of the respective embodiments is a monomeric rhCollagen.

By “monomeric” it is meant a rhCollagen as described herein which is soluble in an aqueous solution and does not form fibrillar aggregates.

In some of any of the embodiments described herein, the human recombinant collagen (rhCollagen) as described herein in any of the respective embodiments is a fibrillar rhCollagen.

By “fibrillar” it is meant a rhCollagen as described herein which is in a form of fibrillar aggregates in an aqueous solution containing same. Typically, but not obligatory, fibrillar rhCollagen is formed by subjecting monomeric rhCollagen to a fibrillogenesis buffer, typically featuring a basic pH. An exemplary procedure for forming fibrillar rhCollagen, is described in the Examples section that follows.

Curable collagen:

According to an aspect of some embodiments of the present invention there is provided a composition that comprises a curable collagen. According to some embodiments, the composition is usable in additive manufacturing of a 3D object as described herein (e.g., in bioprinting). According to some embodiments, the composition is usable, or is for use, in the

preparation of a modeling material formulation for an additive manufacturing process (e.g., bioprinting).

By “curable” it is meant herein a material that is capable of undergoing curing, or hardening, as defined herein, when exposed to a suitable curing condition.

5 A curable material is typically hardened or cured by undergoing polymerization and/or cross-linking.

Curable materials are typically polymerizable materials, which undergo polymerization and/or cross-linking when exposed to a suitable curing condition or a suitable curing energy (a suitable energy source). Alternatively, curable materials are thermo-responsive materials, which 10 solidify or harden upon exposure to a temperature change (e.g., heating or cooling). Optionally, curable materials are made of small particles (e.g., nanoparticles or nanoclays) which can undergo curing to form a hardened material. Further optionally, curable materials are biological materials which undergo a reaction to form a hardened or solid material upon a biological reaction (e.g., an enzymatically-catalyzed reaction).

15 In some of any of the embodiments described herein, a curable material is a photopolymerizable material, which polymerizes and/or undergoes cross-linking upon exposure to radiation, as described herein, and in some embodiments the curable material is a UV-curable material, which polymerizes or undergoes cross-linking upon exposure to UV-vis radiation, as described herein.

20 In some of any of the embodiments described herein, when a curable material is exposed to a curing condition (e.g., radiation, reagent), it polymerizes by any one, or combination, of chain elongation, entanglement and cross-linking. The cross-linking can be chemical and/or physical.

25 In some of any of the embodiments described herein, a curable material can be a mono-functional curable material or a multi-functional curable material.

Herein, a mono-functional curable material comprises one curable group – a functional group that can undergo polymerization, entanglement and/or cross-linking when exposed to a curing condition (e.g., radiation, presence of calcium ions).

30 A multi-functional curable material comprises two or more, e.g., 2, 3, 4 or more, curable groups. Multi-functional curable materials can be, for example, di-functional, tri-functional or tetra-functional curable materials, which comprise 2, 3 or 4 curable groups, respectively.

By “curable collagen” it is meant a collagen as described herein in any of the respective embodiments (human recombinant collagen), which features one or more curable groups as defined herein. According to some of any of the embodiments described herein, the curable

collagen is a multi-functional curable material that comprises a plurality of curable groups, as defined herein.

The terms “curable collagen”, “curable rhCollagen” and “rhCollagen featuring one or more (or at least one) curable groups” are used herein interchangeably.

5 According to some of any of the embodiments described herein, the curable collagen comprises an amino acid sequence as described herein in any of the respective embodiments, and features one or more, preferably a plurality of, curable groups generated at at least a portion of the amino acid residues forming the collagen, preferably by covalent attachment of a compound that comprises a curable group to functional groups of the side chains of the amino acid residues.

10 Alternatively, or in addition, curable groups can be generated at the N-terminus and/or C-terminus of one or more the units forming the collagen, for example, by covalent attachment of compound that comprises a curable group to a respective amine or carboxylate.

15 According to some of any of the embodiments described herein, at least a portion of the curable groups in a curable collagen as described herein are cross-linkable groups, which undergo cross-linking when exposed to a curing condition.

In some embodiments, curable groups can undergo polymerization and/or cross-linking via free-radical mechanism.

20 Exemplary such curable groups include acrylic groups, including acrylate, methacrylate, acrylamide and methacrylamide groups. Other free-radical curable groups may include thiols, vinyl ethers and other groups that feature a reactive double bond.

In some embodiments, curable groups can undergo polymerization and/or cross-linking via other mechanisms, such as cationic polymerization, or (cationic or anionic) ring opening polymerization. Exemplary such curable groups include, but are not limited to, epoxy-containing groups, caprolactam, caprolactone, oxetane, and vinyl ether.

25 Other curable groups can include, for example, formation of amide bonds between functional carboxylate and amine group (each being a curable group that reacts with the other and can effect cross-linking); formation of urethane between isocyanate groups and hydroxyl groups via polycondensation in the presence of a catalyst and/or upon exposure to UV radiation; and formation of disulfide bonds between two thiols.

30 Any other curable groups are contemplated.

The curable groups in the curable collagen can be generated by means of chemical reactions between a material that comprises or can generate the curable group(s) when reacted with chemically-compatible functional groups present in the collagen, as described herein, either directly, or be means of a spacer or a linker, using chemistries well known in the art. For

example, a material that comprises a curable group and a functional group can be reacted with a compatible functional group in the collagen, for example, a functional group in an amino acid side chain, such that the curable group is a substituent of the amino acid side chain.

5 In some embodiments, a compatible functional group is first generated within the collagen by chemical modification of chemical groups of the collagen, and is then reacted with a material that comprises or generates a curable group upon the reaction.

Whenever a curable collagen comprises more than one curable group, the curable groups can be the same or different.

10 According to some of any of the embodiments described herein, at least a portion, or all, of the curable groups in a curable collagen of the present embodiments are photopolymerizable groups (e.g., UV-curable groups) that are capable of undergoing polymerization and/or cross-linking upon exposure to irradiation as described herein.

According to some of any of the embodiments described herein there the curable group is a photocurable or photopolymerizable group (e.g., an acrylate or methacrylate).

15 Alternatively, or in addition, the curable group is a thiol-containing group, which provides disulfide bridge upon curing.

Alternatively, or in addition, the curable group or moiety is cured upon undergoing a chemical reaction, such as glycation or conjugation (using coupling agents such as EDC).

20 According to some embodiments, the curable groups comprise an amine and a carboxyl group which form peptide bonds upon curing.

According to some of any of the embodiments described herein, at least a portion, or all, of the curable groups in a curable collagen of the present embodiments are acrylic groups, as defined herein.

25 According to some of any of the embodiments described herein, an acrylic group such as methacrylamide can be generated by reacting an acrylate or methacrylate (e.g., acrylic acid, methacrylic acid, acrylic or methacrylic ester, acrylic or methacrylic anhydride) with an amine functional group (of, for example, lysine residues).

According to some of any of the embodiments of the present invention, the number of the curable groups in a curable collagen as described herein can determine the degree of curing (e.g., 30 the degree of cross-linking) and can be manipulated in order to achieve a desired curing (e.g., cross-linking) degree.

According to some of any of the embodiments described herein, the curable collagen features a plurality of acrylamide or methacrylamide curable groups generated by reacting with lysine residues as described herein.

According to some of any of the embodiments described herein, the curable collagen features a plurality of acrylamide or methacrylamide curable groups substituting the amine groups of lysine residues in the collagen.

In some embodiments, at least 50 %, or at least 60 %, or at least 70 %, of the lysine residues in the collagen are substituted by a methacrylamide or acrylamide group. In some embodiments, the curable collagen features from 70 % to 100 %, or from 80 % to 100 %, or from 90 % to 100 %, of its lysine residues substituted by a methacrylamide or acrylamide group, including any intermediate values and subranges therebetween.

According to an aspect of some embodiments of the present invention there is provided a process of preparing a curable rhCollagen as described herein. The process is effected, in some embodiments, by reacting a material that comprises a curable group or which generates a curable group with the rhCollagen, in accordance with the embodiments described herein.

The number of curable groups in the rhCollagen can be controlled by manipulating the amount of the material reacted with the rhCollagen for generating the curable groups.

In some embodiments, the material is used in a molar excess with respect to the respective functional groups that are reacted therewith, for example, in a mol ratio of 2:1, 5:1, 10:1, 15:1, 20:1 30:1, 50:1, or, for example, from 1.1:1 to 50:1, including any intermediate values and subranges therebetween, with respect to the chemically compatible functional groups in the rhCollagen (e.g., the amino acid residues featuring such functional groups), or with respect to the rhCollagen.

According to some of any of the embodiments described herein, the curable collagen is a recombinant human type I collagen as described herein in any of the respective embodiments and any combination thereof.

Modeling material formulation(s):

According to the present embodiments described herein, in at least one of the layers formed during the AM (bioprinting process), the dispensed modeling material formulation comprises a biological component or material as described herein and is regarded as bio-ink, as described herein.

According to the present embodiments, the building material comprises at least one modeling material formulation that comprises a curable recombinant human collagen, as described herein in any of the respective embodiments. Such a modeling material formulation is also referred to herein as rhCollagen-containing formulation.

According to some of any of the embodiments described herein, the rhCollagen-containing formulation further comprises a carrier, and in some of these embodiments, the carrier is an aqueous carrier.

The aqueous carrier can be water, a buffer featuring pH in a range of from about 4 to 5 about 10, or from about 6 to about 8, or from about 7 to about 7.4, a basic aqueous solution or an acidic aqueous solution.

The aqueous carrier can comprise salts and other water-soluble materials at varying concentrations. In some embodiments, a concentration of a salt in the carrier ranges from about 0.1 mM to about 0.2 M, or from about 0.1 mM to about 0.1 M, or from about 0.1 mM to about 10 100 mM, or from about 0.1 mM to about 50 mM, or from about 0.1 mM to about 20 mM, including an intermediate values and subranges therebetween.

In some embodiments, the aqueous carrier comprises salts at physiologically acceptable concentrations, such that the formulation features osmolarity around a physiological osmolarity.

In some embodiments the aqueous carrier comprises a phosphate salt, for example, a 15 sodium phosphate monobasic (NaH_2PO_4) and/or a sodium phosphate dibasic (sodium hydrogen phosphate; Na_2HPO_4). In some embodiments, the total concentration of the phosphate salt(s) is about 0.1 M.

In some embodiments, the aqueous carrier comprises NaCl or any other physiologically acceptable salt.

20 In some embodiments, the aqueous carrier comprises a phosphate buffer and in some embodiments, the aqueous carrier comprises a phosphate buffer saline, which comprises sodium phosphate monobasic and/or sodium phosphate dibasic and NaCl .

The phosphate buffer saline (PBS) can be a commercially available PBS (e.g., DPBS) or a custom-made buffer featuring a desirable pH and/or osmolarity.

25 In exemplary embodiments, the aqueous carrier comprises a phosphate buffer that comprises a phosphate sodium salt as described herein at a concentration of about 0.1M and NaCl at a concentration of from about 0 mM to about 200 mM, including any intermediate value and subranges therebetween.

Any other buffers are also usable in the context of the present embodiments.

30 In some of any of the embodiments described herein, the aqueous carrier comprises an acid.

In some embodiments, a concentration of the acid is lower than 100 mM, and can be, for example, of from 0.1 mM to 50 mM, or from 0.1 mM to 30 mM, or from 0.1 mM to 40 mM, or

from 0.1 mM to 30 mM, or from 1 to 30 mM, or from 10 to 30 Mm, including any intermediate values and subranges therebetween.

The acid can be an inorganic acid (e.g., HCl) or an organic acid, preferably which is water soluble at the above-indicated concentrations (e.g., acetic acid).

5 In some of any of the embodiments described herein, the aqueous carrier comprises a culturing medium. The culturing medium can be a commercially available culturing medium or a custom-made culturing medium. The culture medium can be any liquid medium which allows at least cell survival. Such a culture medium can include, for example, salts, sugars, amino acids and minerals in the appropriate concentrations and with various additives and those of skills in 10 the art are capable of determining a suitable culture medium to specific cell types. Non-limiting examples of such culture medium include, phosphate buffered saline, DMEM, MEM, RPMI 1640, McCoy's 5A medium, medium 199 and IMDM (available e.g., from Biological Industries, Beth Ha'emek, Israel; Gibco-Invitrogen Corporation products, Grand Island, NY, USA).

15 The culture medium may be supplemented with various antibiotics (e.g., Penicillin and Streptomycin), growth factors or hormones, specific amino acids (e.g., L-glutamin) cytokines and the like.

20 In some of any of the embodiments described herein, a concentration of the curable recombinant human collagen in the modeling material formulation containing same ranges from 0.5 mg/mL to 50 mg/mL, or from 0.5 mg/mL to 20 mg/mL, or from 1 mg/mL to 50 mg/mL, or from 1 mg/mL to 50 mg/mL, or from 1 mg/mL to 40 mg/mL, or from 1 mg/mL to 30 mg/mL, or 25 from 2 mg/mL to 20 mg/mL, or from 5 mg/mL to 15 mg/mL, including any intermediate values and subranges therebetween.

25 A concentration of the curable rhCollagen in a modeling material formulation containing same can affect the rheological properties of the formulation and of the hardened formulation obtained upon dispensing, and can be manipulated in accordance with AM methodology and conditions employed and desired properties of the final object or a portion thereof.

According to some of any of the embodiments described herein, the modeling material formulation features a shear-thinning behavior and is a shear-thinning formulation.

30 According to some of any of the embodiments described herein, the modeling material formulation features a thermal-thinning behavior and a thermal-thinning formulation.

The term "shear-thinning" describes a property of a fluidic material that is reflected by a decrease in its viscosity (increase in its fluidity) upon application of shear forces (under shear strain). In some of the present embodiments, a shear-thinning material is such that exhibits a significant, e.g., at least 100 %, reduction in its shear modulus upon increasing the shear strain

from about 1% to above 50 %. Shear-thinning materials therefore exhibit a shear-dependent viscosity profile.

The term “thermal-thinning” describes a property of a fluidic material that is reflected by a decrease in its viscosity (increase in its fluidity) upon application of heat energy (increase in temperature). In some of the present embodiments, thermal-thinning materials feature a decrease in viscosity by at least 10 % upon a temperature increase of 5 °C. Thermal-thinning materials therefore exhibit a temperature-dependent viscosity profile.

According to some of any of the embodiments described herein, the rhCollagen-containing formulation is both shear-thinning and thermal-thinning formulation, as defined herein.

According to some of any of the embodiments described herein, the modeling material formulation features a viscosity of no more than 2,000 centipoises, or no more than 1,500 centipoises, at a zero shear rate, at 37 °C, when determined using a rheometer as described in the Examples section that follows.

According to some of any of the embodiments described herein, the modeling material formulation features a viscosity of no more than 2000 centipoises, or no more than 1,500 centipoises, at a shear rate of 5 1/sec, at room temperature, when determined using a rheometer as described in the Examples section that follows.

According to some of any of the embodiments described herein, the modeling material formulation features the above-indicated viscosity values when a concentration of the curable collagen is at least 3 mg/mL, or at least 5 mg/mL, for example, is 10 mg/mL.

According to some of any of the embodiments described herein, the modeling material formulation features a viscosity profile at 37 °C which is similar to its viscosity profile at 4 °C.

According to some of any of the embodiments described herein, the modeling material formulation features a viscosity at 37 °C which is lower by at least 10 %, or at least 20 %, than its viscosity at 4 °C, when measured at a shear rate of from 1 to 10 [1/sec], for the same concentration of the curable rhCollagen.

According to some of any of the embodiments described herein, the modeling material formulation features, when hardened, storage modulus (G') of at least 1,000 Pa.

According to some of any of the embodiments described herein, the modeling material features, when hardened (e.g., when exposed a curing condition as described herein in any of the respective embodiments), an increase of at least 10-folds of its storage modulus (G').

According to some of any of the embodiments described herein, the modeling material formulation provides, when hardened, a hydrogel material, formed upon cross-linking of the rhCollagen within the aqueous carrier.

Herein and in the art, the term “hydrogel” describes a three-dimensional fibrous network containing at least 20 %, typically at least 50 %, or at least 80 %, and up to about 99.99 % (by mass) water. A hydrogel can be regarded as a material which is mostly water, yet behaves like a solid or semi-solid due to a three-dimensional crosslinked solid-like network, made of polymeric chains (e.g., collagen chains), within the liquid dispersing medium. The polymeric chains are inter-connected (crosslinked) by chemical bonds (covalent, hydrogen and ionic/complex/metallic bonds, typically covalent bonds).

Herein throughout, whenever polymeric chains or a polymeric material is described, it encompasses polymeric biological materials (e.g., macromolecules) such as peptides, proteins, oligonucleotides and nucleic acids.

Hydrogels may take a physical form that ranges from soft, brittle and weak to hard, elastic and tough material. Soft hydrogels may be characterized by rheological parameters including elastic and viscoelastic parameters, while hard hydrogels are suitably characterized by tensile strength parameters, elastic, storage and loss moduli, as these terms are known in the art.

The softness/hardness of a hydrogel is governed *inter alia* by the chemical composition of the polymer chains, the “degree of cross-linking” (number of interconnected links between the chains), the aqueous media content and composition, and temperature.

A hydrogel, according to some embodiments of the present invention, may contain macromolecular polymeric and/or fibrous elements which are not chemically connected to the main crosslinked network but are rather mechanically intertwined therewith and/or immersed therein. Such macromolecular fibrous elements can be woven (as in, for example, a mesh structure), or non-woven, and can, in some embodiments, serve as reinforcing materials of the hydrogel’s fibrous network. Non-limiting examples of such macromolecules include polycaprolactone, gelatin, gelatin methacrylate, alginate, alginate methacrylate, chitosan, chitosan methacrylate, glycol chitosan, glycol chitosan methacrylate, hyaluronic acid (HA), HA methacrylate, and other non-crosslinked natural or synthetic polymeric chains and the likes. Alternatively, or in addition, such macromolecules are chemically connected to the main crosslinked network of the hydrogel, for example, by acting as a cross-linking agent, or by otherwise forming a part of the three-dimensional network of the hydrogel.

In some embodiments, the hydrogel is porous and in some embodiments, at least a portion of the pores in the hydrogel are nanopores, having an average volume at the nanoscale range.

According to some of any of the embodiments described herein, the rhCollagen-containing modeling material formulation further comprises one or more additional materials,

including, for example, one or more additional curable materials, one or more non-curable materials and/or one or more biological components or materials.

According to some of any of the embodiments described herein, the printing media (the building material) comprises one or more additional materials, including, for example, one or 5 more additional curable materials, one or more non-curable materials and/or one or more biological components.

According to some of any of the embodiments described herein, the additional materials are included in the rhCollagen-containing formulation or in one or more other modeling material formulations.

10 Additional curable materials that can be included in the rhCollagen formulation or in one or more other modeling material formulations can be any curable material as defined herein, and is preferably a biocompatible material.

15 In some embodiments the additional curable material is or comprises a hydrogel, as defined herein, which can form a hardened modeling material, typically upon further cross-linking and/or co-polymerization, when exposed to a curing condition at which the cross-linking and/or co-polymerization reaction occurs. Such curable materials are also referred to herein as hydrogel curable materials.

20 In some of any of the embodiments described herein, a curable material is or comprises a hydrogel forming material, as defined herein, which can form a hydrogel as a hardened modeling material, typically upon cross-linking, entanglement, polymerization and/or co-polymerization, when exposed to a curing condition at which the cross-linking, polymerization and/or co-polymerization, and/or entanglement reaction occurs. Such curable materials are also referred to herein as hydrogel-forming curable materials or as gel-forming materials.

25 The hydrogel, according to embodiments of the present invention, can be of biological origin or synthetically prepared.

According to some embodiments of the present invention, the hydrogel is biocompatible, and is such that when a biological moiety is impregnated or accumulated therein, an activity of the biological moiety is maintained, that is, a change in an activity of the biological moiety is no more than 30 %, or no more than 20 %, or no more than 10 %, compared to an activity of the 30 biological moiety in a physiological medium.

Exemplary polymers or co-polymers usable for forming a hydrogel according to the present embodiments include polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polyvinylpyrrolidone and copolymers of any of the foregoing. Other

examples include polyethers, polyurethanes, and poly(ethylene glycol), functionalized by cross-linking groups or usable in combination with compatible cross linking agents.

Some specific, non-limiting examples, include: poly(2-vinylpiridine), poly(acrylic acid), poly(methacrylic acid), poly(N-isopropylacrylamide), poly(N,N'-methylenbisacrylamide), 5 poly(N-(N-propyl)acrylamide), poly(methacyclic acid), poly(2-hydroxyacrylamide), poly(ethylene glycol) acrylate, poly(ethylene glycol) methacrylate, and polysaccharides such as hyaluronic acid, dextran, alginate, agarose, and the like, and any co-polymer of the foregoing.

Hydrogel precursors (hydrogel-forming materials) forming such polymeric chains are contemplated, including any combination thereof.

10 Hydrogels are typically formed of, or are formed in the presence of, di- or tri- or multi-functional monomers, oligomer or polymers, which are collectively referred to as hydrogel precursors or hydrogel-forming agents or hydrogen-forming materials, having two, three or more polymerizable groups. The presence of more than one polymerizable group renders such precursors cross-linkable, and allow the formation of the three-dimensional network.

15 Exemplary cross-linkable monomers include, without limitation, the family of di- and triacrylates monomers, which have two or three polymerizable functionalities, one of which can be regarded as a cross-linkable functional group. Exemplary diacrylates monomers include, without limitation, methylene diacrylate, and the family of poly(ethylene glycol)_n dimethacrylate (nEGDMA). Exemplary triacrylates monomers include, without limitation, trimethylolpropane 20 triacrylate, pentaerythritol triacrylate, tris (2-hydroxy ethyl) isocyanurate triacrylate, isocyanuric acid tris(2-acryloyloxyethyl) ester, ethoxylated trimethylolpropane triacrylate, pentaerythritol triacrylate and glycerol triacrylate, phosphinylidynetris(oxyethylene) triacrylate.

25 In some of any of the embodiments described herein, a curable material, whether monomeric or oligomeric, can be a mono-functional curable material or a multi-functional curable material.

Exemplary polymers or co-polymers usable for forming a hydrogel according to the present embodiments include polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polyvinylpyrrolidone and copolymers of any of the foregoing. Other examples include polyethers, polyurethanes, and poly(ethylene glycol), functionalized by cross-linking groups or usable in combination with compatible cross linking agents. 30

Some specific, non-limiting examples, include: poly(2-vinylpiridine), poly(acrylic acid), poly(methacrylic acid), poly(N-isopropylacrylamide), poly(N,N'-methylenbisacrylamide), poly(N-(N-propyl)acrylamide), poly(methacyclic acid), poly(2-hydroxyacrylamide), poly

(ethylene glycol) acrylate, poly (ethylene glycol) methacrylate, and polysaccharides such as dextran, alginate, agarose, and the like, and any co-polymer of the foregoing.

Hydrogel precursors (hydrogel-forming materials) forming such polymeric chains are contemplated, including any combination thereof.

5 Curable materials usable in the field of bioprinting are predominantly based on either naturally derived materials, including, for example, Matrigel, Alginate, Pectin, Xanthan gum, Gelatin, Chitosan, Fibrin, Cellulose and Hyaluronic acid, which can be isolated from animal or human tissues, or recombinantly-generated, or synthetically-prepared materials, including, for example, polyethyleneglycol; PEG, gelatin methacrylate; GelMA, poly(propylene oxide); PPO, 10 poly(ethylene oxide); PEO; PEG, polyethyleneglycol-diacrylate, polyglutamic acid, gelatin methacrylate; GelMA, PLGA/PLLA, poly(dimethyl siloxane); Nanocellulose; Pluronic F127, short di-peptides (FF), Fmoc-peptide-based hydrogels such as Fmoc-FF-OH, Fmoc-FRGD-OH, Fmoc-RGDF-OH, Fmoc-2-Nal-OH, Fmoc-FG-OH, and thermoplastic polymers such as Polycaprolactone (PCL), Polylactic acid (PLA) or Poly(D,L-lactide-co-glycolide).

15 Exemplary curable materials usable in the context of the present embodiments include, but are not limited to, Matrigel, Gelatin methacrylate (GelMA), Nanocellulose (nano-scaled structured materials which are UV-curable, including cellulose nanocrystals (CNC), cellulose nanofibrils (CNF), and bacterial cellulose (BC), also referred to as microbial cellulose), Pluronic® materials, including, for example, Pluronic F127 which is fluid at a low temperature 20 forms a gel at a high temperature, above critical micellar concentration (CMC) and Pluronic F127-diacrylate (DA) which is UV-curable, Hyaluronic acid (HA), Acrylated hyaluronic acid (AHA), methacrylated hyaluronic acid (MAHA), Poly-(ethylene glycol) diacrylate (PEGDA), Alginate, Xanthan gum, Pectin, Chitosan which can be crosslinked with a chemical agent such as Glutaraldehyde, Genipin or Sodium Tripolyphosphate (TPP).

25 Exemplary curable materials are described in the Examples section that follows.

Biological components or materials that can be included in one or more modeling material formulations as described herein include, cellular components, including, for example, culturing cells, and other cellular components such as cytokines, chemokines, growth factors; as well as other biological components such as proteins, agents that act to increase cell attachment, 30 cell spreading, cell proliferation, cell differentiation and/or cell migration; an amino acid, peptides, polypeptides, proteins, DNA, RNA, lipids and/or proteoglycans.

Cells may comprise a heterogeneous population of cells or alternatively the cells may comprise a homogeneous population of cells. Such cells can be for example stem cells (such as embryonic stem cells, bone marrow stem cells, cord blood cells, mesenchymal stem cells, adult

tissue stem cells), progenitor cells, or differentiated cells such as chondrocytes, osteoblasts, connective tissue cells (e.g., fibrocytes, fibroblasts and adipose cells), endothelial and epithelial cells. The cells may be naïve or genetically modified.

According to one embodiment of this aspect of the present invention, the cells are 5 mammalian in origin.

Furthermore, the cells may be of autologous origin or non-autologous origin, such as postpartum-derived cells (as described in U.S. Application Nos. 10/887,012 and 10/887,446). Typically the cells are selected according to the desired application.

Suitable proteins which can be used include, but are not limited to, extracellular matrix 10 proteins [e.g., fibrinogen, collagen, fibronectin, vimentin, microtubule-associated protein 1D, Neurite outgrowth factor (NOF), bacterial cellulose (BC), laminin and gelatin], cell adhesion proteins [e.g., integrin, proteoglycan, glycosaminoglycan, laminin, intercellular adhesion molecule (ICAM) 1, N-CAM, cadherin, tenascin, gicerin, RGD peptide and nerve injury induced protein 2 (ninjurin2)], growth factors [epidermal growth factor, transforming growth factor- α , 15 fibroblast growth factor-acidic, bone morphogenic protein, fibroblast growth factor-basic, erythropoietin, thrombopoietin, hepatocyte growth factor, insulin-like growth factor-I, insulin-like growth factor-II, Interferon- β , platelet-derived growth factor, Vascular Endothelial Growth Factor and angiopeptin], cytokines [e.g., M-CSF, IL-1 β , IL-8, beta-thromboglobulin, EMAP-II, G-CSF and IL-10], proteases [pepsin, low specificity chymotrypsin, high specificity 20 chymotrypsin, trypsin, carboxypeptidases, aminopeptidases, proline-endopeptidase, Staphylococcus aureus V8 protease, Proteinase K (PK), aspartic protease, serine proteases, metalloproteases, ADAMTS17, tryptase-gamma, and matriptase-2] and protease substrates.

In addition, calcium phosphate materials, such as hydroxyapatite, for example, in a form 25 of particles, can be used, including, but not limited to, nanoHA and nanoTCP. The particles size should be compatible with the dispensing heads so as to avoid clogging.

Non-curable materials, other than the biological materials as described herein, that can be included in one or more modeling formulations as described herein can be materials that impart a certain property to the formulation or to the hardened formulation and to the part of the object 30 formed thereby. Such a property can be a physical property (e.g., an optical property such as transparency or opacity, color, a spectral property, heat resistance, electrical property and the like), or a mechanical or rheological property such as viscosity, elasticity, storage modulus, loss modulus, stiffness, hardness, and the like. Alternatively, or in addition, non-curable materials can be such that provide a biological function, for example, therapeutically active agents.

Exemplary non-curable materials include thixotropic agents, reinforcing agents, toughening agents, fillers, colorants, pigments, etc.

An exemplary non-curable material includes titanium dioxide.

An exemplary non-curable material includes oxidized cellulose.

5 According to some of any of the embodiments described herein, one or more of the modeling material formulations comprises hyaluronic acid.

According to some of any of the embodiments described herein, one or more of the modeling material formulations comprises hyaluronic acid featuring a curable group as defined herein.

10 According to some of any of the embodiments described herein, one or more of the modeling material formulations comprises one or more biological components or materials such as, but not limited to, cells, growth factors, peptides, heparan sulfate and fibronectin.

15 According to some of any of the embodiments described herein, one or more of the modeling material formulations comprises one or more agents that modify a mechanical property of the formulation and/or the object, as described herein, such as, but not limited to, alginate, hyaluronic acid, fibrinogen, elastin, peptides and a thixotropic agent (e.g., Crystalline nano cellulose (CNC)), oxidized cellulose, titanium dioxide, Clay mineral and carbon nanotubes.

20 In some of any of the embodiments described herein the rhCollagen-containing formulation further comprises one or more additional curable materials as described herein in any of the respective embodiments.

In some of these embodiments, a weight ratio of the curable recombinant human collagen and the additional curable material ranges from 10:1 to 1:2, or from 10:1 to 1:1, or from 5:1 to 2:1, including any intermediate value and subranges therebetween.

25 In some of any of the embodiments described herein the rhCollagen-containing formulation further comprises a thixotropic agent, as defined herein.

30 Herein throughout, the term “thixotropic” describes a property of a fluidic compound or material that is reflected by a time-dependent shear-thinning, that is its viscosity is decreased in correlation with the time at which shear forces are applied, and returns back to its original value when application of shear forces is ceased. In some of the present embodiments, a thixotropic material or agent is such that exhibits or imparts a significant, e.g., at least 100 %, reduction in shear modulus under 50 % strain.

In some of any of the embodiments described herein the rhCollagen-containing formulation further comprises a gel-forming agent, for example, a hydrogel-forming agent as described herein.

In some of any of the embodiments described herein the rhCollagen-containing formulation further comprises a biological component or material as described herein.

In some of any of the embodiments described herein the rhCollagen-containing formulation further comprises one or more curable or non-curable materials as described herein 5 in any of the respective embodiments.

According to some of any of the embodiments described herein the recombinant human collagen is selected from a monomeric collagen and a fibrillar collagen, as exemplified in the Examples section that follows.

According to some of any of the embodiments described herein, the mol ratio of the 10 curable group(s) and the collagen is essentially as exemplified in the Examples section herein.

According to some of any of the embodiments described herein the formulation further comprises hyaluronic acid, as described herein.

According to some of any of the embodiments described herein the formulation further comprises hyaluronic acid featuring a polymerizable group.

15 According to some of any of the embodiments described herein the formulation further comprises one or more biological components such as, but not limited to, a component selected from cells, growth factors, peptides, heparan sulfate and fibronectin.

According to some of any of the embodiments described herein the formulation further 20 comprises one or more agents that modify a mechanical property of the formulation and/or the object, such as, but not limited to, alginate, hyaluronic acid, fibrinogen, elastin, peptides and a thixotropic agent (e.g., Crystalline nano cellulose (CNC)).

According to some of any of the embodiments described herein the formulation features a neutral pH (e.g., from about 6 to about 8).

25 According to some of any of the embodiments described herein the formulation features viscosity parameters essentially as described herein.

According to some of any of the embodiments described herein the formulation features approximately the same viscosity at 4 °C and at a temperature above 10, or above 20 °C (e.g., 37 °C).

30 In embodiments where two or more modeling material formulations are used, two or more formulations are rh-Collagen containing formulations as described herein, which differ from one another by the presence, type and/or concentration of an additional material that is included therein. For example, one formulation can comprise curable rhCollagen, and another formulation can comprise curable rhCollagen and a biological material as described herein. For example, one formulation can comprise curable rhCollagen, and another formulation can comprise curable

rhCollagen and an additional curable material as described herein. For example, one formulation can comprise curable rhCollagen and one additional curable material, and another formulation can comprise curable rhCollagen and another additional curable material as described herein. For example, one formulation can comprise curable rhCollagen and one additional curable material, and another formulation can comprise curable rhCollagen and a non-curable material as described herein. Any other combinations are contemplated.

In some of any of the embodiments described herein, all the curable materials in the building material are cured under the same curing condition. In some embodiments, all curable materials are photocurable.

10 In some of any of the embodiments described herein, a modeling material formulation that comprises a curable material further comprises an agent that promotes curing or hardening of the curable material when exposed to a curing condition.

The concentration of the agent can be determined in accordance with the concentration of the curable material and the desired degree of curing (e.g., desired cross-linking degree).

15 When the curable materials are photocurable materials, the agent is a photoinitiator. The photoinitiator is selected in accordance with the curing mechanism (e.g., free-radical, cationic, etc.).

20 A free-radical photoinitiator may be any compound that produces a free radical on exposure to radiation such as ultraviolet or visible radiation and thereby initiates a polymerization reaction. Non-limiting examples of suitable photoinitiators include benzophenones (aromatic ketones) such as benzophenone, methyl benzophenone, Michler's ketone and xanthones; acylphosphine oxide type photo-initiators such as 2,4,6-trimethylbenzoyldiphenyl phosphine oxide (TMPO), 2,4,6-trimethylbenzoylethoxyphenyl phosphine oxide (TEPO), and bisacylphosphine oxides (BAPO's); benzoins and bezoin alkyl ethers such as benzoin, benzoin 25 methyl ether and benzoin isopropyl ether and the like. Examples of photoinitiators are alpha-amino ketone, and bisacylphosphine oxide (BAPO's).

Exemplary photoinitiators include, but are not limited to, those of the Irgacure® family, riboflavin, rose Bengal, and more.

30 A free-radical photo-initiator may be used alone or in combination with a co-initiator. Co-initiators are used with initiators that need a second molecule to produce a radical that is active in the photocurable free-radical systems. Benzophenone is an example of a photoinitiator that requires a second molecule, such as an amine, to produce a free radical. After absorbing radiation, benzophenone reacts with a tertiary amine by hydrogen abstraction, to generate an alpha-amino radical which initiates polymerization of acrylates. Non-limiting example of a class

of co-initiators are alkanolamines such as triethylamine, methyldiethanolamine and triethanolamine.

Suitable cationic photoinitiators include, for example, compounds which form aprotic acids or Bronsted acids upon exposure to ultraviolet and/or visible light sufficient to initiate 5 polymerization. The photoinitiator used may be a single compound, a mixture of two or more active compounds, or a combination of two or more different compounds, i.e. co-initiators. Non-limiting examples of suitable cationic photoinitiators include aryl diazonium salts, diaryliodonium salts, triarylsulphonium salts, triarylselenonium salts and the like. An exemplary cationic photoinitiator is a mixture of triarylsolfonium hexafluoroantimonate salts.

10 Non-limiting examples of suitable cationic photoinitiators include P-(octyloxyphenyl) phenyliodonium hexafluoroantimonate UVACURE 1600 from Cytec Company (USA), iodonium (4-methylphenyl)(4-(2-methylpropyl)phenyl)-hexafluorophosphate known as Irgacure 250 or Irgacure 270 available from Ciba Speciality Chemicals (Switzerland), mixed 15 arylsulfonium hexafluoroantimonate salts known as UVI 6976 and 6992 available from Lambson Fine Chemicals (England), diaryliodonium hexafluoroantimonate known as PC 2506 available from Polyset Company (USA), (tolylcumyl) iodonium tetrakis (pentafluorophenyl) borate known as Rhodorsil® Photoinitiator 2074 available from Bluestar Silicones (USA), iodonium bis(4-dodecylphenyl)-(OC-6-11)-hexafluoro antimonate known as Tego PC 1466 from 20 Evonik Industries AG (Germany).

20 ***The object:***

Herein throughout, in the context of bioprinting, the term "object" describes a final product of the additive manufacturing which comprises, in at least a portion thereof, a biological component. This term refers to the product obtained by a bioprinting method as described herein, after removal of the support material, if such has been used as part of the uncured building 25 material.

The term "object" as used herein throughout refers to a whole object or a part thereof.

In the context of the present embodiments, the object comprises in at least a portion thereof a collagen-based material.

30 By "collagen-based material" it is meant a material that comprises collagen, preferably a recombinant human collagen as described herein in any of the respective embodiments and any combination thereof.

In some of any of the embodiments described herein, the collagen-based material comprises a scaffold, for example, a hydrogel scaffold, made of a three-dimensional fibrillar network that comprises recombinant human collagen as described herein.

In some of any of the embodiments described herein, the collagen-based material comprises polymerized and/or cross-linked recombinant human collagen, in which a plurality of monomeric and/or fibrillar collagen units are linked to one another to thereby form a three-dimensional network.

5 The three-dimension network or scaffold can be in a form of, for example, a film, a sponge, a porous structure, a hydrogel, and any other form, according to a desired need.

In some of any of the embodiments described herein, the object is in a form of a tissue or organ, which comprises, in at least a portion thereof, a collagen-based material as described herein. Such an object can be formulated in accordance with a respective 3D printing data of a 10 desired organ or tissue, using, in addition to the curable collagen as described herein, additional curable materials and biological materials as described herein.

In some embodiments, the object is an implantable object. In some embodiments, the object is an artificial skin. In some embodiments, the object is an artificial tissue (e.g., connective tissue, or muscle tissue such as cardiac tissue and pancreatic tissue). Examples of 15 connective tissues include, but are not limited to, cartilage (including, elastic, hyaline, and fibrocartilage), adipose tissue, reticular connective tissue, embryonic connective tissues (including mesenchymal connective tissue and mucous connective tissue), tendons, ligaments, and bone.

In some embodiments, the object is usable in, or is for use in, constructing an artificial 20 organ or tissue.

The object can further comprise hardened materials formed of one or more of the additional curable materials as described herein in any of the respective embodiments, biological components or materials, as described herein in any of the respective embodiments, and/or non-curable materials as described herein in any of the respective embodiments.

25 In some embodiments, the object is in a form of a collagen scaffold or film, that can be used in research or therapeutic applications, for example, in repairing a damaged tissue, for example, upon seeding culturing cells therein, or in wound healing.

The scaffolds may be administered to subjects in need thereof for the regeneration of tissue such as connective tissue, muscle tissue such as cardiac tissue and pancreatic tissue.

30 The films can be used to construct biomedical devices such as, for example, collagen membranes for hemodialysis.

According to some embodiments, films or scaffolds can be used in cell cultures.

The phrase "cell culture" or "culture" as used herein refers to the maintenance of cells in an artificial, e.g., an in vitro environment. It is to be understood, however, that the term "cell

culture" is a generic term and may be used to encompass the cultivation not only of individual prokaryotic (e.g., bacterial) or eukaryotic (e.g., animal, plant and fungal) cells, but also of tissues, organs, organ systems or whole organisms.

In some embodiments, the films or scaffolds can be used in a wound healing process.

5 In some embodiments, collagen films provided herein are used to prevent adhesions following tendon injuries, to lengthen levator palpebrae muscles ophthalmic surgery, and to repair transected nerves. Collagen films provided herein may further be used for burn dressings and in healing of bone defects.

10 The object of the present embodiments comprises a myriad of other uses including, but not limited to, in the treatment of diseases such as interstitial cystitis, scleroderma, and rheumatoid arthritis cosmetic surgery, as a healing aid for burn patients, as a wound-healing agent, as a dermal filler, for spinal fusion procedures, for urethral bulking, in duraplasty procedures, for reconstruction of bone and a wide variety of dental, orthopedic and surgical purposes.

15 **Kits:**

According to an aspect of some embodiments of the present invention, there is provided a kit that comprises a curable rhCollagen as described herein in any of the respective embodiments.

20 According to some embodiments, the kit comprises a composition that comprises curable rhCollagen as described herein in any of the respective embodiments.

According to some embodiments, the composition comprises the curable rhCollagen in a lyophilized form.

According to some embodiments, the composition comprises the curable rhCollagen and an aqueous solution or carrier.

25 According to some of any of the embodiments described herein, the kit is identified for use, or is usable, as a modeling material formulation for additive manufacturing (e.g., bioprinting) of an object as described herein in any of the respective embodiments.

According to some of any of the embodiments described herein, the kit further comprises an aqueous carrier, as described herein in any of the respective embodiments. In some 30 embodiments, the composition and the aqueous carrier are packaged individually within the kit.

Alternatively, the kit includes instructions to prepare a modeling material formulation as described herein, by mixing the composition with the aqueous carrier.

It is expected that during the life of a patent maturing from this application many relevant curable biocompatible materials, bioprinting media, and/or bioprinting technologies will be developed and the scope of embodiments related to curable biocompatible materials, bioprinting media, and/or bioprinting technologies is intended to include all such new technologies *a priori*.

5 As used herein the term "about" refers to $\pm 10\%$ or $\pm 5\%$.

The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".

The term "consisting of" means "including and limited to".

10 The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed 15 composition, method or structure.

As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one 15 compound" may include a plurality of compounds, including mixtures thereof.

Throughout this application, various embodiments of this invention may be presented in 20 a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

25 Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

30 As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

As used herein, the term “treating” includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.

5 It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain 10 features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

15

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.

Materials:

20 Human recombinant collagen (rhCollagen) type I expressed and isolated from transgenic tobacco plants was produced and supplied by CollPlant Ltd (Israel).

Type I Bovine Collagen (PureCol®) and Bovine-based Methacrylated collagen were purchased from Advanced Biomatrix, USA.

25 Methacrylic anhydride, glycidyl methacrylate, triethylamine, tetrabutylammonium bromide, 2,4,6-Trinitrobenzenesulfonic acid (TNBS), 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure 2959), sodium phosphate monobasic anhydrous, HCl 1N, HCl \geq 37 %, sodium bicarbonate, Titanium dioxide (TiO₂), Hepes Buffer, Eosin Y, N-Vinylpyrrolidone and NaOH were purchased from Sigma Aldrich Ltd, Israel.

30 Dulbaco Phosphate buffer saline (DPBS), X10 DPBS, Foetal Bovine Serum (FBS), DMEM high glucose and penicillin/streptomycin were purchased from Biological Industries Ltd, Israel.

Sodium phosphate dibasic anhydrous was purchased from Canton, India.

Ethanol absolute and acetone were purchased from Bio-Lab Ltd, Israel.

Hyaluronic acid was purchased by Lifecore, USA.

Acetic acid was purchased from JT Baker or Advanced Biometrix.

Oxidized cellulose was received from Synthesia.

PVAMA (polyvinyl alcohol methacrylate) was provided by Prof. Shoseyov.

TEA (triethanolamine) was purchased from J.T. Baker

5 Nano-hydroxyapatite (nanoHA) and Nano-tricalcium phosphate (nanoTCP) were purchased from Fluidinova.

Buffer stock solutions preparation:

Fibrillogenesis buffer (FB): sodium phosphate dibasic was dissolved in double distilled water (DDW) to a final concentration of 162 mM. The solution was titrated to pH 11.2 with 10N 10 NaOH.

Medium preparation: 50 mL of fetal bovine serum and 5 mL of penicillin/streptomycin (10,000 units/mL and 10 mg/mL respectively) were added under aseptic conditions to 500 mL of DMEM high glucose medium. The medium was gently mixed and kept in fridge.

15 Phosphate Buffer (0.1 M)/Saline (0.016M) preparation (300 mOs/L): 1M Phosphate buffer was prepared as follows: 31.6 mL of 1M sodium phosphate dibasic were mixed with 68.4 mL of 1M sodium phosphate monobasic. The obtained 1M Phosphate Buffer was diluted to 0.1M by adding DDW (9:1, vol/vol). NaCl was added to a final concentration of 15.8 mM to achieve physiological osmolarity (300 mOs/L).

20 Phosphate buffer (0.1M; pH 7.4)/Saline (11.3 mM) (physiological osmolarity) preparation: 1M Phosphate buffer was prepared as follows: 77.4 mL of 1M sodium phosphate dibasic were mixed with 22.6 mL of 1M sodium phosphate monobasic. The obtained 1M Phosphate Buffer was diluted to 0.1M by adding DDW (9:1, vol/vol). NaCl was added to a final concentration of 11.3 mM to achieve physiological osmolarity (300 mOs/L).

25 Washing buffer: HCl was added to the fibrillogenesis buffer to reach a final concentration of 16.2 mM sodium phosphate dibasic and 10 mM HCl. pH was adjusted to 7.2-7.4 with 10N NaOH.

Instrumental Data:

30 ^1H -NMR spectra were recorded at 25 °C on a Bruker Avance II spectrometer, operating at a 1H resonance frequency of 500 MHz, using D_2O as a solvent. The analysis was quantitative NMR using 64 scans for signal-to-noise averaging, and a recycle delay of 8.6 sec. Values provided represent the δ (normalized chemical shift) in ppm.

Viscosity and G'/G'' measurements were performed on a HAAKE RheoStress600 rheometer (Thermo Electron Corporation) with a temperature-controlled cell chamber, using a

C60/1°Ti or C35/1°Ti cone-plate set ups. Analysis of cross-linked (hardened) discs was performed using PP20 serrated spindle and 20 mm serrated plate set up.

In-situ crosslinked experiments were conducted on TA discovery hybrid temperature controlled rheometer with a UV chamber.

5 Other measurements were performed as described in the following.

EXAMPLE 1

Methacrylation of rhCollagen

10 Fibrillar rhCollagen-methacrylamide and monomeric rhCollagen-methacrylamide were prepared by reaction of lysine and hydroxylysine residues of the collagen with methacrylic anhydride in aqueous medium as described below, and stored at 4 °C light protected until further use.

Fibrillar rhCollagen-methacrylamide:

15 3 to 10 mg/mL fibrillar rhCollagen-methacrylamide (rhCollagen-MA) was synthesized either in a 1X washing buffer as described herein, a fibrillogenesis buffer as described herein or DDW, at room temperature (R.T.) or at 12 °C.

20 In an exemplary procedure, fibrillar rhCollagen-MA was synthesized in DDW as follow: monomeric rhCollagen 3-4 mg/mL solution in 10mM HCl, (CollageTM) was mixed with fibrillogenesis buffer at 9:1 v/v ratio and stirred for 1 hour at R.T, receiving fibrils. The solution was centrifuged at 7500 rpm at 4 °C for 30 minutes, and the supernatant was thereafter discarded. The remaining pellet was re-suspended in equal volume of washing buffer and centrifuged at the same conditions. Thereafter, the sediment fibrils were re-suspended in DDW to obtain a 10 mg/mL solution. The concentration was confirmed by percent solid measurements. Methacrylic anhydride was added drop-wise under nitrogen flow at room 25 temperature at 10 to 20 molar ratio with respect to collagen lysines (10-20 fold), and the reaction solution pH was monitored over time and adjusted to pH 7 with 10N NaOH. After 24 hours reaction, the mixture was dialyzed against washing buffer (pH=7) using 100 kDa cutoff dialysis tubing (Spectrum Laboratories Inc, CA, US) for 3 days at 4 °C with at least 6 changes of the dialysate (washing buffer in this case), to remove reaction by-products, and was thereafter 30 lyophilized for 3-4 days.

The extent of modification of rhCollagen was quantified using TNBS (2,4,6-Trinitrobenzenesulfonic acid) colorimetric assay. This assay quantifies the molar content of free, non-reacted ϵ -amino groups derived from lysine and hydroxyl lysine, and accordingly the degree of functionalization.

The assay was conducted in accordance with a previously described protocol [Sashidhar et al., Journal of Immunological Methods.1994, 167, 121-127], and based on Habeeb [Habeeb A.F.S.A, Analytical Biochemistry. 1966, 14, 328-336]. Briefly, freshly prepared 0.4 mL of 0.01 % (v/v) TNBS was added to 0.4 mL of 0.1-2 mg/mL fibrillar rhCollagen-MA in sodium bicarbonate 4 %. After 2 hours reaction at 40 °C, 0.2 mL of 1N HCl and 0.4 mL of 10 % (v/v) SDS were added. The absorbance was measured at 335 nm in a spectrophotometer in a 1mL polystyrene cuvette. A control (blank) was prepared with the same procedure except that sodium bicarbonate buffer was added instead of rhCollagen-MA solution. The absorption of 1-2 mg/mL native fibrillar rhCollagen prepared with the same conditions was recorded for calibration.

Table 1 below presents the data obtained for the degree of functionalization for batches obtained upon reacting the fibrillar rhCollagen with 10-folds, 15-folds or 20-folds mol ratio of methacrylic anhydride, as determined by the TNBS assay.

Table 1

MA:Fibrillar rhCollagen mol ratio	Degree of methacrylation [%]
10:1	98.1
15:1	95.5
20:1	92.9

These results demonstrate the high modification of the fibrillar rhCollagen at all MA concentrations, and suggest that adding the methacrylic reagent at a molar ratio of 10:1 may be preferable for receiving maximal functionalization of the fibrillar rhCollagen.

Monomeric rhCollagen-methacrylamide:

Monomeric rhCollagen-methacrylamide was synthesized while using 200 mM of MOPS, phosphate, or Tris buffer with the addition of 150 mM NaCl.

In an exemplary procedure, 200 mM MOPS and 150 mM NaCl were added to 3-4 mg/mL collageTM (a solution of Monomeric rhCollagen in 10 mM HCl and the solution was stirred at room temperature until clear solution was obtained. Thereafter, 1 to 20-fold molar ratio excess of methacrylic anhydride was added drop-wise under nitrogen flow at 12 °C, and the pH was adjusted over time to pH 7 with 10N NaOH. After 24 hours reaction, the mixture was initially dialyzed against 10 mM HCl/20 mM NaCl (pH=2) with 100 kDa cutoff dialysis hollow fiber cartridge (GE Healthcare), at least 5 changes of the dialysate, followed by dialysis against 10 mM HCl. The material was then lyophilized.

The structural properties of non-modified monomeric rhCollagen and the degree of methacrylation of collagen lysine amines of rhCollagen (also referred to herein as Coll-MA) were analyzed by ^1H -NMR spectroscopy (500MHz). Representative spectra are shown in FIG. 1 for Coll-MA synthesized with 10-folds molar excess of methacrylic anhydride. The signals of 5 the methyl function and acrylic protons of the introduced methacrylate are indicated as (b) and (c), respectively; the lysine methylene signals of non-modified rhCollagen as (a).

The spectrum of the non-modified rhCollagen was in high agreement with collagen spectra reported in the literature [R. Ravichandran et.al; *J. Mater. Chem. B*, 2016, 4, 318-326].

The degree of methacrylation can be calculated from the obtained spectrum using a 10 quantitative analysis technique. The signal at δ =3 ppm (a) is ascribed to the lysine methylene groups in Collagen, and was significantly reduced after methacrylation. Compared to non-modified rhCollagen, new signals can be observed at 1.9 ppm (b) and 5.4-5.7 ppm (c) in the 15 spectrum of Coll-MA, which are assigned to the methyl function and the acrylic protons of the introduced methacrylic groups, respectively, confirming a successful attachment of the methacrylate to the collagen.

EXAMPLE 2

Viscosity Measurements of rh-Collagen and rh-Collagen-MA

Solutions preparation for viscosity measurements:

20 PureCol® and Collage™ in DPBS: 8 ml of monomeric collagen solutions (3 mg/mL in 10 mM HCl), either rhCollagen (Collage™) or bovine collagen (PureCol®) were neutralized by adding 1 mL of DPBS X10. The solution was then brought to pH 7-7.5 by titration with 0.1N NaOH. Double distilled water (DDW) was then added to reach a final volume of 10 mL. Samples were incubated at 37 °C for at least 90 minutes before measurements were performed 25 (either at 37 °C or 4 °C).

Collage™ in fibrillogenesis buffer: 9 ml of monomeric rhCollagen (Collage™) solution (3.79 mg/mL in 10 mM HCl) was neutralized by adding 1 mL of fibrillogenesis buffer. Samples were incubated at 37 °C for at least 90 minutes before measurements were performed (either at 37 °C or 4 °C).

30 Fibrillar rhCollagen-methacrylamide in DPBS: Lyophilized fibrillar rhCollagen-MA prepared in DDW and dialyzed vs. washing buffer (as described in Example 1 hereinabove, using 10:1 molar ratio of MA:rhCollagen) was dissolved in DPBS to a concentration of 10 mg/mL. Samples were incubated at 37 °C for at least 90 minutes before measurements were performed (either at 37 °C or 4 °C).

Monomeric rhCollagen-methacrylamide in acetic acid: 10 mg/ml rhCollagen-methacrylamide solution in 20 mM Acetic acid was prepared by adding the appropriate medium volume to the lyophilized material and mixing at room temperature until receiving complete dissolution.

5 Bovine collagen-methacrylate in acetic acid: 10 mg/ml Bovine collagen-methacrylate solution in 20 mM Acetic acid was prepared by adding the appropriate medium volume (Advanced BioMatrix) to the lyophilized material and mixing at room temperature until receiving complete dissolution.

Temperature dependence of rhCollagen/bovine collagen viscosity:

10 Figure 2 presents comparative plots showing the viscosity of rhCollagen (CollageTM) and Bovine Collagen (PureCol) in DPBS expressed as a function of shear rate at T = 4 °C (blue, dashed and solid line, respectively) and T = 37 °C (red, dashed and solid line, respectively). Bovine collagen (solid lines) shows clear temperature dependence of the zero shear rate viscosity (η_0), i.e., the viscosity plateau at low shear rate values, having at 37 °C (red) η_0 values that are 15 more than one order of magnitude higher than the values at 4 °C (blue). On the contrary, rhCollagen (dashed lines) shows no significant difference between η_0 values at 4 °C and 37 °C.

Figure 3 presents comparative plots showing the viscosity of rhCollagen neutralized in FB, prepared as described hereinabove, and indicate a very similar behavior, i.e., the viscosity at 4 °C and 37 °C is almost identical, at all shear rates.

20 ***Viscosity of rhCollagen-methacrylamide:***

Figure 4 presents comparative plots showing the viscosity of fibrillar rhCollagen-MA in DPBS at 4 °C (blue line) and 37 °C (red line), and indicate that the profiles are similar (both are shear thinning) but not identical, yet, the zero shear rate values are around 1000 cP at both temperatures.

25 Figure 5 presents comparative plots further demonstrating the thermal stability and, importantly, the decrease in viscosity within a range of increased working (e.g., jetting) temperatures, compared with an increase in viscosity as the temperature increases shown for bovine-based methacrylated curable collagen. Viscosity measurements were performed with increased temperature steps, for 10 mg/ml rhCollagen-MA solution in 20 mM acetic acid (blue) 30 and for bovine-based curable collagen in acetic acid (red), as recorded in the rheometer using Rotational temperature steps CR mode with 5 [1/sec] rate. The acetic acid solutions were prepared as described hereinabove.

56
EXAMPLE 3***Characterization of hardened rh-Collagen-MA******rhCollagen-MA photocrosslinking for loss and storage moduli measurements:***

rhCollagen-MA crosslinked scaffolds were formed in two different preparations, aimed
5 to be examined in two individual experiments, respectively.

A photoinitiator 10% (v/v) stock solution was prepared as follows: Irgacure 2959 was dissolved in ethanol absolute/DDW 1:1 solution to a final concentration of 100 mg/mL.

In the first preparation, 1-2 wt % fibrillar rhCollagen-MA synthesized with 10-fold molar excess of the methacrylic reagent were dissolved in DPBS 0.1 M at room temperature, then
10 Irgacure 2959 0.1 % was added into 1 mL final volume of solution replicates which were injected into a discoid mold. Thereafter, curing process was performed from a distance of 1.5 cm for 7 and 10 seconds at an averaged intensity of 670 mW/cm² using mercury light source, resulting in cross-linked scaffolds.

The second preparation included 2 different batches of fibrillar rhCollagen-MA, synthesized with 15-fold and 20-fold molar excess of the methacrylic reagent. 1-2 wt % were dissolved in DPBS 0.1 M, and Irgacure 2959 0.1 % was added to achieve a final volume of 1.5 mL. In order to obtain highly crosslinked scaffolds, curing process was performed from a distance of 2 cm for 60 seconds at an averaged intensity of 420 mW/cm², using mercury light source.
15

20 Scaffolds' storage and loss moduli Measurements:

The rheological behavior of rhCollagen crosslinked discs was investigated using parallel plate system employing PP20 serrated spindle and 20 mm serrate plate set up. Characterization of the non-crosslinked rhCollagen-MA was performed using C60/1°Ti cone-plate elements.

In order to evaluate the rheological behavior of rhCollagen-MA, two sets of experiments
25 were performed individually.

In the first set, oscillation over time analysis was conducted at 37 °C and is presented in Figures 6-AB. 1 mL samples were subjected to oscillation forces at controlled stress mode, while applying 5 Pa shear stress at 1 Hz frequency and 37 °C for 300 seconds. Figure 6A presents loss/storage moduli (G'/G'') and the tan (delta) values before UV curing, and Figure 6B presents these values following exposure to light curing (following curing by cross-linking upon addition of a photoinitiator). The cured samples, 1 ml discs, were tested as the gap was adjusted to 90 % of the original sample height. G' and G'' values were averaged at the range of 150-300 seconds in all measurements.
30

5 The results demonstrate that the storage modulus of the rhCollagen-MA increases by 2-folds upon illumination (curing by irradiation) in the presence of a photoinitiator. Moreover, the results demonstrate the ability to control the scaffold properties by changing the rhCollagen-MA concentration and time of illumination (irradiation; exposure to a curing condition). High differences between G' and G'' values, and close-to-zero $\tan(\delta)$ values of the cross-linked discs indicate an elastic-like behavior.

10 In the second set, 1.5 mL cured (cross-linked) discs were characterized by applying oscillations under frequency sweep at 37 °C. G' was recorded under 1 Pa shear stress at frequency range of 0.01-100 Hz. To initiate measurement, the spindle was lowered to contact the hydrogel surface, and then further lowered until the axial force of the instrument was equal to 0.4 N.

15 Prior to all measurements, samples were kept on the plate covered with humidity lid for 1 minute, in order to reach temperature equilibrium.

20 The results are presented in Figure 7, and show that 1.5 mL discs illuminated for 60 seconds feature higher G' values. G' increases with increasing rhCollagen-MA concentration and increasing degree of methacrylation, indicating the ability to control the scaffolds properties.

In situ crosslinking of rhCollagen-MA:

25 A solution of 15 mg/ml monomeric rhCollagen-MA in 10 mM HCl was prepared by adding the appropriate volume of the medium to the lyophilized material, and after full dissolution, 0.1% of Irgacure photoinitiator was added to each replicate.

30 *In situ* crosslinking of rhCollagen-MA was tested by applying oscillation forces over time at 25 °C using 7 % strain and angular frequency of 5 rad/sec. 80µl solution was placed in 20 mm parallel plate geometry, and G' and complexed viscosity properties were first measured prior to cross-linking as described hereinabove. Thereafter an external UV 365 nm light source was introduced, and the properties of the sample were recorded over time during the cross-linking reaction on the plate.

35 The results are presented in Figure 8. As shown therein, an immediate sharp increase in the tested properties was observed during a short period, reaching a plateau after less than 30 seconds, indicating a good curability of the formulation. After 60 seconds curing, light source was off and values were kept measured post curing over time, showing similar values and indicating stability.

58
EXAMPLE 4***Characterization of rhCollagen-MA Formulations in varying mediums and/or with varying additives******Preparation of DMEM Formulations:***

5 rhCollagen-methacrylamide in DMEM: Lyophilized fibrillar rhCollagen-methacrylamide (prepared as described in Example 1 hereinabove, using with 15:1 molar ratio of MA:rhCollagen) was dissolved in DMEM medium to final concentrations of 20 and 26 mg/mL.

10 rhCollagen-methacrylamide/Hyaluronic Acid in DMEM: Hyaluronic Acid was added to a solution of fibrillar rhCollagen-MA to obtain final concentrations of 10 mg/mL HA and 20 mg/mL rhCollagen-MA in DMEM medium.

Preparation of Hyaluronic Acid methacrylate (HAMA):

15 500 mg of HA were functionalized as described by Leach et al. [Leach et.al. 2002, Biotechnology and Bioengineering, vol. 82, no. 5]. Briefly, 1.8 mL of triethylamine, 1.8 mL of glycidyl methacrylate, and 1.8 grams of tetrabutyl ammonium bromide were added separately to 50 mL of 10 mg/mL HA solution in DDW, while thoroughly mixing the reaction mixture before the addition of each component. The obtained reaction mixture was stirred overnight at room temperature, and thereafter the HAMA was precipitated by adding 20-folds volume of acetone and was then re-dissolved in DDW. The precipitation process was repeated twice to eliminate all possible side products, and the obtained reaction product was then lyophilized.

20 rhCollagen-methacrylamide/Hyaluronic Acid methacrylate (HAMA) in DMEM: Hyaluronic Acid methacrylate prepared as described hereinabove was added to a solution of fibrillar rhCollagen-MA to obtain final concentrations of 10 mg/mL HA-MA and 20 mg/mL rhCollagen-MA in DMEM medium.

Viscosity of DMEM Formulations:

25 The viscosity of rhCollagen-MA in DMEM at 25 °C, alone and in the presence of hyaluronic acid (HA) or HA-MA (prepared as described in Example 1) was tested, and the obtained data is presented in Figure 9.

30 As can be seen therein, the typical shear thinning behavior of the rhCollagen shown in Figures 2 and 3 is maintained also for the rhCollagen-MA with and without the addition of HA/HA-MA. Upon increasing the concentration of rhCollagen from 20 to 26 mg/mL (green and red line respectively) the zero shear viscosity increases, and the same is observed upon the addition of 10 mg/mL HA or HAMA (which leads to final polymer concentration of 30 mg/mL).

Preparation of formulations in 0.1M Phosphate buffer 0.1M (pH 7.4)/ NaCl 11.3 mM:

Stock solutions of 7.5 mg/ml monomeric rhCollagen-methacrylamide (10 fold) in Phosphate Buffer (0.1 M)/Saline (11.3 mM), 30 mg/ml PVAMA in Phosphate Buffer (0.1 M)/Saline (11.3 mM), 30 mg/ml TiO₂ in Phosphate Buffer (0.1 M)/Saline (11.3 mM), 30 mg/ml 5 Oxidized Cellulose in Phosphate Buffer (0.1 M)/Saline (11.3 mM) were prepared. HAMA was purchased from Advanced BioMatrix and dissolved to 10 mg/ml in 10 mM HCl. 4.5 ml of HAMA solution were eventually neutralized by adding 0.5 ml of 1M Phosphate buffer + 113 mM NaCl.

Preparation of monomeric rhCollagen-methacrylamide in Phosphate Buffer (0.1 M)/Saline (11.3 mM): Stock solution of monomeric rhCollagen methacrylamide was dilute to 10 5mg/ml with 0.1M Phosphate Buffer (pH7.4) +11.3 mM NaCl

Preparation of rhCollagen-methacrylamide and HAMA in Phosphate Buffer (0.1 M)/Saline (11.3 mM): Solutions of CollagenMA (monomeric rhCollagen-methacrylamide) and HAMA in a weight ratio of collagenMA:HAMA 5:1 and 2:1 were prepared by mixing the 15 appropriate amount of the collagenMA and HAMA stock solutions described herein above with Phosphate Buffer (0.1 M)/Saline (11.3 mM) to obtain final concentrations of 5 mg/ml CollMA and 1 mg/ml HAMA (5:1 ratio) and 5mg/ml coll MA and 2.5 mg/ml HAMA (2:1 ratio), respectively.

Preparation of rhCollagen-methacrylamide and PVAMA in Phosphate Buffer (0.1 M)/Saline (11.3 mM): CollagenMA (monomeric rhCollagen-methacrylamide) and PVAMA in a weight ratio of collagenMA:PVAMA 5:1, 2:1 and 1:2 were prepared by mixing the appropriate 20 amount of the collagenMA and PVAMA stock solutions described herein above with Phosphate Buffer (0.1 M)/Saline (11.3 mM) to obtain final concentrations of 5mg/ml CollMA and 1mg/ml PVAMA (5:1 ratio), 5mg/ml collMA and 2.5mg/ml PVAMA (2:1 ratio) and 5mg/ml CollMA and 10mg/ml PVAMA (1:2 ratio),

Preparation of rhCollagen-methacrylamide and Titanium Dioxide (TiO₂) in Phosphate Buffer (0.1 M)/Saline (11.3 mM): CollagenMA (monomeric rhCollagen-methacrylamide) and Titanium Dioxide (TiO₂) in a weight ratio of collagenMA:Titanium Dioxide (TiO₂) of 5:1, 2:1 and 1:2 were prepared by mixing the appropriate amount of the collagenMA and Titanium 30 Dioxide (TiO₂) stock solutions described herein above with Phosphate Buffer (0.1 M)/Saline (11.3 mM) to obtain final concentrations of 5 mg/ml CollMA and 1 mg/ml Titanium Dioxide (TiO₂) (5:1 ratio), 5 mg/ml collMA and 2.5 mg/ml Titanium Dioxide (TiO₂) (2:1 ratio) and 5mg/ml CollMA and 10 mg/ml Titanium Dioxide (TiO₂) (1:2 ratio).

Preparation of rhCollagen-methacrylamide and oxidized cellulose in Phosphate Buffer (0.1 M)/Saline (11.3 mM): CollagenMA (monomeric rhCollagen-methacrylamide) and oxidized cellulose in a weight ratio of collagenMA:oxidized cellulose of 5:1, 2:1 and 1:2 were prepared by mixing the appropriate amount of the collagenMA and oxidized cellulose stock solutions 5 described hereinabove with Phosphate Buffer (0.1 M)/Saline (11.3 mM) to obtain final concentrations of 5 mg/ml CollMA and 1 mg/ml oxidized cellulose (5:1 ratio), 5mg/ml collMA and 2.5 mg/ml oxidized cellulose (2:1 ratio) and 5 mg/ml CollMA and 10 mg/ml oxidized cellulose (1:2 ratio).

Viscosity of formulations in 0.1M Phosphate buffer 0.1M (pH 7.4)/ NaCl 11.3 mM:

10 The viscosity of formulations containing 5 mg/ml rhCollagen methacrylate (rhCollagen-MA; col) enriched with different additives (polivinyl alcohol methacrylate (PVAMA), hyaluronic acid methacrylate (HAMA), Titaniuud DiOxide (TiO₂) and oxidized cellulose (OC)) at collagenMA:additive ratios of 5:1, 2:1 and 1:2, in 0.1 M Phosphate buffer pH 7.4 / 11.3mM NaCl (physiological osmolarity), prepared as described herein, was tested. Measurements were 15 performed at T = 22 °C, using a cone on plate configuration (spindle C35/1 Ti Thermo HAAKE Rheo Stress 600 instrument). The obtained data is presented in Figures 10-13.

20 Figure 10 presents comparative plots showing the viscosity of 5 mg/ml rhCollagen-MA (col; black curve) and 5 mg/ml rhCollagen-MA + Polyvinyl alcohol methacrylate (PVAMA; green curves) at rhCollagen-MA:PVAMA weight ratio of 5:1 (green solid curve), 2:1 (green dashed curve), 1:2 (green dotted curve).

Figure 11 presents comparative plots showing the viscosity of 5 mg/ml rhCollagen-MA (col; black curve) and 5 mg/ml rhCollagen-MA + HAMA (blue curves) at rhCollagen-MA:HAMA weight ratio of 5:1 (blue solid curve) and 2:1 (blue dashed curve).

25 Figure 12 presents comparative plots showing the viscosity of 5 mg/ml rhCollagen-MA (col; black curve) and 5 mg/ml rhCollagen-MA + TiO₂ (red curves) at rhCollagen-MA:HAMA weight ratio of 5:1 (red solid curve), 2:1 (red dashed curve), 1:2 (red dotted curve).

30 Figure 13 presents comparative plots showing the viscosity of 5 mg/ml rhCollagen-MA (col; black curve) and 5 mg/ml rhCollagen-MA + oxidized cellulose (orange curves) at rhCollagen-MA:HAMA weight ratio of 5:1 (orange solid curve), 2:1 (orange dashed curve), 1:2 (orange dotted curve).

Cured rhCollagen-MA formulations in 0.1M Phosphate buffer 0.1M (pH 7.4)/ NaCl 11.3 mM:

The above-described formulations, containing rhCollagen-MA alone or with the different additives at 2:1 collagen:additive weight ratio were mixed with the photoinitiator 2-Hydroxy-

61
4'-(2-hydroxyethoxy)-2-methylpropiophenone (0.1 %). 130 μ L of the formulations were introduced in a silicon mold (8 mm X 8 mm X 8 mm) and illuminated for 20 seconds with UV light (365 nm) at a distance of 1.5 cm.

Figure 14 presents images of the obtained mold objects.

5 ***Viscosity of rhCollagen-MA Formulations in phosphate buffer and in HCl and G' measurements of cured objects made therefrom:***

10 mg/ml monomeric rhCollagen-MA (10-fold) solutions in phosphate buffer 0.1M/NaCl 15.8 mM (about 16 mM) or in 10 mM HCl were prepared by adding the appropriate volume of the medium to the lyophilized material. After complete dissolution the formulation's viscosity 10 was tested before curing.

The viscosity of these formulations at increased frequency was recorded in a rheometer using Rotational CR mode at room temperature, and the obtained data is presented in Figure 15. As shown therein, a 0.1M phosphate buffer/0.016M NaCl (total of 300 mOs/L) formulation 15 presents higher viscosity (blue line) than a 10 mM HCl (red line) and 20 mM Acetic Acid (data not shown). The shear thinning behavior in this phosphate buffer medium is more pronounced compared with all other tested media.

These formulations were also subjected to curing at 365 nm by UV LED source. 1.6 ml of solution with 0.1 % photoinitiator was injected into a discoid mold and curing was performed using 100 mW/cm² for 90 seconds, and G' values at increased frequency of the cured objects was 20 measured in a rheometer using Oscillation CR mode at 37 °C.

The obtained data is shown in Figure 16, indicating a higher storage modulus of the cured objects formed of a phosphate buffer-based formulation.

EXAMPLE 5

25 A liquid solution of 20 mg/ml, monomeric rhCollagen-MA (prepared using 10-folds molar excess of MA) in Hepes Buffered saline was mixed with N-vinyl pyrrolidinone and Eosin Y/TEA (triethanolamine) as a photoinitiator. 120 microliters were then dispensed in a silicon mold (8 mm X 8 mm X 3mm) and covered with a mouse skin patch (Science in Action Ltd.). The formulation was polymerized transdermally by illuminating the external side of the skin 30 patch with white light from a white LED torch for 6 minutes.

Figure 17 presented a photograph, taken using a camera, of the skin patch following illumination, and show that the rhCollagen-MA polymerized and was integrated into the skin tissue.

62
EXAMPLE 6

Monomeric rhCollagen-MA alone and rhCollagen-MA (monomeric) combined with calcium phosphate particles were evaluated in a cell proliferation assay using Normal human dermal fibroblasts (Promocell).

5 Objects (scaffolds) were prepared from lyophilized rhCollagen-MA dissolved in DDW containing (1) rhCollagen-MA alone, 9 mg/ml; (2) rhCollagen-MA, 9 mg/ml and nano-hydroxyapatite (nanoHA), 7 mg/ml; and (3) rhCollagen-MA, 9 mg/ml and nano-tricalcium phosphate (nanoTCP), 7 mg/ml. Each solution was subjected to UV curing, lyophilized and sterilized with ethylene oxide (ETO). Normal human dermal fibroblasts were seeded on the
10 scaffolds and cell proliferation was measured using colorimetric assay (WST-1) on day 1, 3 and 7. Figure 18 presents the obtained data and demonstrate good cell proliferation in all tested formulations.

15 Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

20 All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

1. A process of additive manufacturing a three-dimensional object featuring, in at least a portion thereof, a collagen-based material, the process comprising sequentially forming a plurality of layers in a configured pattern corresponding to a shape of the object,

wherein at least a portion of said layers are formed of a modeling material formulation that comprises a plant-derived recombinant human Type I collagen featuring at least one photocurable group, at a temperature of at least 20 °C,

thereby manufacturing the three-dimensional object.

2. The process of claim 1, wherein at least a portion of said layers are formed of a modeling material formulation that comprises at least one curable material other than said plant-derived recombinant human Type I collagen featuring said photocurable group; and/or of a modeling material formulation that comprises an agent that modifies a mechanical and/or rheological and/or physical property of the formulation and/or of a respective portion of the object; and/or of a modeling material formulation that comprises a biological material other than said plant-derived recombinant human Type I collagen.

3. The process of claim 1 or 2, wherein said modeling material formulation features a viscosity of no more than 2,000 centipoises, or no more than 1,500 centipoises, at a zero shear strain rate, at 37 °C, or at a shear strain rate of 5 1/sec, at room temperature, wherein a concentration of said plant-derived recombinant human Type I collagen featuring said photocurable group is at least 3 mg/mL.

4. The process of any one of claims 1 to 3, wherein said modeling material features, when hardened, an increase of at least 10-folds of its storage modulus (G').

5. The process of any one of claims 1 to 4, wherein forming said portion of said layers is at a temperature of 37 °C.

6. A three-dimensional biological object obtainable by the process of any one of claims 1 to 5.

7. The three-dimensional biological object of claim 6, for use in repairing a damaged tissue and/or as an artificial tissue or organ.

8. A formulation for use in additive manufacturing of a three-dimensional object that comprises, in at least a portion thereof, a collagen-based material, the formulation comprising a plant-derived recombinant human Type I collagen featuring at least one photocurable group and an aqueous carrier, the formulation featuring a viscosity of no more than 2000 centipoises, or no more than 1,500 centipoises, at a shear strain rate of 5 1/sec, at room temperature, or at a zero shear strain rate, at 37 °C, wherein a concentration of said plant-derived recombinant human Type I collagen featuring at least one photocurable group is at least 3 mg/mL.

9. The formulation of claim 8, further comprising at least one curable material other than said plant-derived recombinant human Type I collagen featuring said photocurable group; and/or an agent that modifies a mechanical and/or rheological and/or physical property of the formulation and/or of a respective portion of the object; and/or a biological material other than said plant-derived recombinant human Type I collagen.

10. The formulation of claim 8 or 9, featuring a viscosity of no more than 2,000 centipoises, or no more than 1,500 centipoises, wherein a concentration of said plant-derived recombinant human Type I collagen featuring said photocurable group is at least 3 mg/mL.

11. The formulation of any one of claims 8 to 10, featuring, when hardened, an increase of at least 10-folds of its storage modulus (G').













FIG. 1



**FIG. 2****FIG. 3**



**FIG. 4****FIG. 5**




**FIG. 6A****FIG. 6B**



**FIG. 7****FIG. 8**

**FIG. 9**

**FIG. 10****FIG. 11**

**FIG. 12****FIG. 13**

**FIG. 14****FIG. 15****FIG. 16**

**FIG. 17****FIG. 18**

PCTIL2018050627-seq1-000001-EN.txt
SEQUENCE LISTING

<110> CollPlant Ltd.
Shoseyov, Oded
ORR, Nadav
SEROR MAKNOUZ, Jasmine
ZARKA, Revital

<120> ADDITIVE MANUFACTURING USING RECOMBINANT COLLAGEN-CONTAINING FORMULATION

<130> 73710

<150> US 62/517,179

<151> 2017-06-09

<160> 16

<170> PatentIn version 3.5

<210> 1
<211> 1464
<212> PRT
<213> Homo sapiens

<400> 1

Met Phe Ser Phe Val Asp Leu Arg Leu Leu Leu Leu Ala Ala Thr
1 5 10 15

Ala Leu Leu Thr His Gly Gln Glu Gly Gln Val Glu Gly Gln Asp
20 25 30

Glu Asp Ile Pro Pro Ile Thr Cys Val Gln Asn Gly Leu Arg Tyr His
35 40 45

Asp Arg Asp Val Trp Lys Pro Glu Pro Cys Arg Ile Cys Val Cys Asp
50 55 60

Asn Gly Lys Val Leu Cys Asp Asp Val Ile Cys Asp Glu Thr Lys Asn
65 70 75 80

Cys Pro Gly Ala Glu Val Pro Glu Gly Glu Cys Cys Pro Val Cys Pro
85 90 95

Asp Gly Ser Glu Ser Pro Thr Asp Gln Glu Thr Thr Gly Val Glu Gly

100

105

110

Pro Lys Gly Asp Thr Gly Pro Arg Gly Pro Arg Gly Pro Ala Gly Pro
115 120 125

Pro Gly Arg Asp Gly Ile Pro Gly Gln Pro Gly Leu Pro Gly Pro Pro
130 135 140

Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala
145 150 155 160

Pro Gln Leu Ser Tyr Gly Tyr Asp Glu Lys Ser Thr Gly Gly Ile Ser
165 170 175

Val Pro Gly Pro Met Gly Pro Ser Gly Pro Arg Gly Leu Pro Gly Pro
180 185 190

Pro Gly Ala Pro Gly Pro Gln Gly Phe Gln Gly Pro Pro Gly Glu Pro
195 200 205

Gly Glu Pro Gly Ala Ser Gly Pro Met Gly Pro Arg Gly Pro Pro Gly
210 215 220

Pro Pro Gly Lys Asn Gly Asp Asp Gly Glu Ala Gly Lys Pro Gly Arg
225 230 235 240

Pro Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly Leu Pro
245 250 255

Gly Thr Ala Gly Leu Pro Gly Met Lys Gly His Arg Gly Phe Ser Gly
260 265 270

Leu Asp Gly Ala Lys Gly Asp Ala Gly Pro Ala Gly Pro Lys Gly Glu
275 280 285

Pro Gly Ser Pro Gly Glu Asn Gly Ala Pro Gly Gln Met Gly Pro Arg
290 295 300

Gly Leu Pro Gly Glu Arg Gly Arg Pro Gly Ala Pro Gly Pro Ala Gly

305 310 315 320

Ala Arg Gly Asn Asp Gly Ala Thr Gly Ala Ala Gly Pro Pro Gly Pro
325 330 335Thr Gly Pro Ala Gly Pro Pro Gly Phe Pro Gly Ala Val Gly Ala Lys
340 345 350Gly Glu Ala Gly Pro Gln Gly Pro Arg Gly Ser Glu Gly Pro Gln Gly
355 360 365Val Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Ala Ala Gly Pro
370 375 380Ala Gly Asn Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly Ala Asn
385 390 395 400Gly Ala Pro Gly Ile Ala Gly Ala Pro Gly Phe Pro Gly Ala Arg Gly
405 410 415Pro Ser Gly Pro Gln Gly Pro Gly Gly Pro Pro Gly Pro Lys Gly Asn
420 425 430Ser Gly Glu Pro Gly Ala Pro Gly Ser Lys Gly Asp Thr Gly Ala Lys
435 440 445Gly Glu Pro Gly Pro Val Gly Val Gln Gly Pro Pro Gly Pro Ala Gly
450 455 460Glu Glu Gly Lys Arg Gly Ala Arg Gly Glu Pro Gly Pro Thr Gly Leu
465 470 475 480Pro Gly Pro Pro Gly Glu Arg Gly Gly Pro Gly Ser Arg Gly Phe Pro
485 490 495Gly Ala Asp Gly Val Ala Gly Pro Lys Gly Pro Ala Gly Glu Arg Gly
500 505 510

Ser Pro Gly Pro Ala Gly Pro Lys Gly Ser Pro Gly Glu Ala Gly Arg

515

520

525

Pro Gly Glu Ala Gly Leu Pro Gly Ala Lys Gly Leu Thr Gly Ser Pro
530 535 540

Gly Ser Pro Gly Pro Asp Gly Lys Thr Gly Pro Pro Gly Pro Ala Gly
545 550 555 560

Gln Asp Gly Arg Pro Gly Pro Pro Gly Ala Arg Gly Gln
565 570 575

Ala Gly Val Met Gly Phe Pro Gly Pro Lys Gly Ala Ala Gly Glu Pro
580 585 590

Gly Lys Ala Gly Glu Arg Gly Val Pro Gly Pro Pro Gly Ala Val Gly
595 600 605

Pro Ala Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Pro Gly Pro
610 615 620

Ala Gly Pro Ala Gly Glu Arg Gly Glu Gln Gly Pro Ala Gly Ser Pro
625 630 635 640

Gly Phe Gln Gly Leu Pro Gly Pro Ala Gly Pro Pro Gly Glu Ala Gly
645 650 655

Lys Pro Gly Glu Gln Gly Val Pro Gly Asp Leu Gly Ala Pro Gly Pro
660 665 670

Ser Gly Ala Arg Gly Glu Arg Gly Phe Pro Gly Glu Arg Gly Val Gln
675 680 685

Gly Pro Pro Gly Pro Ala Gly Pro Arg Gly Ala Asn Gly Ala Pro Gly
690 695 700

Asn Asp Gly Ala Lys Gly Asp Ala Gly Ala Pro Gly Ala Pro Gly Ser
705 710 715 720

Gln Gly Ala Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Ala Ala

725

730

735

Gly Leu Pro Gly Pro Lys Gly Asp Arg Gly Asp Ala Gly Pro Lys Gly
740 745 750

Ala Asp Gly Ser Pro Gly Lys Asp Gly Val Arg Gly Leu Thr Gly Pro
755 760 765

Ile Gly Pro Pro Gly Pro Ala Gly Ala Pro Gly Asp Lys Gly Glu Ser
770 775 780

Gly Pro Ser Gly Pro Ala Gly Pro Thr Gly Ala Arg Gly Ala Pro Gly
785 790 795 800

Asp Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Phe Ala Gly Pro
805 810 815

Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly Glu Pro Gly Asp Ala
820 825 830

Gly Ala Lys Gly Asp Ala Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly
835 840 845

Pro Pro Gly Pro Ile Gly Asn Val Gly Ala Pro Gly Ala Lys Gly Ala
850 855 860

Arg Gly Ser Ala Gly Pro Pro Gly Ala Thr Gly Phe Pro Gly Ala Ala
865 870 875 880

Gly Arg Val Gly Pro Pro Gly Pro Ser Gly Asn Ala Gly Pro Pro Gly
885 890 895

Pro Pro Gly Pro Ala Gly Lys Glu Gly Lys Gly Pro Arg Gly Glu
900 905 910

Thr Gly Pro Ala Gly Arg Pro Gly Glu Val Gly Pro Pro Gly Pro Pro
915 920 925

Gly Pro Ala Gly Glu Lys Gly Ser Pro Gly Ala Asp Gly Pro Ala Gly

930

935

940

Ala Pro Gly Thr Pro Gly Pro Gln Gly Ile Ala Gly Gln Arg Gly Val
 945 950 955 960

Val Gly Leu Pro Gly Gln Arg Gly Glu Arg Gly Phe Pro Gly Leu Pro
 965 970 975

Gly Pro Ser Gly Glu Pro Gly Lys Gln Gly Pro Ser Gly Ala Ser Gly
 980 985 990

Glu Arg Gly Pro Pro Gly Pro Met Gly Pro Pro Gly Leu Ala Gly Pro
 995 1000 1005

Pro Gly Glu Ser Gly Arg Glu Gly Ala Pro Gly Ala Glu Gly Ser
 1010 1015 1020

Pro Gly Arg Asp Gly Ser Pro Gly Ala Lys Gly Asp Arg Gly Glu
 1025 1030 1035

Thr Gly Pro Ala Gly Pro Pro Gly Ala Pro Gly Ala Pro Gly Ala
 1040 1045 1050

Pro Gly Pro Val Gly Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu
 1055 1060 1065

Thr Gly Pro Ala Gly Pro Ala Gly Pro Val Gly Pro Val Gly Ala
 1070 1075 1080

Arg Gly Pro Ala Gly Pro Gln Gly Pro Arg Gly Asp Lys Gly Glu
 1085 1090 1095

Thr Gly Glu Gln Gly Asp Arg Gly Ile Lys Gly His Arg Gly Phe
 1100 1105 1110

Ser Gly Leu Gln Gly Pro Pro Gly Pro Pro Gly Ser Pro Gly Glu
 1115 1120 1125

Gln Gly Pro Ser Gly Ala Ser Gly Pro Ala Gly Pro Arg Gly Pro

1130

1135

1140

Pro Gly Ser Ala Gly Ala Pro Gly Lys Asp Gly Leu Asn Gly Leu
 1145 1150 1155

Pro Gly Pro Ile Gly Pro Pro Gly Pro Arg Gly Arg Thr Gly Asp
 1160 1165 1170

Ala Gly Pro Val Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
 1175 1180 1185

Pro Gly Pro Pro Ser Ala Gly Phe Asp Phe Ser Phe Leu Pro Gln
 1190 1195 1200

Pro Pro Gln Glu Lys Ala His Asp Gly Gly Arg Tyr Tyr Arg Ala
 1205 1210 1215

Asp Asp Ala Asn Val Val Arg Asp Arg Asp Leu Glu Val Asp Thr
 1220 1225 1230

Thr Leu Lys Ser Leu Ser Gln Gln Ile Glu Asn Ile Arg Ser Pro
 1235 1240 1245

Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp Leu Lys
 1250 1255 1260

Met Cys His Ser Asp Trp Lys Ser Gly Glu Tyr Trp Ile Asp Pro
 1265 1270 1275

Asn Gln Gly Cys Asn Leu Asp Ala Ile Lys Val Phe Cys Asn Met
 1280 1285 1290

Glu Thr Gly Glu Thr Cys Val Tyr Pro Thr Gln Pro Ser Val Ala
 1295 1300 1305

Gln Lys Asn Trp Tyr Ile Ser Lys Asn Pro Lys Asp Lys Arg His
 1310 1315 1320

Val Trp Phe Gly Glu Ser Met Thr Asp Gly Phe Gln Phe Glu Tyr

1325

1330

1335

Gly Gly Gln Gly Ser Asp Pro Ala Asp Val Ala Ile Gln Leu Thr
 1340 1345 1350

Phe Leu Arg Leu Met Ser Thr Glu Ala Ser Gln Asn Ile Thr Tyr
 1355 1360 1365

His Cys Lys Asn Ser Val Ala Tyr Met Asp Gln Gln Thr Gly Asn
 1370 1375 1380

Leu Lys Lys Ala Leu Leu Leu Gln Gly Ser Asn Glu Ile Glu Ile
 1385 1390 1395

Arg Ala Glu Gly Asn Ser Arg Phe Thr Tyr Ser Val Thr Val Asp
 1400 1405 1410

Gly Cys Thr Ser His Thr Gly Ala Trp Gly Lys Thr Val Ile Glu
 1415 1420 1425

Tyr Lys Thr Thr Lys Thr Ser Arg Leu Pro Ile Ile Asp Val Ala
 1430 1435 1440

Pro Leu Asp Val Gly Ala Pro Asp Gln Glu Phe Gly Phe Asp Val
 1445 1450 1455

Gly Pro Val Cys Phe Leu
 1460

<210> 2
 <211> 1366
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Leu Ser Phe Val Asp Thr Arg Thr Leu Leu Leu Leu Ala Val Thr
 1 5 10 15

Leu Cys Leu Ala Thr Cys Gln Ser Leu Gln Glu Glu Thr Val Arg Lys
 20 25 30

PCTIL2018050627-seql-000001-EN.txt

Gly Pro Ala Gly Asp Arg Gly Pro Arg Gly Glu Arg Gly Pro Pro Gly
35 40 45

Pro Pro Gly Arg Asp Gly Glu Asp Gly Pro Thr Gly Pro Pro Gly Pro
50 55 60

Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala Ala Gln
65 70 75 80

Tyr Asp Gly Lys Gly Val Gly Leu Gly Pro Gly Pro Met Gly Leu Met
85 90 95

Gly Pro Arg Gly Pro Pro Gly Ala Ala Gly Ala Pro Gly Pro Gln Gly
100 105 110

Phe Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln Thr Gly Pro
115 120 125

Ala Gly Ala Arg Gly Pro Ala Gly Pro Pro Gly Lys Ala Gly Glu Asp
130 135 140

Gly His Pro Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Val Val Gly
145 150 155 160

Pro Gln Gly Ala Arg Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Phe
165 170 175

Lys Gly Ile Arg Gly His Asn Gly Leu Asp Gly Leu Lys Gly Gln Pro
180 185 190

Gly Ala Pro Gly Val Lys Gly Glu Pro Gly Ala Pro Gly Glu Asn Gly
195 200 205

Thr Pro Gly Gln Thr Gly Ala Arg Gly Leu Pro Gly Glu Arg Gly Arg
210 215 220

Val Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Ser Asp Gly Ser Val
225 230 235 240

PCTIL2018050627-seql-000001-EN.txt

Gly Pro Val Gly Pro Ala Gly Pro Ile Gly Ser Ala Gly Pro Pro Gly
245 250 255

Phe Pro Gly Ala Pro Gly Pro Lys Gly Glu Ile Gly Ala Val Gly Asn
260 265 270

Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg Gly Glu Val Gly Leu Pro
275 280 285

Gly Leu Ser Gly Pro Val Gly Pro Pro Gly Asn Pro Gly Ala Asn Gly
290 295 300

Leu Thr Gly Ala Lys Gly Ala Ala Gly Leu Pro Gly Val Ala Gly Ala
305 310 315 320

Pro Gly Leu Pro Gly Pro Arg Gly Ile Pro Gly Pro Val Gly Ala Ala
325 330 335

Gly Ala Thr Gly Ala Arg Gly Leu Val Gly Glu Pro Gly Pro Ala Gly
340 345 350

Ser Lys Gly Glu Ser Gly Asn Lys Gly Glu Pro Gly Ser Ala Gly Pro
355 360 365

Gln Gly Pro Pro Gly Pro Ser Gly Glu Glu Gly Lys Arg Gly Pro Asn
370 375 380

Gly Glu Ala Gly Ser Ala Gly Pro Pro Gly Pro Pro Gly Leu Arg Gly
385 390 395 400

Ser Pro Gly Ser Arg Gly Leu Pro Gly Ala Asp Gly Arg Ala Gly Val
405 410 415

Met Gly Pro Pro Gly Ser Arg Gly Ala Ser Gly Pro Ala Gly Val Arg
420 425 430

Gly Pro Asn Gly Asp Ala Gly Arg Pro Gly Glu Pro Gly Leu Met Gly
435 440 445

PCTIL2018050627-seql-000001-EN.txt

Pro Arg Gly Leu Pro Gly Ser Pro Gly Asn Ile Gly Pro Ala Gly Lys
450 455 460

Glu Gly Pro Val Gly Leu Pro Gly Ile Asp Gly Arg Pro Gly Pro Ile
465 470 475 480

Gly Pro Ala Gly Ala Arg Gly Glu Pro Gly Asn Ile Gly Phe Pro Gly
485 490 495

Pro Lys Gly Pro Thr Gly Asp Pro Gly Lys Asn Gly Asp Lys Gly His
500 505 510

Ala Gly Leu Ala Gly Ala Arg Gly Ala Pro Gly Pro Asp Gly Asn Asn
515 520 525

Gly Ala Gln Gly Pro Pro Gly Pro Gln Gly Val Gln Gly Gly Lys Gly
530 535 540

Glu Gln Gly Pro Ala Gly Pro Pro Gly Phe Gln Gly Leu Pro Gly Pro
545 550 555 560

Ser Gly Pro Ala Gly Glu Val Gly Lys Pro Gly Glu Arg Gly Leu His
565 570 575

Gly Glu Phe Gly Leu Pro Gly Pro Ala Gly Pro Arg Gly Glu Arg Gly
580 585 590

Pro Pro Gly Glu Ser Gly Ala Ala Gly Pro Thr Gly Pro Ile Gly Ser
595 600 605

Arg Gly Pro Ser Gly Pro Pro Gly Pro Asp Gly Asn Lys Gly Glu Pro
610 615 620

Gly Val Val Gly Ala Val Gly Thr Ala Gly Pro Ser Gly Pro Ser Gly
625 630 635 640

Leu Pro Gly Glu Arg Gly Ala Ala Gly Ile Pro Gly Gly Lys Gly Glu
645 650 655

PCTIL2018050627-seql-000001-EN.txt

Lys Gly Glu Pro Gly Leu Arg Gly Glu Ile Gly Asn Pro Gly Arg Asp
660 665 670

Gly Ala Arg Gly Ala Pro Gly Ala Val Gly Ala Pro Gly Pro Ala Gly
675 680 685

Ala Thr Gly Asp Arg Gly Glu Ala Gly Ala Ala Gly Pro Ala Gly Pro
690 695 700

Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg Gly Glu Val Gly Pro Ala
705 710 715 720

Gly Pro Asn Gly Phe Ala Gly Pro Ala Gly Ala Ala Gly Gln Pro Gly
725 730 735

Ala Lys Gly Glu Arg Gly Ala Lys Gly Pro Lys Gly Glu Asn Gly Val
740 745 750

Val Gly Pro Thr Gly Pro Val Gly Ala Ala Gly Pro Ala Gly Pro Asn
755 760 765

Gly Pro Pro Gly Pro Ala Gly Ser Arg Gly Asp Gly Gly Pro Pro Gly
770 775 780

Met Thr Gly Phe Pro Gly Ala Ala Gly Arg Thr Gly Pro Pro Gly Pro
785 790 795 800

Ser Gly Ile Ser Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys Glu
805 810 815

Gly Leu Arg Gly Pro Arg Gly Asp Gln Gly Pro Val Gly Arg Thr Gly
820 825 830

Glu Val Gly Ala Val Gly Pro Pro Gly Phe Ala Gly Glu Lys Gly Pro
835 840 845

Ser Gly Glu Ala Gly Thr Ala Gly Pro Pro Gly Thr Pro Gly Pro Gln
850 855 860

PCTIL2018050627-seql-000001-EN.txt

Gly Leu Leu Gly Ala Pro Gly Ile Leu Gly Leu Pro Gly Ser Arg Gly
865 870 875 880

Glu Arg Gly Leu Pro Gly Val Ala Gly Ala Val Gly Glu Pro Gly Pro
885 890 895

Leu Gly Ile Ala Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly Ala Val
900 905 910

Gly Ser Pro Gly Val Asn Gly Ala Pro Gly Glu Ala Gly Arg Asp Gly
915 920 925

Asn Pro Gly Asn Asp Gly Pro Pro Gly Arg Asp Gly Gln Pro Gly His
930 935 940

Lys Gly Glu Arg Gly Tyr Pro Gly Asn Ile Gly Pro Val Gly Ala Ala
945 950 955 960

Gly Ala Pro Gly Pro His Gly Pro Val Gly Pro Ala Gly Lys His Gly
965 970 975

Asn Arg Gly Glu Thr Gly Pro Ser Gly Pro Val Gly Pro Ala Gly Ala
980 985 990

Val Gly Pro Arg Gly Pro Ser Gly Pro Gln Gly Ile Arg Gly Asp Lys
995 1000 1005

Gly Glu Pro Gly Glu Lys Gly Pro Arg Gly Leu Pro Gly Leu Lys
1010 1015 1020

Gly His Asn Gly Leu Gln Gly Leu Pro Gly Ile Ala Gly His His
1025 1030 1035

Gly Asp Gln Gly Ala Pro Gly Ser Val Gly Pro Ala Gly Pro Arg
1040 1045 1050

Gly Pro Ala Gly Pro Ser Gly Pro Ala Gly Lys Asp Gly Arg Thr
1055 1060 1065

PCTIL2018050627-seql-000001-EN.txt

Gly His Pro Gly Thr Val Gly Pro Ala Gly Ile Arg Gly Pro Gln
1070 1075 1080

Gly His Gln Gly Pro Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro
1085 1090 1095

Gly Pro Pro Gly Val Ser Gly Gly Tyr Asp Phe Gly Tyr Asp
1100 1105 1110

Gly Asp Phe Tyr Arg Ala Asp Gln Pro Arg Ser Ala Pro Ser Leu
1115 1120 1125

Arg Pro Lys Asp Tyr Glu Val Asp Ala Thr Leu Lys Ser Leu Asn
1130 1135 1140

Asn Gln Ile Glu Thr Leu Leu Thr Pro Glu Gly Ser Arg Lys Asn
1145 1150 1155

Pro Ala Arg Thr Cys Arg Asp Leu Arg Leu Ser His Pro Glu Trp
1160 1165 1170

Ser Ser Gly Tyr Tyr Trp Ile Asp Pro Asn Gln Gly Cys Thr Met
1175 1180 1185

Asp Ala Ile Lys Val Tyr Cys Asp Phe Ser Thr Gly Glu Thr Cys
1190 1195 1200

Ile Arg Ala Gln Pro Glu Asn Ile Pro Ala Lys Asn Trp Tyr Arg
1205 1210 1215

Ser Ser Lys Asp Lys Lys His Val Trp Leu Gly Glu Thr Ile Asn
1220 1225 1230

Ala Gly Ser Gln Phe Glu Tyr Asn Val Glu Gly Val Thr Ser Lys
1235 1240 1245

Glu Met Ala Thr Gln Leu Ala Phe Met Arg Leu Leu Ala Asn Tyr
1250 1255 1260

PCTIL2018050627-seql-000001-EN.txt

Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile Ala Tyr
1265 1270 1275

Met Asp Glu Glu Thr Gly Asn Leu Lys Lys Ala Val Ile Leu Gln
1280 1285 1290

Gly Ser Asn Asp Val Glu Leu Val Ala Glu Gly Asn Ser Arg Phe
1295 1300 1305

Thr Tyr Thr Val Leu Val Asp Gly Cys Ser Lys Lys Thr Asn Glu
1310 1315 1320

Trp Gly Lys Thr Ile Ile Glu Tyr Lys Thr Asn Lys Pro Ser Arg
1325 1330 1335

Leu Pro Phe Leu Asp Ile Ala Pro Leu Asp Ile Gly Gly Ala Asp
1340 1345 1350

Gln Glu Phe Phe Val Asp Ile Gly Pro Val Cys Phe Lys
1355 1360 1365

<210> 3

<211> 1464

<212> PRT

<213> Homo sapiens

<400> 3

Met Phe Ser Phe Val Asp Leu Arg Leu Leu Leu Leu Ala Ala Thr
1 5 10 15

Ala Leu Leu Thr His Gly Gln Glu Gly Gln Val Glu Gly Gln Asp
20 25 30

Glu Asp Ile Pro Pro Ile Thr Cys Val Gln Asn Gly Leu Arg Tyr His
35 40 45

Asp Arg Asp Val Trp Lys Pro Glu Pro Cys Arg Ile Cys Val Cys Asp
50 55 60

PCTIL2018050627-seql-000001-EN.txt

Asn Gly Lys Val Leu Cys Asp Asp Val Ile Cys Asp Glu Thr Lys Asn
65 70 75 80

Cys Pro Gly Ala Glu Val Pro Glu Gly Glu Cys Cys Pro Val Cys Pro
85 90 95

Asp Gly Ser Glu Ser Pro Thr Asp Gln Glu Thr Thr Gly Val Glu Gly
100 105 110

Pro Lys Gly Asp Thr Gly Pro Arg Gly Pro Arg Gly Pro Ala Gly Pro
115 120 125

Pro Gly Arg Asp Gly Ile Pro Gly Gln Pro Gly Leu Pro Gly Pro Pro
130 135 140

Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala
145 150 155 160

Pro Gln Leu Ser Tyr Gly Tyr Asp Glu Lys Ser Thr Gly Gly Ile Ser
165 170 175

Val Pro Gly Pro Met Gly Pro Ser Gly Pro Arg Gly Leu Pro Gly Pro
180 185 190

Pro Gly Ala Pro Gly Pro Gln Gly Phe Gln Gly Pro Pro Gly Glu Pro
195 200 205

Gly Glu Pro Gly Ala Ser Gly Pro Met Gly Pro Arg Gly Pro Pro Gly
210 215 220

Pro Pro Gly Lys Asn Gly Asp Asp Gly Glu Ala Gly Lys Pro Gly Arg
225 230 235 240

Pro Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly Leu Pro
245 250 255

Gly Thr Ala Gly Leu Pro Gly Met Lys Gly His Arg Gly Phe Ser Gly
260 265 270

PCTIL2018050627-seql-000001-EN.txt

Leu Asp Gly Ala Lys Gly Asp Ala Gly Pro Ala Gly Pro Lys Gly Glu
275 280 285

Pro Gly Ser Pro Gly Glu Asn Gly Ala Pro Gly Gln Met Gly Pro Arg
290 295 300

Gly Leu Pro Gly Glu Arg Gly Arg Pro Gly Ala Pro Gly Pro Ala Gly
305 310 315 320

Ala Arg Gly Asn Asp Gly Ala Thr Gly Ala Ala Gly Pro Pro Gly Pro
325 330 335

Thr Gly Pro Ala Gly Pro Pro Gly Phe Pro Gly Ala Val Gly Ala Lys
340 345 350

Gly Glu Ala Gly Pro Gln Gly Pro Arg Gly Ser Glu Gly Pro Gln Gly
355 360 365

Val Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Ala Ala Gly Pro
370 375 380

Ala Gly Asn Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly Ala Asn
385 390 395 400

Gly Ala Pro Gly Ile Ala Gly Ala Pro Gly Phe Pro Gly Ala Arg Gly
405 410 415

Pro Ser Gly Pro Gln Gly Pro Gly Gly Pro Pro Gly Pro Lys Gly Asn
420 425 430

Ser Gly Glu Pro Gly Ala Pro Gly Ser Lys Gly Asp Thr Gly Ala Lys
435 440 445

Gly Glu Pro Gly Pro Val Gly Val Gln Gly Pro Pro Gly Pro Ala Gly
450 455 460

Glu Glu Gly Lys Arg Gly Ala Arg Gly Glu Pro Gly Pro Thr Gly Leu
465 470 475 480

PCTIL2018050627-seql-000001-EN.txt

Pro Gly Pro Pro Gly Glu Arg Gly Gly Pro Gly Ser Arg Gly Phe Pro
485 490 495

Gly Ala Asp Gly Val Ala Gly Pro Lys Gly Pro Ala Gly Glu Arg Gly
500 505 510

Ser Pro Gly Pro Ala Gly Pro Lys Gly Ser Pro Gly Glu Ala Gly Arg
515 520 525

Pro Gly Glu Ala Gly Leu Pro Gly Ala Lys Gly Leu Thr Gly Ser Pro
530 535 540

Gly Ser Pro Gly Pro Asp Gly Lys Thr Gly Pro Pro Gly Pro Ala Gly
545 550 555 560

Gln Asp Gly Arg Pro Gly Pro Pro Gly Pro Pro Gly Ala Arg Gly Gln
565 570 575

Ala Gly Val Met Gly Phe Pro Gly Pro Lys Gly Ala Ala Gly Glu Pro
580 585 590

Gly Lys Ala Gly Glu Arg Gly Val Pro Gly Pro Pro Gly Ala Val Gly
595 600 605

Pro Ala Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Pro Gly Pro
610 615 620

Ala Gly Pro Ala Gly Glu Arg Gly Glu Gln Gly Pro Ala Gly Ser Pro
625 630 635 640

Gly Phe Gln Gly Leu Pro Gly Pro Ala Gly Pro Pro Gly Glu Ala Gly
645 650 655

Lys Pro Gly Glu Gln Gly Val Pro Gly Asp Leu Gly Ala Pro Gly Pro
660 665 670

Ser Gly Ala Arg Gly Glu Arg Gly Phe Pro Gly Glu Arg Gly Val Gln
675 680 685

PCTIL2018050627-seql-000001-EN.txt

Gly Pro Pro Gly Pro Ala Gly Pro Arg Gly Ala Asn Gly Ala Pro Gly
690 695 700

Asn Asp Gly Ala Lys Gly Asp Ala Gly Ala Pro Gly Ala Pro Gly Ser
705 710 715 720

Gln Gly Ala Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Ala Ala
725 730 735

Gly Leu Pro Gly Pro Lys Gly Asp Arg Gly Asp Ala Gly Pro Lys Gly
740 745 750

Ala Asp Gly Ser Pro Gly Lys Asp Gly Val Arg Gly Leu Thr Gly Pro
755 760 765

Ile Gly Pro Pro Gly Pro Ala Gly Ala Pro Gly Asp Lys Gly Glu Ser
770 775 780

Gly Pro Ser Gly Pro Ala Gly Pro Thr Gly Ala Arg Gly Ala Pro Gly
785 790 795 800

Asp Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Phe Ala Gly Pro
805 810 815

Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly Glu Pro Gly Asp Ala
820 825 830

Gly Ala Lys Gly Asp Ala Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly
835 840 845

Pro Pro Gly Pro Ile Gly Asn Val Gly Ala Pro Gly Ala Lys Gly Ala
850 855 860

Arg Gly Ser Ala Gly Pro Pro Gly Ala Thr Gly Phe Pro Gly Ala Ala
865 870 875 880

Gly Arg Val Gly Pro Pro Gly Pro Ser Gly Asn Ala Gly Pro Pro Gly
885 890 895

PCTIL2018050627-seql-000001-EN.txt

Pro Pro Gly Pro Ala Gly Lys Glu Gly Gly Lys Gly Pro Arg Gly Glu
900 905 910

Thr Gly Pro Ala Gly Arg Pro Gly Glu Val Gly Pro Pro Gly Pro Pro
915 920 925

Gly Pro Ala Gly Glu Lys Gly Ser Pro Gly Ala Asp Gly Pro Ala Gly
930 935 940

Ala Pro Gly Thr Pro Gly Pro Gln Gly Ile Ala Gly Gln Arg Gly Val
945 950 955 960

Val Gly Leu Pro Gly Gln Arg Gly Glu Arg Gly Phe Pro Gly Leu Pro
965 970 975

Gly Pro Ser Gly Glu Pro Gly Lys Gln Gly Pro Ser Gly Ala Ser Gly
980 985 990

Glu Arg Gly Pro Pro Gly Pro Met Gly Pro Pro Gly Leu Ala Gly Pro
995 1000 1005

Pro Gly Glu Ser Gly Arg Glu Gly Ala Pro Gly Ala Glu Gly Ser
1010 1015 1020

Pro Gly Arg Asp Gly Ser Pro Gly Ala Lys Gly Asp Arg Gly Glu
1025 1030 1035

Thr Gly Pro Ala Gly Pro Pro Gly Ala Pro Gly Ala Pro Gly Ala
1040 1045 1050

Pro Gly Pro Val Gly Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu
1055 1060 1065

Thr Gly Pro Ala Gly Pro Ala Gly Pro Val Gly Pro Val Gly Ala
1070 1075 1080

Arg Gly Pro Ala Gly Pro Gln Gly Pro Arg Gly Asp Lys Gly Glu
1085 1090 1095

PCTIL2018050627-seql-000001-EN.txt

Thr Gly Glu Gln Gly Asp Arg Gly Ile Lys Gly His Arg Gly Phe
1100 1105 1110

Ser Gly Leu Gln Gly Pro Pro Gly Pro Pro Gly Ser Pro Gly Glu
1115 1120 1125

Gln Gly Pro Ser Gly Ala Ser Gly Pro Ala Gly Pro Arg Gly Pro
1130 1135 1140

Pro Gly Ser Ala Gly Ala Pro Gly Lys Asp Gly Leu Asn Gly Leu
1145 1150 1155

Pro Gly Pro Ile Gly Pro Pro Gly Pro Arg Gly Arg Thr Gly Asp
1160 1165 1170

Ala Gly Pro Val Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
1175 1180 1185

Pro Gly Pro Pro Ser Ala Gly Phe Asp Phe Ser Phe Leu Pro Gln
1190 1195 1200

Pro Pro Gln Glu Lys Ala His Asp Gly Gly Arg Tyr Tyr Arg Ala
1205 1210 1215

Asp Asp Ala Asn Val Val Arg Asp Arg Asp Leu Glu Val Asp Thr
1220 1225 1230

Thr Leu Lys Ser Leu Ser Gln Gln Ile Glu Asn Ile Arg Ser Pro
1235 1240 1245

Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp Leu Lys
1250 1255 1260

Met Cys His Ser Asp Trp Lys Ser Gly Glu Tyr Trp Ile Asp Pro
1265 1270 1275

Asn Gln Gly Cys Asn Leu Asp Ala Ile Lys Val Phe Cys Asn Met
1280 1285 1290

PCTIL2018050627-seql-000001-EN.txt

Glu Thr Gly Glu Thr Cys Val Tyr Pro Thr Gln Pro Ser Val Ala
1295 1300 1305

Gln Lys Asn Trp Tyr Ile Ser Lys Asn Pro Lys Asp Lys Arg His
1310 1315 1320

Val Trp Phe Gly Glu Ser Met Thr Asp Gly Phe Gln Phe Glu Tyr
1325 1330 1335

Gly Gly Gln Gly Ser Asp Pro Ala Asp Val Ala Ile Gln Leu Thr
1340 1345 1350

Phe Leu Arg Leu Met Ser Thr Glu Ala Ser Gln Asn Ile Thr Tyr
1355 1360 1365

His Cys Lys Asn Ser Val Ala Tyr Met Asp Gln Gln Thr Gly Asn
1370 1375 1380

Leu Lys Lys Ala Leu Leu Leu Gln Gly Ser Asn Glu Ile Glu Ile
1385 1390 1395

Arg Ala Glu Gly Asn Ser Arg Phe Thr Tyr Ser Val Thr Val Asp
1400 1405 1410

Gly Cys Thr Ser His Thr Gly Ala Trp Gly Lys Thr Val Ile Glu
1415 1420 1425

Tyr Lys Thr Thr Lys Thr Ser Arg Leu Pro Ile Ile Asp Val Ala
1430 1435 1440

Pro Leu Asp Val Gly Ala Pro Asp Gln Glu Phe Gly Phe Asp Val
1445 1450 1455

Gly Pro Val Cys Phe Leu
1460

<210> 4
<211> 1366
<212> PRT

PCTIL2018050627-seql-000001-EN.txt

<213> Homo sapiens

<400> 4

Met Leu Ser Phe Val Asp Thr Arg Thr Leu Leu Leu Leu Ala Val Thr
1 5 10 15

Leu Cys Leu Ala Thr Cys Gln Ser Leu Gln Glu Glu Thr Val Arg Lys
20 25 30

Gly Pro Ala Gly Asp Arg Gly Pro Arg Gly Glu Arg Gly Pro Pro Gly
35 40 45

Pro Pro Gly Arg Asp Gly Glu Asp Gly Pro Thr Gly Pro Pro Gly Pro
50 55 60

Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala Ala Gln
65 70 75 80

Tyr Asp Gly Lys Gly Val Gly Leu Gly Pro Gly Pro Met Gly Leu Met
85 90 95

Gly Pro Arg Gly Pro Pro Gly Ala Ala Gly Ala Pro Gly Pro Gln Gly
100 105 110

Phe Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln Thr Gly Pro
115 120 125

Ala Gly Ala Arg Gly Pro Ala Gly Pro Pro Gly Lys Ala Gly Glu Asp
130 135 140

Gly His Pro Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Val Val Gly
145 150 155 160

Pro Gln Gly Ala Arg Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Phe
165 170 175

Lys Gly Ile Arg Gly His Asn Gly Leu Asp Gly Leu Lys Gly Gln Pro
180 185 190

PCTIL2018050627-seql-000001-EN.txt

Gly Ala Pro Gly Val Lys Gly Glu Pro Gly Ala Pro Gly Glu Asn Gly
195 200 205

Thr Pro Gly Gln Thr Gly Ala Arg Gly Leu Pro Gly Glu Arg Gly Arg
210 215 220

Val Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Ser Asp Gly Ser Val
225 230 235 240

Gly Pro Val Gly Pro Ala Gly Pro Ile Gly Ser Ala Gly Pro Pro Gly
245 250 255

Phe Pro Gly Ala Pro Gly Pro Lys Gly Glu Ile Gly Ala Val Gly Asn
260 265 270

Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg Gly Glu Val Gly Leu Pro
275 280 285

Gly Leu Ser Gly Pro Val Gly Pro Pro Gly Asn Pro Gly Ala Asn Gly
290 295 300

Leu Thr Gly Ala Lys Gly Ala Ala Gly Leu Pro Gly Val Ala Gly Ala
305 310 315 320

Pro Gly Leu Pro Gly Pro Arg Gly Ile Pro Gly Pro Val Gly Ala Ala
325 330 335

Gly Ala Thr Gly Ala Arg Gly Leu Val Gly Glu Pro Gly Pro Ala Gly
340 345 350

Ser Lys Gly Glu Ser Gly Asn Lys Gly Glu Pro Gly Ser Ala Gly Pro
355 360 365

Gln Gly Pro Pro Gly Pro Ser Gly Glu Glu Gly Lys Arg Gly Pro Asn
370 375 380

Gly Glu Ala Gly Ser Ala Gly Pro Pro Gly Pro Pro Gly Leu Arg Gly
385 390 395 400

PCTIL2018050627-seql-000001-EN.txt

Ser Pro Gly Ser Arg Gly Leu Pro Gly Ala Asp Gly Arg Ala Gly Val
405 410 415

Met Gly Pro Pro Gly Ser Arg Gly Ala Ser Gly Pro Ala Gly Val Arg
420 425 430

Gly Pro Asn Gly Asp Ala Gly Arg Pro Gly Glu Pro Gly Leu Met Gly
435 440 445

Pro Arg Gly Leu Pro Gly Ser Pro Gly Asn Ile Gly Pro Ala Gly Lys
450 455 460

Glu Gly Pro Val Gly Leu Pro Gly Ile Asp Gly Arg Pro Gly Pro Ile
465 470 475 480

Gly Pro Ala Gly Ala Arg Gly Glu Pro Gly Asn Ile Gly Phe Pro Gly
485 490 495

Pro Lys Gly Pro Thr Gly Asp Pro Gly Lys Asn Gly Asp Lys Gly His
500 505 510

Ala Gly Leu Ala Gly Ala Arg Gly Ala Pro Gly Pro Asp Gly Asn Asn
515 520 525

Gly Ala Gln Gly Pro Pro Gly Pro Gln Gly Val Gln Gly Gly Lys Gly
530 535 540

Glu Gln Gly Pro Ala Gly Pro Pro Gly Phe Gln Gly Leu Pro Gly Pro
545 550 555 560

Ser Gly Pro Ala Gly Glu Val Gly Lys Pro Gly Glu Arg Gly Leu His
565 570 575

Gly Glu Phe Gly Leu Pro Gly Pro Ala Gly Pro Arg Gly Glu Arg Gly
580 585 590

Pro Pro Gly Glu Ser Gly Ala Ala Gly Pro Thr Gly Pro Ile Gly Ser
595 600 605

PCTIL2018050627-seql-000001-EN.txt

Arg Gly Pro Ser Gly Pro Pro Gly Pro Asp Gly Asn Lys Gly Glu Pro
610 615 620

Gly Val Val Gly Ala Val Gly Thr Ala Gly Pro Ser Gly Pro Ser Gly
625 630 635 640

Leu Pro Gly Glu Arg Gly Ala Ala Gly Ile Pro Gly Gly Lys Gly Glu
645 650 655

Lys Gly Glu Pro Gly Leu Arg Gly Glu Ile Gly Asn Pro Gly Arg Asp
660 665 670

Gly Ala Arg Gly Ala Pro Gly Ala Val Gly Ala Pro Gly Pro Ala Gly
675 680 685

Ala Thr Gly Asp Arg Gly Glu Ala Gly Ala Ala Gly Pro Ala Gly Pro
690 695 700

Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg Gly Glu Val Gly Pro Ala
705 710 715 720

Gly Pro Asn Gly Phe Ala Gly Pro Ala Gly Ala Ala Gly Gln Pro Gly
725 730 735

Ala Lys Gly Glu Arg Gly Ala Lys Gly Pro Lys Gly Glu Asn Gly Val
740 745 750

Val Gly Pro Thr Gly Pro Val Gly Ala Ala Gly Pro Ala Gly Pro Asn
755 760 765

Gly Pro Pro Gly Pro Ala Gly Ser Arg Gly Asp Gly Gly Pro Pro Gly
770 775 780

Met Thr Gly Phe Pro Gly Ala Ala Gly Arg Thr Gly Pro Pro Gly Pro
785 790 795 800

Ser Gly Ile Ser Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys Glu
805 810 815

PCTIL2018050627-seql-000001-EN.txt

Gly Leu Arg Gly Pro Arg Gly Asp Gln Gly Pro Val Gly Arg Thr Gly
820 825 830

Glu Val Gly Ala Val Gly Pro Pro Gly Phe Ala Gly Glu Lys Gly Pro
835 840 845

Ser Gly Glu Ala Gly Thr Ala Gly Pro Pro Gly Thr Pro Gly Pro Gln
850 855 860

Gly Leu Leu Gly Ala Pro Gly Ile Leu Gly Leu Pro Gly Ser Arg Gly
865 870 875 880

Glu Arg Gly Leu Pro Gly Val Ala Gly Ala Val Gly Glu Pro Gly Pro
885 890 895

Leu Gly Ile Ala Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly Ala Val
900 905 910

Gly Ser Pro Gly Val Asn Gly Ala Pro Gly Glu Ala Gly Arg Asp Gly
915 920 925

Asn Pro Gly Asn Asp Gly Pro Pro Gly Arg Asp Gly Gln Pro Gly His
930 935 940

Lys Gly Glu Arg Gly Tyr Pro Gly Asn Ile Gly Pro Val Gly Ala Ala
945 950 955 960

Gly Ala Pro Gly Pro His Gly Pro Val Gly Pro Ala Gly Lys His Gly
965 970 975

Asn Arg Gly Glu Thr Gly Pro Ser Gly Pro Val Gly Pro Ala Gly Ala
980 985 990

Val Gly Pro Arg Gly Pro Ser Gly Pro Gln Gly Ile Arg Gly Asp Lys
995 1000 1005

Gly Glu Pro Gly Glu Lys Gly Pro Arg Gly Leu Pro Gly Leu Lys
1010 1015 1020

PCTIL2018050627-seql-000001-EN.txt

Gly His Asn Gly Leu Gln Gly Leu Pro Gly Ile Ala Gly His His
1025 1030 1035

Gly Asp Gln Gly Ala Pro Gly Ser Val Gly Pro Ala Gly Pro Arg
1040 1045 1050

Gly Pro Ala Gly Pro Ser Gly Pro Ala Gly Lys Asp Gly Arg Thr
1055 1060 1065

Gly His Pro Gly Thr Val Gly Pro Ala Gly Ile Arg Gly Pro Gln
1070 1075 1080

Gly His Gln Gly Pro Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro
1085 1090 1095

Gly Pro Pro Gly Val Ser Gly Gly Gly Tyr Asp Phe Gly Tyr Asp
1100 1105 1110

Gly Asp Phe Tyr Arg Ala Asp Gln Pro Arg Ser Ala Pro Ser Leu
1115 1120 1125

Arg Pro Lys Asp Tyr Glu Val Asp Ala Thr Leu Lys Ser Leu Asn
1130 1135 1140

Asn Gln Ile Glu Thr Leu Leu Thr Pro Glu Gly Ser Arg Lys Asn
1145 1150 1155

Pro Ala Arg Thr Cys Arg Asp Leu Arg Leu Ser His Pro Glu Trp
1160 1165 1170

Ser Ser Gly Tyr Tyr Trp Ile Asp Pro Asn Gln Gly Cys Thr Met
1175 1180 1185

Asp Ala Ile Lys Val Tyr Cys Asp Phe Ser Thr Gly Glu Thr Cys
1190 1195 1200

Ile Arg Ala Gln Pro Glu Asn Ile Pro Ala Lys Asn Trp Tyr Arg
1205 1210 1215

PCTIL2018050627-seql-000001-EN.txt

Ser Ser Lys Asp Lys Lys His Val Trp Leu Gly Glu Thr Ile Asn
1220 1225 1230

Ala Gly Ser Gln Phe Glu Tyr Asn Val Glu Gly Val Thr Ser Lys
1235 1240 1245

Glu Met Ala Thr Gln Leu Ala Phe Met Arg Leu Leu Ala Asn Tyr
1250 1255 1260

Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile Ala Tyr
1265 1270 1275

Met Asp Glu Glu Thr Gly Asn Leu Lys Lys Ala Val Ile Leu Gln
1280 1285 1290

Gly Ser Asn Asp Val Glu Leu Val Ala Glu Gly Asn Ser Arg Phe
1295 1300 1305

Thr Tyr Thr Val Leu Val Asp Gly Cys Ser Lys Lys Thr Asn Glu
1310 1315 1320

Trp Gly Lys Thr Ile Ile Glu Tyr Lys Thr Asn Lys Pro Ser Arg
1325 1330 1335

Leu Pro Phe Leu Asp Ile Ala Pro Leu Asp Ile Gly Gly Ala Asp
1340 1345 1350

Gln Glu Phe Phe Val Asp Ile Gly Pro Val Cys Phe Lys
1355 1360 1365

<210> 5
<211> 1489
<212> PRT
<213> Homo sapiens

<400> 5

Met Ala His Ala Arg Val Leu Leu Leu Ala Leu Ala Val Leu Ala Thr
1 5 10 15

Ala Ala Val Ala Val Ala Ser Ser Ser Ser Phe Ala Asp Ser Asn Pro

20

25

30

Ile Arg Pro Val Thr Asp Arg Ala Ala Ser Thr Leu Ala Gln Leu Gln
35 40 45

Glu Glu Gly Gln Val Glu Gly Gln Asp Glu Asp Ile Pro Pro Ile Thr
50 55 60

Cys Val Gln Asn Gly Leu Arg Tyr His Asp Arg Asp Val Trp Lys Pro
65 70 75 80

Glu Pro Cys Arg Ile Cys Val Cys Asp Asn Gly Lys Val Leu Cys Asp
85 90 95

Asp Val Ile Cys Asp Glu Thr Lys Asn Cys Pro Gly Ala Glu Val Pro
100 105 110

Glu Gly Glu Cys Cys Pro Val Cys Pro Asp Gly Ser Glu Ser Pro Thr
115 120 125

Asp Gln Glu Thr Thr Gly Val Glu Gly Pro Lys Gly Asp Thr Gly Pro
130 135 140

Arg Gly Pro Arg Gly Pro Ala Gly Pro Pro Gly Arg Asp Gly Ile Pro
145 150 155 160

Gly Gln Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
165 170 175

Pro Pro Gly Leu Gly Asn Phe Ala Pro Gln Leu Ser Tyr Gly Tyr
180 185 190

Asp Glu Lys Ser Thr Gly Gly Ile Ser Val Pro Gly Pro Met Gly Pro
195 200 205

Ser Gly Pro Arg Gly Leu Pro Gly Pro Pro Gly Ala Pro Gly Pro Gln
210 215 220

Gly Phe Gln Gly Pro Pro Gly Glu Pro Gly Glu Pro Gly Ala Ser Gly

225 230 235 240

Pro Met Gly Pro Arg Gly Pro Pro Gly Pro Pro Gly Lys Asn Gly Asp
245 250 255Asp Gly Glu Ala Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Pro Pro
260 265 270Gly Pro Gln Gly Ala Arg Gly Leu Pro Gly Thr Ala Gly Leu Pro Gly
275 280 285Met Lys Gly His Arg Gly Phe Ser Gly Leu Asp Gly Ala Lys Gly Asp
290 295 300Ala Gly Pro Ala Gly Pro Lys Gly Glu Pro Gly Ser Pro Gly Glu Asn
305 310 315 320Gly Ala Pro Gly Gln Met Gly Pro Arg Gly Leu Pro Gly Glu Arg Gly
325 330 335Arg Pro Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Asn Asp Gly Ala
340 345 350Thr Gly Ala Ala Gly Pro Pro Gly Pro Thr Gly Pro Ala Gly Pro Pro
355 360 365Gly Phe Pro Gly Ala Val Gly Ala Lys Gly Glu Ala Gly Pro Gln Gly
370 375 380Pro Arg Gly Ser Glu Gly Pro Gln Gly Val Arg Gly Glu Pro Gly Pro
385 390 395 400Pro Gly Pro Ala Gly Ala Ala Gly Pro Ala Gly Asn Pro Gly Ala Asp
405 410 415Gly Gln Pro Gly Ala Lys Gly Ala Asn Gly Ala Pro Gly Ile Ala Gly
420 425 430

Ala Pro Gly Phe Pro Gly Ala Arg Gly Pro Ser Gly Pro Gln Gly Pro

435 440 445

Gly Gly Pro Pro Gly Pro Lys Gly Asn Ser Gly Glu Pro Gly Ala Pro
450 455 460Gly Ser Lys Gly Asp Thr Gly Ala Lys Gly Glu Pro Gly Pro Val Gly
465 470 475 480Val Gln Gly Pro Pro Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala
485 490 495Arg Gly Glu Pro Gly Pro Thr Gly Leu Pro Gly Pro Pro Gly Glu Arg
500 505 510Gly Gly Pro Gly Ser Arg Gly Phe Pro Gly Ala Asp Gly Val Ala Gly
515 520 525Pro Lys Gly Pro Ala Gly Glu Arg Gly Ser Pro Gly Pro Ala Gly Pro
530 535 540Lys Gly Ser Pro Gly Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro
545 550 555 560Gly Ala Lys Gly Leu Thr Gly Ser Pro Gly Ser Pro Gly Pro Asp Gly
565 570 575Lys Thr Gly Pro Pro Gly Pro Ala Gly Gln Asp Gly Arg Pro Gly Pro
580 585 590Pro Gly Pro Pro Gly Ala Arg Gly Gln Ala Gly Val Met Gly Phe Pro
595 600 605Gly Pro Lys Gly Ala Ala Gly Glu Pro Gly Lys Ala Gly Glu Arg Gly
610 615 620Val Pro Gly Pro Pro Gly Ala Val Gly Pro Ala Gly Lys Asp Gly Glu
625 630 635 640

Ala Gly Ala Gln Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly Glu Arg

645

650

655

Gly Glu Gln Gly Pro Ala Gly Ser Pro Gly Phe Gln Gly Leu Pro Gly
 660 665 670

Pro Ala Gly Pro Pro Gly Glu Ala Gly Lys Pro Gly Glu Gln Gly Val
 675 680 685

Pro Gly Asp Leu Gly Ala Pro Gly Pro Ser Gly Ala Arg Gly Glu Arg
 690 695 700

Gly Phe Pro Gly Glu Arg Gly Val Gln Gly Pro Pro Gly Pro Ala Gly
 705 710 715 720

Pro Arg Gly Ala Asn Gly Ala Pro Gly Asn Asp Gly Ala Lys Gly Asp
 725 730 735

Ala Gly Ala Pro Gly Ala Pro Gly Ser Gln Gly Ala Pro Gly Leu Gln
 740 745 750

Gly Met Pro Gly Glu Arg Gly Ala Ala Gly Leu Pro Gly Pro Lys Gly
 755 760 765

Asp Arg Gly Asp Ala Gly Pro Lys Gly Ala Asp Gly Ser Pro Gly Lys
 770 775 780

Asp Gly Val Arg Gly Leu Thr Gly Pro Ile Gly Pro Pro Gly Pro Ala
 785 790 795 800

Gly Ala Pro Gly Asp Lys Gly Glu Ser Gly Pro Ser Gly Pro Ala Gly
 805 810 815

Pro Thr Gly Ala Arg Gly Ala Pro Gly Asp Arg Gly Glu Pro Gly Pro
 820 825 830

Pro Gly Pro Ala Gly Phe Ala Gly Pro Pro Gly Ala Asp Gly Gln Pro
 835 840 845

Gly Ala Lys Gly Glu Pro Gly Asp Ala Gly Ala Lys Gly Asp Ala Gly

850 855 860

Pro Pro Gly Pro Ala Gly Pro Ala Gly Pro Pro Gly Pro Ile Gly Asn
865 870 875 880Val Gly Ala Pro Gly Ala Lys Gly Ala Arg Gly Ser Ala Gly Pro Pro
885 890 895Gly Ala Thr Gly Phe Pro Gly Ala Ala Gly Arg Val Gly Pro Pro Gly
900 905 910Pro Ser Gly Asn Ala Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys
915 920 925Glu Gly Gly Lys Gly Pro Arg Gly Glu Thr Gly Pro Ala Gly Arg Pro
930 935 940Gly Glu Val Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Glu Lys Gly
945 950 955 960Ser Pro Gly Ala Asp Gly Pro Ala Gly Ala Pro Gly Thr Pro Gly Pro
965 970 975Gln Gly Ile Ala Gly Gln Arg Gly Val Val Gly Leu Pro Gly Gln Arg
980 985 990Gly Glu Arg Gly Phe Pro Gly Leu Pro Gly Pro Ser Gly Glu Pro Gly
995 1000 1005Lys Gln Gly Pro Ser Gly Ala Ser Gly Glu Arg Gly Pro Pro Gly
1010 1015 1020Pro Met Gly Pro Pro Gly Leu Ala Gly Pro Pro Gly Glu Ser Gly
1025 1030 1035Arg Glu Gly Ala Pro Gly Ala Glu Gly Ser Pro Gly Arg Asp Gly
1040 1045 1050

Ser Pro Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly Pro Ala Gly

1055

1060

1065

Pro Pro Gly Ala Pro Gly Ala Pro Gly Ala Pro Gly Pro Val Gly
 1070 1075 1080

Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu Thr Gly Pro Ala Gly
 1085 1090 1095

Pro Ala Gly Pro Val Gly Pro Ala Gly Ala Arg Gly Pro Ala Gly
 1100 1105 1110

Pro Gln Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly Glu Gln Gly
 1115 1120 1125

Asp Arg Gly Ile Lys Gly His Arg Gly Phe Ser Gly Leu Gln Gly
 1130 1135 1140

Pro Pro Gly Pro Pro Gly Ser Pro Gly Glu Gln Gly Pro Ser Gly
 1145 1150 1155

Ala Ser Gly Pro Ala Gly Pro Arg Gly Pro Pro Gly Ser Ala Gly
 1160 1165 1170

Ala Pro Gly Lys Asp Gly Leu Asn Gly Leu Pro Gly Pro Ile Gly
 1175 1180 1185

Pro Pro Gly Pro Arg Gly Arg Thr Gly Asp Ala Gly Pro Val Gly
 1190 1195 1200

Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Ser
 1205 1210 1215

Ala Gly Phe Asp Phe Ser Phe Leu Pro Gln Pro Pro Gln Glu Lys
 1220 1225 1230

Ala His Asp Gly Gly Arg Tyr Tyr Arg Ala Asp Asp Ala Asn Val
 1235 1240 1245

Val Arg Asp Arg Asp Leu Glu Val Asp Thr Thr Leu Lys Ser Leu

1250 1255 1260

Ser Gln Gln Ile Glu Asn Ile Arg Ser Pro Glu Gly Ser Arg Lys
 1265 1270 1275

Asn Pro Ala Arg Thr Cys Arg Asp Leu Lys Met Cys His Ser Asp
 1280 1285 1290

Trp Lys Ser Gly Glu Tyr Trp Ile Asp Pro Asn Gln Gly Cys Asn
 1295 1300 1305

Leu Asp Ala Ile Lys Val Phe Cys Asn Met Glu Thr Gly Glu Thr
 1310 1315 1320

Cys Val Tyr Pro Thr Gln Pro Ser Val Ala Gln Lys Asn Trp Tyr
 1325 1330 1335

Ile Ser Lys Asn Pro Lys Asp Lys Arg His Val Trp Phe Gly Glu
 1340 1345 1350

Ser Met Thr Asp Gly Phe Gln Phe Glu Tyr Gly Gly Gln Gly Ser
 1355 1360 1365

Asp Pro Ala Asp Val Ala Ile Gln Leu Thr Phe Leu Arg Leu Met
 1370 1375 1380

Ser Thr Glu Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser
 1385 1390 1395

Val Ala Tyr Met Asp Gln Gln Thr Gly Asn Leu Lys Lys Ala Leu
 1400 1405 1410

Leu Leu Lys Gly Ser Asn Glu Ile Glu Ile Arg Ala Glu Gly Asn
 1415 1420 1425

Ser Arg Phe Thr Tyr Ser Val Thr Val Asp Gly Cys Thr Ser His
 1430 1435 1440

Thr Gly Ala Trp Gly Lys Thr Val Ile Glu Tyr Lys Thr Thr Lys

1445

1450

1455

Thr Ser Arg Leu Pro Ile Ile Asp Val Ala Pro Leu Asp Val Gly
 1460 1465 1470

Ala Pro Asp Gln Glu Phe Gly Phe Asp Val Gly Pro Val Cys Phe
 1475 1480 1485

Leu

<210> 6
 <211> 1389
 <212> PRT
 <213> Homo sapiens

<400> 6

Met Ala His Ala Arg Val Leu Leu Leu Ala Leu Ala Val Leu Ala Thr
 1 5 10 15

Ala Ala Val Ala Val Ala Ser Ser Ser Ser Phe Ala Asp Ser Asn Pro
 20 25 30

Ile Arg Pro Val Thr Asp Arg Ala Ala Ser Thr Leu Ala Gln Leu Leu
 35 40 45

Gln Glu Glu Thr Val Arg Lys Gly Pro Ala Gly Asp Arg Gly Pro Arg
 50 55 60

Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Arg Asp Gly Glu Asp Gly
 65 70 75 80

Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu
 85 90 95

Gly Gly Asn Phe Ala Ala Gln Tyr Asp Gly Lys Gly Val Gly Leu Gly
 100 105 110

Pro Gly Pro Met Gly Leu Met Gly Pro Arg Gly Pro Pro Gly Ala Ala
 115 120 125

PCTIL2018050627-seql-000001-EN.txt

Gly Ala Pro Gly Pro Gln Gly Phe Gln Gly Pro Ala Gly Glu Pro Gly
130 135 140

Glu Pro Gly Gln Thr Gly Pro Ala Gly Ala Arg Gly Pro Ala Gly Pro
145 150 155 160

Pro Gly Lys Ala Gly Glu Asp Gly His Pro Gly Lys Pro Gly Arg Pro
165 170 175

Gly Glu Arg Gly Val Val Gly Pro Gln Gly Ala Arg Gly Phe Pro Gly
180 185 190

Thr Pro Gly Leu Pro Gly Phe Lys Gly Ile Arg Gly His Asn Gly Leu
195 200 205

Asp Gly Leu Lys Gly Gln Pro Gly Ala Pro Gly Val Lys Gly Glu Pro
210 215 220

Gly Ala Pro Gly Glu Asn Gly Thr Pro Gly Gln Thr Gly Ala Arg Gly
225 230 235 240

Leu Pro Gly Glu Arg Gly Arg Val Gly Ala Pro Gly Pro Ala Gly Ala
245 250 255

Arg Gly Ser Asp Gly Ser Val Gly Pro Val Gly Pro Ala Gly Pro Ile
260 265 270

Gly Ser Ala Gly Pro Pro Gly Phe Pro Gly Ala Pro Gly Pro Lys Gly
275 280 285

Glu Ile Gly Ala Val Gly Asn Ala Gly Pro Thr Gly Pro Ala Gly Pro
290 295 300

Arg Gly Glu Val Gly Leu Pro Gly Leu Ser Gly Pro Val Gly Pro Pro
305 310 315 320

Gly Asn Pro Gly Ala Asn Gly Leu Thr Gly Ala Lys Gly Ala Ala Gly
325 330 335

PCTIL2018050627-seql-000001-EN.txt

Leu Pro Gly Val Ala Gly Ala Pro Gly Leu Pro Gly Pro Arg Gly Ile
340 345 350

Pro Gly Pro Val Gly Ala Ala Gly Ala Thr Gly Ala Arg Gly Leu Val
355 360 365

Gly Glu Pro Gly Pro Ala Gly Ser Lys Gly Glu Ser Gly Asn Lys Gly
370 375 380

Glu Pro Gly Ser Ala Gly Pro Gln Gly Pro Pro Gly Pro Ser Gly Glu
385 390 395 400

Glu Gly Lys Arg Gly Pro Asn Gly Glu Ala Gly Ser Ala Gly Pro Pro
405 410 415

Gly Pro Pro Gly Leu Arg Gly Ser Pro Gly Ser Arg Gly Leu Pro Gly
420 425 430

Ala Asp Gly Arg Ala Gly Val Met Gly Pro Pro Gly Ser Arg Gly Ala
435 440 445

Ser Gly Pro Ala Gly Val Arg Gly Pro Asn Gly Asp Ala Gly Arg Pro
450 455 460

Gly Glu Pro Gly Leu Met Gly Pro Arg Gly Leu Pro Gly Ser Pro Gly
465 470 475 480

Asn Ile Gly Pro Ala Gly Lys Glu Gly Pro Val Gly Leu Pro Gly Ile
485 490 495

Asp Gly Arg Pro Gly Pro Ile Gly Pro Ala Gly Ala Arg Gly Glu Pro
500 505 510

Gly Asn Ile Gly Phe Pro Gly Pro Lys Gly Pro Thr Gly Asp Pro Gly
515 520 525

Lys Asn Gly Asp Lys Gly His Ala Gly Leu Ala Gly Ala Arg Gly Ala
530 535 540

PCTIL2018050627-seql-000001-EN.txt

Pro Gly Pro Asp Gly Asn Asn Gly Ala Gln Gly Pro Pro Gly Pro Gln
545 550 555 560

Gly Val Gln Gly Gly Lys Gly Glu Gln Gly Pro Ala Gly Pro Pro Gly
565 570 575

Phe Gln Gly Leu Pro Gly Pro Ser Gly Pro Ala Gly Glu Val Gly Lys
580 585 590

Pro Gly Glu Arg Gly Leu His Gly Glu Phe Gly Leu Pro Gly Pro Ala
595 600 605

Gly Pro Arg Gly Glu Arg Gly Pro Pro Gly Glu Ser Gly Ala Ala Gly
610 615 620

Pro Thr Gly Pro Ile Gly Ser Arg Gly Pro Ser Gly Pro Pro Gly Pro
625 630 635 640

Asp Gly Asn Lys Gly Glu Pro Gly Val Val Gly Ala Val Gly Thr Ala
645 650 655

Gly Pro Ser Gly Pro Ser Gly Leu Pro Gly Glu Arg Gly Ala Ala Gly
660 665 670

Ile Pro Gly Gly Lys Gly Glu Lys Gly Glu Pro Gly Leu Arg Gly Glu
675 680 685

Ile Gly Asn Pro Gly Arg Asp Gly Ala Arg Gly Ala His Gly Ala Val
690 695 700

Gly Ala Pro Gly Pro Ala Gly Ala Thr Gly Asp Arg Gly Glu Ala Gly
705 710 715 720

Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg Gly Ser Pro Gly Glu
725 730 735

Arg Gly Glu Val Gly Pro Ala Gly Pro Asn Gly Phe Ala Gly Pro Ala
740 745 750

PCTIL2018050627-seql-000001-EN.txt

Gly Ala Ala Gly Gln Pro Gly Ala Lys Gly Glu Arg Gly Gly Lys Gly
755 760 765

Pro Lys Gly Glu Asn Gly Val Val Gly Pro Thr Gly Pro Val Gly Ala
770 775 780

Ala Gly Pro Ala Gly Pro Asn Gly Pro Pro Gly Pro Ala Gly Ser Arg
785 790 795 800

Gly Asp Gly Gly Pro Pro Gly Met Thr Gly Phe Pro Gly Ala Ala Gly
805 810 815

Arg Thr Gly Pro Pro Gly Pro Ser Gly Ile Ser Gly Pro Pro Gly Pro
820 825 830

Pro Gly Pro Ala Gly Lys Glu Gly Leu Arg Gly Pro Arg Gly Asp Gln
835 840 845

Gly Pro Val Gly Arg Thr Gly Glu Val Gly Ala Val Gly Pro Pro Gly
850 855 860

Phe Ala Gly Glu Lys Gly Pro Ser Gly Glu Ala Gly Thr Ala Gly Pro
865 870 875 880

Pro Gly Thr Pro Gly Pro Gln Gly Leu Leu Gly Ala Pro Gly Ile Leu
885 890 895

Gly Leu Pro Gly Ser Arg Gly Glu Arg Gly Leu Pro Gly Val Ala Gly
900 905 910

Ala Val Gly Glu Pro Gly Pro Leu Gly Ile Ala Gly Pro Pro Gly Ala
915 920 925

Arg Gly Pro Pro Gly Ala Val Gly Ser Pro Gly Val Asn Gly Ala Pro
930 935 940

Gly Glu Ala Gly Arg Asp Gly Asn Pro Gly Asn Asp Gly Pro Pro Gly
945 950 955 960

PCTIL2018050627-seql-000001-EN.txt

Arg Asp Gly Gln Pro Gly His Lys Gly Glu Arg Gly Tyr Pro Gly Asn
965 970 975

Ile Gly Pro Val Gly Ala Ala Gly Ala Pro Gly Pro His Gly Pro Val
980 985 990

Gly Pro Ala Gly Lys His Gly Asn Arg Gly Glu Thr Gly Pro Ser Gly
995 1000 1005

Pro Val Gly Pro Ala Gly Ala Val Gly Pro Arg Gly Pro Ser Gly
1010 1015 1020

Pro Gln Gly Ile Arg Gly Asp Lys Gly Glu Pro Gly Glu Lys Gly
1025 1030 1035

Pro Arg Gly Leu Pro Gly Phe Lys Gly His Asn Gly Leu Gln Gly
1040 1045 1050

Leu Pro Gly Ile Ala Gly His His Gly Asp Gln Gly Ala Pro Gly
1055 1060 1065

Ser Val Gly Pro Ala Gly Pro Arg Gly Pro Ala Gly Pro Ser Gly
1070 1075 1080

Pro Ala Gly Lys Asp Gly Arg Thr Gly His Pro Gly Thr Val Gly
1085 1090 1095

Pro Ala Gly Ile Arg Gly Pro Gln Gly His Gln Gly Pro Ala Gly
1100 1105 1110

Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Val Ser Gly
1115 1120 1125

Gly Gly Tyr Asp Phe Gly Tyr Asp Gly Asp Phe Tyr Arg Ala Asp
1130 1135 1140

Gln Pro Arg Ser Ala Pro Ser Leu Arg Pro Lys Asp Tyr Glu Val
1145 1150 1155

PCTIL2018050627-seql-000001-EN.txt

Asp Ala Thr Leu Lys Ser Leu Asn Asn Gln Ile Glu Thr Leu Leu
1160 1165 1170

Thr Pro Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp
1175 1180 1185

Leu Arg Leu Ser His Pro Glu Trp Ser Ser Gly Tyr Tyr Trp Ile
1190 1195 1200

Asp Pro Asn Gln Gly Cys Thr Met Glu Ala Ile Lys Val Tyr Cys
1205 1210 1215

Asp Phe Pro Thr Gly Glu Thr Cys Ile Arg Ala Gln Pro Glu Asn
1220 1225 1230

Ile Pro Ala Lys Asn Trp Tyr Arg Ser Ser Lys Asp Lys Lys His
1235 1240 1245

Val Trp Leu Gly Glu Thr Ile Asn Ala Gly Ser Gln Phe Glu Tyr
1250 1255 1260

Asn Val Glu Gly Val Thr Ser Lys Glu Met Ala Thr Gln Leu Ala
1265 1270 1275

Phe Met Arg Leu Leu Ala Asn Tyr Ala Ser Gln Asn Ile Thr Tyr
1280 1285 1290

His Cys Lys Asn Ser Ile Ala Tyr Met Asp Glu Glu Thr Gly Asn
1295 1300 1305

Leu Lys Lys Ala Val Ile Leu Gln Gly Ser Asn Asp Val Glu Leu
1310 1315 1320

Val Ala Glu Gly Asn Ser Arg Phe Thr Tyr Thr Val Leu Val Asp
1325 1330 1335

Gly Cys Ser Lys Lys Thr Asn Glu Trp Gly Lys Thr Ile Ile Glu
1340 1345 1350

Tyr Lys Thr Asn Lys Pro Ser Arg Leu Pro Phe Leu Asp Ile Ala
 1355 1360 1365

Pro Leu Asp Ile Gly Gly Ala Asp His Glu Phe Phe Val Asp Ile
 1370 1375 1380

Gly Pro Val Cys Phe Lys
 1385

<210> 7
 <211> 5927
 <212> DNA
 <213> Homo sapiens

<400> 7		
tcgtcggagc agacgggagt ttctcctcg ggtcggagca ggaggcacgc ggagtgtgag	60	
gccacgcatg agcggacgct aacccctcc ccagccacaa agagtctaca tgtcttagggt	120	
ctagacatgt tcagcttgc ggacctccgg ctccctgctcc tcttagcggc caccgcctc	180	
ctgacgcacg gccaagagga aggc当地 gggccaaatc acgaagacat cccaccaatc	240	
acctgcgtac agaacggcct caggtaccat gaccgagacg tgtggaaacc cgagccctgc	300	
cggatctgctg tctgc当地 cggcaagggtg ttgtgc当地 acgtgatctg tgacgagacc	360	
aagaactgcc ccggccgcca agtccccgag ggc当地 ggtctgctg cccgc当地 ggc	420	
tcagagtcac ccaccgacca agaaaccacc ggc当地 cgagg gacccaaagg agacactggc	480	
ccccgaggcc caaggggacc cgc当地 gccc cctggccgag atggcatccc tggacagcct	540	
ggacttcccg gaccccccgg acccccccgg cctccggac cccctggcct cggaggaaac	600	
tttgc当地 ccc agctgtctta tggctatgat gagaatcaa cc当地 gaggaat ttccgtgc当地	660	
ggccccc当地 gg gtc当地 ctgg tcctcgatggt ctccctggcc cccctggc当地 acctggc当地	720	
caaggcttcc aaggctccccc tggctgagcct ggc当地 ggc当地 gagctt当地 cagg tcccatgggt	780	
ccccgaggcc ccccgaggcc cctggaaag aatggagatg atggggaaagc tggaaaacct	840	
ggc当地 gtc当地 ctgg gtgagcgtgg gcctc当地 tgg cctc当地 gaggtg ctc当地 gaggtt gccc当地 ggaaca	900	
gctggc当地 tccctcc ctggaaatgaa gggacacaga ggtttcagtg gtttggatgg tgccaaaggaa	960	

PCTIL2018050627-seql-000001-EN.txt

gatgctggtc	ctgctggtcc	taagggtgag	cctggcagcc	ctggtaaaa	tggagctcct	1020
ggtcagatgg	ccccccgtgg	cctgcctgg	gagagaggtc	gccctggagc	ccctggccct	1080
gctggtgctc	gtggaaatga	tggtgctact	ggtgctgccc	ggccccctgg	tcccaccggc	1140
cccgctggtc	ctcctggctt	ccctggtgct	gttggtgcta	agggtgaagc	tggccccaa	1200
gggccccgag	gctctgaagg	tccccaggg	gtgcgtggtg	agcctggccc	ccctggccct	1260
gctggtgctg	ctggccctgc	tggaaaccct	ggtgctgatg	gacagcctgg	tgctaaaggt	1320
gccaatggtg	ctcctggtat	tgctggtgct	cctggcttcc	ctggtgcccg	aggcccctct	1380
ggaccccagg	ccccggcgg	ccctcctgg	cccaagggt	acagcggta	acctggtgct	1440
cctggcagca	aaggagacac	tggtgctaag	ggagagcctg	gccctgttgg	tgttcaagga	1500
ccccctggcc	ctgctggaga	ggaaggaaag	cgaggagctc	gaggtgaacc	cggaccact	1560
ggcctgccc	gacccctgg	cgagcgtgg	ggacctggta	gccgtggttt	ccctggcgca	1620
gatggtgtt	ctggtccaa	gggtccc	ggtgaacgtg	gttctcctgg	ccctgctggc	1680
cccaaaggat	ctcctggta	agctggtcgt	cccggtgaag	ctggtctgcc	tggtgc	1740
ggtctgactg	gaagccctgg	cagccctgg	cctgatggca	aaactggccc	ccctggccc	1800
gccggtaag	atggtc	cggacccca	ggcccacctg	gtgcccgtgg	tcaggctgg	1860
gtgatggat	tccctggacc	taaagg	gctggagagc	ccggcaaggc	tggagagcga	1920
ggtgttccc	gacccctgg	cgctgtcggt	cctgctggca	aagatggaga	ggctggagct	1980
cagggacccc	ctggccctgc	tggccc	ggcgagagag	gtgaacaagg	ccctgctggc	2040
tccccggat	tccagggtct	ccctgg	gctggc	caggtgaagc	aggcaaacc	2100
ggtgaacagg	gtgttctgg	agac	ccctgg	cctctggagc	aagaggcgag	2160
agagg	ctggcgagcg	tgg	gttgc	gttccc	gttcc	2220
cccaacgg	ctccggcaa	cgatgg	gttgc	gttccc	gttcc	2280
ggtagccagg	gccc	c	atgc	atgc	atgc	2340
ccagggccta	agg	gtgac	ggat	ggat	ggat	2400
aaagatggcg	tccgtgg	gactgg	attgg	attgg	attgg	2460
ggtgacaagg	gtgaa	gtgaa	gtgaa	gtgaa	gtgaa	2520

PCTIL2018050627-seql-000001-EN.txt

cccgagacc	gtggtaggcc	tggcccccc	ggccctgctg	gcttgctgg	ccccctgg	2580
gctgacggcc	aacctggtgc	taaaggcgaa	cctggtgatg	ctggtgctaa	aggcgatgct	2640
ggtccccctg	gccctgccgg	accgcgttga	ccccctggcc	ccattggtaa	tgttggtgct	2700
cctggagcca	aagggtgctcg	cggcagcgct	ggtccccctg	gtgctactgg	tttccctgg	2760
gctgctggcc	gagtcggtcc	tcctggccccc	tctggaaatg	ctggacccccc	tggccctcct	2820
ggtcctgctg	gcaaagaagg	cggcaaagggt	ccccgtggtg	agactggccc	tgctggacgt	2880
cctggtaag	ttggtcccccc	tggtccccct	ggccctgctg	gcgagaaagg	atcccctgg	2940
gctgatggtc	ctgctggtgc	tcctggtaact	cccgccctc	aaggatttgc	tggacagcgt	3000
ggtgtggtcg	gcctgcctgg	tcagagagga	gagagaggct	tccctggtct	tcctggccccc	3060
tctggtaac	ctggcaaaca	aggccctct	ggagcaagtg	gtgaacgtgg	tccccctgg	3120
cccatgggcc	cccctggatt	ggctggaccc	cctggtaat	ctggacgtga	gggggctcct	3180
ggtggcgaag	gttccccctgg	acgagacggt	tctcctggcg	ccaagggtga	ccgtggtgag	3240
accggccccc	ctggacccccc	tggtgctcct	ggtgctcctg	gtgccccctgg	ccccgttggc	3300
cctgctggca	agagtggtga	tcgtggtgag	actggccctg	ctggcccccgc	cggcctgtc	3360
ggccctgttg	gcccgggtgg	ccccggccgga	ccccaaaggcc	cccgtggtga	caagggtgag	3420
acaggcgaac	agggcgacag	aggcataaaag	ggtcaccgtg	gcttctctgg	cctccagggt	3480
ccccctggcc	ctcctggctc	tcctggtgaa	caagggtccct	ctggagccctc	tggcctgtct	3540
ggtccccgag	gtccccctgg	ctctgctgg	gctcctggca	aagatggact	caacggctc	3600
cctggcccca	ttgggcccccc	tggcctcgc	ggtcgcactg	gtgatgctgg	tcctgttggt	3660
ccccccggcc	ctcctggacc	tcctggtccc	cctggccctc	ccagcgctgg	tttcgacttc	3720
agcttcctgc	cccagccacc	tcaagagaag	gctcacgtg	gtggccgcta	ctaccgggct	3780
gatgatgcca	atgtggttcg	tgaccgtgac	ctcgaggtgg	acaccacccct	caagagcctg	3840
agccagcaga	tcgagaacat	ccggagccca	gagggcagcc	gcaagaaccc	cggccgcacc	3900
tgccgtgacc	tcaagatgtg	ccactctgac	tggaagagtg	gagagactg	gattgacccccc	3960
aaccaaggct	gcaacctgga	tgccatcaa	gtcttctgca	acatggagac	tggtgagacc	4020
tgcgtgtacc	ccactcagcc	cagtgtggcc	cagaagaact	ggtacatcag	caagaacccccc	4080

PCTIL2018050627-seql-000001-EN.txt

aaggacaaga	ggcatgtctg	gttcggcgag	agcatgaccg	atggattcca	gttcgagttat	4140
ggcggccagg	gctccgaccc	tgccgatgtg	gccatccagc	tgaccttcct	gcccgtatg	4200
tccaccgagg	cctcccagaa	catcacctac	cactgcaaga	acagcgtggc	ctacatggac	4260
cagcagactg	gcaacacctaa	gaaggccctg	ctcctccagg	gctccaacga	gatcgagatc	4320
cgcggccagg	gcaacagccg	cttcacccat	agcgtcaactg	tcgatggctg	cacgagtcac	4380
accggagcct	ggggcaagac	agtgattgaa	tacaaaacca	ccaagacctc	ccgcctgccc	4440
atcatcgatg	tggcccccctt	ggacgttggt	gccccagacc	aggaattcgg	cttcgacgtt	4500
ggccctgtct	gcttcctgta	aactccctcc	atcccaacct	ggctccctcc	cacccaacca	4560
actttcccc	caacccggaa	acagacaagc	aacccaaact	gaaccccctc	aaaagccaaa	4620
aatgggaga	caatttcaca	tggactttgg	aaaatatttt	tttcctttgc	attcatctct	4680
caaacttagt	ttttatcttt	gaccaaccga	acatgaccaa	aaacccaaag	tgcattcaac	4740
cttaccaaaa	aaaaaaaaaa	aaaaagaata	aataaataac	tttttaaaaaa	aggaagcttg	4800
gtccacttgc	ttgaagaccc	atgcgggggt	aagtcccttt	ctgcccgtt	ggcttatgaa	4860
accccaatgc	tgccctttct	gctccttct	ccacaccccc	cttggggcct	cccctccact	4920
ccttccaaa	tctgtctccc	cagaagacac	aggaaacaat	gtattgtctg	cccagcaatc	4980
aaaggcaatg	ctcaaacacc	caagtggccc	ccaccctcag	cccgctcctg	ccgcggcagc	5040
accccccaggc	cctgggggac	ctggggttct	cagactgcca	aagaagcctt	gccatctggc	5100
gctcccatgg	ctcttgcaac	atctccctt	cgttttgag	ggggtcatgc	cgggggagcc	5160
accagccct	cactgggttc	ggaggagagt	caggaaggc	cacgacaaag	cagaaacatc	5220
ggatttgggg	aacgcgtgtc	aatcccttgt	gccgcagggc	tgggcgggag	agactgttct	5280
gttccttgc	taactgtgtt	gctgaaagac	tacctcggtc	ttgtcttgat	gtgtcaccgg	5340
ggcaactgcc	tgggggcggg	gatgggggca	gggtggaagc	ggctccccc	tttataccaa	5400
aggtgctaca	tctatgtgtat	gggtgggtg	gggagggaaat	cactggtgct	atagaaattg	5460
agatgcccc	ccaggccagc	aatgttcct	ttttgttcaa	agtctatttt	tattccttga	5520
tatttttctt	tttttttttt	ttttttgtg	gatggggact	tgtgaatttt	tctaaaggtg	5580
ctatccaaca	tgggaggaga	gcgtgtgcgg	ctccagccca	gcccgctgct	cactttccac	5640

PCTIL2018050627-seql-000001-EN.txt

cctctctcca	cctgcctctg	gcttctcagg	cctctgctct	ccgacacctc	tcctctgaaa	5700
ccctcctcca	cagctgcagc	ccatcctccc	ggctccctcc	tagtctgtcc	tgcgtcctct	5760
gtccccgggt	ttcagagaca	acttccaaa	gcacaaagca	gtttttcccc	ctaggggtgg	5820
gaggaagcaa	aagactctgt	acctattttg	tatgtgtata	ataatttgag	atgttttaa	5880
ttattttat	tgctggaata	aagcatgtgg	aaatgaccca	aacataa		5927

<210> 8
<211> 5411
<212> DNA
<213> Homo sapiens

<400> 8	gtgtccata	gtgtttccaa	acttggaaag	ggcgggggag	ggcggggagga	tgcggagggc	60
ggaggtatgc	agacaacgag	tcaagatttc	cccttgaag	cctcaaaagt	gtccacgtcc		120
tcaaaaagaa	tggaaccaat	ttaagaagcc	agccccgtgg	ccacgtccct	tcccccattc		180
gctccctcct	ctgcgcccc	gcaggctcct	cccagctgtg	gctgcccggg	cccccagccc		240
cagccctccc	attggtgag	gcccttttgg	aggcaccta	gggccaggga	aactttgcc		300
gtataaatag	ggcagatccg	ggctttatta	ttttagcacc	acggcagcag	gaggttcgg		360
ctaagttgga	ggtactggcc	acgactgcat	gcccgcgccc	gccaggtgat	acctccgccc		420
gtgaccagg	ggctctgcga	cacaaggagt	ctgcatgtct	aagtgctaga	catgctcagc		480
tttgtggata	cgcggacttt	gttgctgctt	gcagtaacct	tatgcctagc	aacatgccaa		540
tctttacaag	aggaaactgt	aagaaaggc	ccagccggag	atagaggacc	acgtggagaa		600
aggggtccac	caggcccccc	aggcagagat	ggtgaagatg	gtcccacagg	ccctcctggt		660
ccacctggtc	ctcctggccc	ccctggtctc	ggtggaaact	ttgctgctca	gtatgatgga		720
aaaggagttg	gacttggccc	tggaccaatg	ggcttaatgg	gacctagagg	cccacctggt		780
gcagctggag	ccccaggccc	tcaaggtttc	caaggacctg	ctggtgagcc	tggtgaacct		840
ggtcaaactg	gtcctgcagg	tgctcgtggt	ccagctggcc	ctcctggcaa	ggctggtgaa		900
gatggtcacc	ctggaaaacc	cggacgacct	ggtgagagag	gagttgttgg	accacagggt		960
gctcgtggtt	tccctggaac	tcctggactt	cctggcttca	aaggcattag	gggacacaat		1020
ggtctggatg	gattgaaggg	acagcccggt	gctcctggtg	tgaagggtga	acctggtgcc		1080

PCTIL2018050627-seql-000001-EN.txt

cctggtgaaa atggaactcc aggtcaaaca ggagccgtg ggcttcctgg tgagagagga	1140
cgtttggtg cccctggccc agctggtgcc cgtggcagtg atggaagtgt gggtcccgta	1200
ggtcctgctg gtcccatgg gtctgctggc cctccaggct tcccagggtgc ccctggcccc	1260
aagggtgaaa ttggagctgt tggtaacgct ggtcctgctg gtcccgccgg tccccgtggt	1320
gaagtgggtc ttccaggcct ctccggcccc gttggacctc ctggtaatcc tggagcaaac	1380
ggccttactg gtgccaaggg tgctgctggc cttccggcg ttgctggggc tcccgccctc	1440
cctggacccc gcggtattcc tggccctgtt ggtgctgccc gtgctactgg tgccagagga	1500
cttggtggtg agcctggtcc agctggctcc aaaggagaga gcggtaacaa gggtgagccc	1560
ggctctgctg ggcccaagg tcctcctggt cccagtggtg aagaaggaaa gagaggccct	1620
aatgggaag ctggatctgc cggccctcca ggacccctg ggctgagagg tagtcctggt	1680
tctcgtggtc ttcctggagc tcatggcaga gctggcgtca tggccctcc tgtagtcgt	1740
ggtgcaagtg gccctgctgg agtccgagga cctaattggag atgctggtcg ccctggggag	1800
cctggtctca tgggacccag aggtttccct gttccctg gaaatatcgg ccccgctgga	1860
aaagaaggta ctgtcggcct ccctggcatc gacggcaggc ctggcccaat tggccagct	1920
ggagcaagag gagagcctgg caacatttggaa ttccctggac ccaaaggccc cactgggtat	1980
cctggcaaaa acggtgataa aggtcatgct ggtttgctg gtgctcgaaa tgctccaggt	2040
cctgatggaa acaatggtgc tcagggaccc cctggaccac agggtgttca aggtggaaaa	2100
ggtaacagg gtcccccctgg tcctccaggc ttccagggtc tgcctggccc ctcaaggccc	2160
gctggtaag ttggcaaacc aggagaaagg ggtctccatg gtgagttgg tctccctggt	2220
cctgctggtc caagagggaa acgcggtccc ccaggtgaga gtgggtctgc cggtcctact	2280
ggtcctattg gaagccgagg tccttctggaa cccccaggc ctgatggaaa caagggtgaa	2340
cctgggttgg ttggtgctgt gggcactgct ggtccatctg gtcctagtgg actccaggaa	2400
gagaggggtg ctgctggcat acctggaggc aaggagaaaa agggtaacc tggtctcaga	2460
ggtaaattt gtaaccctgg cagagatggt gtcgtggtg ctccgtgtc tgttaggtgcc	2520
cctggtcctg ctggagccac aggtgaccgg ggcgaagctg gggctgctgg tcctgctgg	2580
cctgctggtc ctcggggaaag ccctggtgaa cgtggtgagg tcggtcctgc tggcccaat	2640

PCTIL2018050627-seql-000001-EN.txt

ggatttgctg gtcctgctgg tgctgctggc caacctggtg ctaaaggaga aagaggagcc	2700
aaaggcccta agggtaaaa cggtgttggt ggtcccacag gccccgttgg agctgctggc	2760
ccagctggtc caaatggtcc ccccggtcct gctggaagtc gtgggtatgg aggccccct	2820
ggtatgactg gtttccctgg tgctgctgga cggactggtc ccccaggacc ctctggatt	2880
tctggccctc ctggcccccc tggcctgct gggaaagaag ggcttcgtgg tcctcgtgg	2940
gaccaaggtc cagttggccg aactggagaa gtaggtgcag ttggtcccc tggcttcgct	3000
ggtgagaagg gtccctctgg agaggctggt actgctggac ctccctggcac tccaggtcct	3060
cagggtcttc ttggtgctcc tggtattctg ggtctccctg gctcgagagg tgaacgtgg	3120
ctaccaggtg ttgctggtgc tgtgggtgaa cctggtcctc ttggcattgc cggccctcct	3180
ggggccctgt gtcctccctgg tgctgtgggt agtcctggag tcaacggtgc tcctggtaa	3240
gctggtcgtg atggcaaccc tgggaacgat ggtccccag gtcgcgatgg tcaacccgga	3300
cacaaggag agcgcggta ccctggcaat attggccctcg ttggtgctgc aggtgcaccc	3360
ggtcctcatg gccccgtggg tcctgctggc aaacatggaa accgtggtga aactggtcct	3420
tctggtcctg ttggtcctgc tggtgctgtt ggcccaagag gtcctagtgg cccacaaggc	3480
attcgtggcg ataagggaga gcccggtgaa aagggggcca gaggtcttcc tggcttaaag	3540
ggacacaatg gattgcaagg tctgcctggt atcgctggtc accatggtga tcaaggtgct	3600
cctggctccg tgggtcctgc tggccttagg ggccctgctg gtccttctgg ccctgctgg	3660
aaagatggtc gcactggaca tcctggtaca gttggacctg ctggcattcg aggcctcag	3720
ggtcaccaag gccctgctgg cccccctggt cccctggcc ctccctggacc tccaggtgt	3780
agcgggtgt gttatgactt tggttacgat ggagacttct acaggcgtga ccagcctcgc	3840
tcagcacctt ctctcagacc caaggactat gaagttgatg ctactctgaa gtctctcaac	3900
aaccagattg agacccttct tactcctgaa ggctctagaa agaaccgc tcgcacatgc	3960
cgtgacttga gactcagcca cccagagtgg agcagtggtt actactggat tgacccta	4020
caaggatgca ctatggatgc tatcaaagta tactgtgatt tctctactgg cgaaacctgt	4080
atccgggccc aacctaaaa catcccagcc aagaactggt ataggagctc caaggacaag	4140
aaacacgtct ggcttaggaga aactatcaat gctggcagcc agtttgaata taatgtagaa	4200

PCTIL2018050627-seql-000001-EN.txt

ggagtgactt ccaaggaaat ggctacccaa cttgccttca tgcgcctgct ggccaactat	4260
gcctctcaga acatcaccta ccactgcaag aacagcattg catacatgga tgaggagact	4320
ggcaacctga aaaaggctgt cattctacag ggctctaattg atgttgaact tgttgctgag	4380
ggcaacagca ggttcactta cactgttctt gtagatggct gctctaaaaa gacaaatgaa	4440
tggggaaaga caatcattga atacaaaaca aataagccat cacgcctgcc cttccttgat	4500
attgcacctt tggacatcgg tggtgctgac caggaattct ttgtggacat tggcccagtc	4560
tgtttcaat aaatgaactc aatctaaatt aaaaaagaaa gaaatttcaa aaaactttct	4620
ctttgccatt tcttcttctt ctttttaac tcaaagctga atccttccat ttcttctgca	4680
catctacttg cttaaattgt gggcaaaaga gaaaaagaag gattgatcag agcattgtgc	4740
aatacagttt cattaactcc ttcccccgct cccccaaaaa tttgaatttt ttttcaaca	4800
ctcttacacc tggatggaa aatgtcaacc tttgttaagaa aacccaaata aaaattgaaa	4860
aataaaaaacc ataaacattt gcaccacttg tggctttga atatcttcca cagagggaaag	4920
tttaaaaccc aaacttccaa aggttaaac tacctcaaaa cacttccca tgagtgtgat	4980
ccacattgtt aggtgctgac ctagacagag atgaactgag gtccttgttt tgtttggtc	5040
ataatacaaa ggtgctaatt aatagtattt cagatacttg aagaatgtt atggtgctag	5100
aagaatttga gaagaaatac tcctgtattt agttgtatcg tgtggtgtat tttttaaaaa	5160
atttgatttgcattcatat tttccatctt attcccaatt aaaagtatgc agattatttgc	5220
cccaaatctt ctccagattc agcattgtt cttgccagt ctcattttca tcttcttcca	5280
tggttccaca gaagcttgc ttcttggca agcagaaaaa ttaaattgtt cctatattgt	5340
atatgtgaga tggtaataa aattgtgaaa aaaatgaaat aaagcatgtt tggtttccaa	5400
aaagaacata t	5411

<210> 9
 <211> 4467
 <212> DNA
 <213> Homo sapiens

<400> 9
 atggctcacg ctcgtttctt cttccctcgct ctgcgtttt tggcaacagc tgctgtggct

PCTIL2018050627-seql-000001-EN.txt

gtggcttcta	gttcttcttt	tgctgattca	aaccctatta	gacctgttac	tgatagagca	120
gcttccactt	tggctcaatt	gcaagaggag	ggccaggttg	agggccaaga	tgaggatatc	180
cctccaatta	catgcgtgca	aatggcttg	cgttaccacg	atagggatgt	gtggaaacct	240
gaaccttgtc	gtatctgtgt	gtgtgataac	ggcaaggtgc	tctgcgatga	tgttatctgc	300
gatgagacaa	aaaattgccc	tggcgctgaa	gttcctgagg	gcgagtgttgc	ccctgtgtgc	360
cctgatggtt	ccgagtcggcc	aactgatcag	gaaactactg	gcgtggaggg	cccaaaaagga	420
gatactggtc	cacgtggtcc	taggggtcca	gcaggtcctc	caggtagaga	tggtattcca	480
ggccagcctg	gattgccagg	accaccaggc	ccacctggcc	caccaggacc	tcctggtctt	540
ggtgaaatt	tcgctccaca	actctcttat	ggctatgatg	agaagtcaac	aggtggattt	600
tccgttccag	gtcctatggg	accatccgga	ccaagaggtc	tcccaggtcc	tccaggtgct	660
cctggacctc	aaggcttca	aggacctcca	ggcgaaccag	gagaaccagg	cgcttctgga	720
ccaatgggcc	caaggggacc	acctggccca	ccagaaaaaa	atggcgatga	tggcgaagct	780
ggaaagcctg	gtcgtcctgg	agagagaggt	cctcctggcc	cacagggtgc	aagaggcttgc	840
ccaggaactg	ctggcttgcc	tggaatgaag	ggacataggg	gcttctccgg	cctcgatggc	900
gctaagggtg	atgctggccc	tgctggacca	aagggcgagc	caggttcccc	tggagaaaac	960
ggtgctcctg	gacaaatggg	tcctcgtgga	cttccaggag	aaaggggtcg	tccaggcgct	1020
ccaggaccag	caggtgctag	ggaaaacgtat	ggtgcaacag	gcgctgctgg	ccctcctggc	1080
ccaactggtc	ctgctggccc	tccaggattc	ccaggcgcag	ttggagctaa	aggagaagca	1140
ggaccacagg	gccctagggg	ttctgaagga	cctcagggtg	ttagaggtga	accaggtcct	1200
ccaggcccag	ctggagcagc	tggccagca	ggaaatccag	gtgctgatgg	tcaacctgga	1260
gctaaggcg	ctaattggcgc	accaggtatc	gcaggcgcac	caggtttcc	tggcgctaga	1320
ggcccaagtg	gtcctcaagg	accaggtgga	ccaccaggtc	caaaaggcaa	ttctggcgaa	1380
cctggcgctc	caggttctaa	aggagatact	ggtgctaaag	gcgaaccagg	acctgttggt	1440
gttcagggtc	ctcctggtcc	tgctggagaa	gaagggaaaaaa	gaggtgctcg	tggagaaccca	1500
ggaccaactg	gacttcctgg	acccctgtgt	gaacgtggcg	gacctggctc	aaggggtttc	1560
cctggagctg	atggagtgcc	aggccaaaaa	ggccctgctg	gagagagagg	ttcaccaggt	1620

PCTIL2018050627-seql-000001-EN.txt

ccagctggtc ctaaggcgc ccctggtaa gcaggttagac caggcgaagc aggattgcca	1680
ggcgcaaagg gattgacagg ctctcctggt agtcctggcc cagatggaaa aacaggccca	1740
ccaggtccag caggacaaga tggacgtcca ggcccaccag gtcctcctgg agcaagggga	1800
caagctggcg ttatgggttt tccaggacct aaaggtgctg ctggagagcc aggaaaggca	1860
ggtgaaagag gagttcctgg tccaccagga gcagtgggtc ctgctggcaa agatggtaa	1920
gctggagcac agggccctcc aggccctgct ggcccagctg gcgaacgtgg agaacaaggc	1980
ccagctggta gtccaggatt tcaaggattt cctggccctg ctggccctcc aggagaagca	2040
ggaaaacctg gagaacaagg agttcctggt gatttggag cacctggacc ttcaggagca	2100
cgtggtaaaa gaggcttccc tggcgagagg ggtgttcaag gtccaccagg tccagcagga	2160
cctagaggtg ctaatggcgc tcctggcaac gatggagcaa aaggtgatgc tggtgctcct	2220
ggcgacactg gaagtcaggg tgctcctggta ttgcaaggaa tgcctggaga gaggggtgct	2280
gctggcttgc caggccaaa gggcgatagg ggtgatgctg gaccaaagg tgctgatggaa	2340
tccccaggaa aagatggagt tcgtggtctt actggccaa tcggacactcc aggccctgct	2400
ggcgctccag gtgataaggg ccaaagtggc ccaagtgac ctgctggacc tactggtgct	2460
agaggtgcac ctggtgatag gggtaacact ggaccacactg gtccagctgg ttttgctgg	2520
cctcctggag ctgatggaca acctggcgca aagggtgaac caggtgatgc tggcgcaaag	2580
ggagatgctg gtccacactgg acctgctggt ccagcaggcc cccctggggcc aatcgtaat	2640
gttggagcac caggtgctaa gggagctagg gttccgctg gtccacactgg agcaacagga	2700
tttccaggcg ctgctggtag agttggccca ccaggccat ccggaaacgc aggccctcct	2760
ggtcctccag gtcctgctgg caaggagggt ggcaaaggac caaggggcga aactggccct	2820
gctggtagac ctggcgaagt tggccctcct ggaccacccag gtccagcagg agaaaaaggt	2880
tccccaggag ctgatggccc agctggtgct ccaggaactc caggccctca aggtattgct	2940
ggacagagag gcgttgggg actccctggt caaaggggag agagaggatt tccaggcttg	3000
ccaggaccta gtggagaacc tggaaaacaa ggcccatcag ggcgtatgg agagcgtgga	3060
cctcctggcc ctatgggacc tcctggattt gctggcccac ctggcgaatc aggtcgtgaa	3120
ggcgacccag ggcgagaagg atcacctgga agagatggat cccctggcgtc taaaggcgat	3180

PCTIL2018050627-seql-000001-EN.txt

cgtggagaaa	ctgggccagc	aggcccacca	ggcgcaccag	gtgcacctgg	cgctccagga	3240
cctgtggac	cagctggaaa	atccggagat	aggggcgaga	caggcccagc	aggaccagct	3300
ggacctgttg	gccctgctgg	cgctcgtgga	ccagcaggac	ctcaaggacc	aaggggagat	3360
aaggagaaaa	caggcgaaca	aggcgatagg	ggcattaagg	gtcatagggg	ttttagtggc	3420
ctccagggtc	ctcctggccc	acctggatca	ccaggagaac	agggaccatc	tggtgcttcc	3480
ggcccagctg	gtccaagagg	acctccagga	tcagctggtg	cacctggaaa	agatggtctt	3540
aacggtctcc	caggaccaat	cggccctcca	ggacctagag	gaagaacagg	agatgctggc	3600
cctgttggcc	ctccaggacc	tcctggtcca	ccaggtccac	ctggcctcc	atcagctgga	3660
ttcgattttt	catttcttcc	acagccacca	caagagaaag	ctcacgatgg	cggcagatata	3720
taccgtgctg	atgatgctaa	cgttggtagg	gatagagatt	tggaagtgg	tacaactttg	3780
aaatccctct	cccagcaaat	tgaaaacatt	agatctccag	aaggttcacg	taaaaaccca	3840
gctagaacat	gtcgtgattt	gaaaatgtgt	cactccgatt	ggaaaagtgg	tgaatactgg	3900
attgatccaa	atcagggctg	taatctcgat	gctatcaaag	tttctgtaa	catggaaaca	3960
ggcgaacat	gcgttatcc	tactcaacct	tccgtggctc	agaaaaattt	gtacatctca	4020
aaaaatccta	aagataagag	gcacgtttgg	ttcggtaaa	gtatgactga	tggatttcaa	4080
tttgagtagc	gcggtaagg	tagttagtcca	gctgatgtgg	ctattcaact	cacattttt	4140
cgtcttatgt	ccacagaggc	atcacaaaac	atcacttacc	actgcaaaaa	cagtgtggct	4200
tatatggatc	aacaaacagg	aaaccttaag	aaggcttttc	tttgaaggg	ctcaaacgag	4260
attgagatta	gagcagaggg	caactcaagg	tttacttatt	cagttactgt	tgatggctgc	4320
acttcacata	ctggcgctt	ggtaaaaca	gttatcgagt	ataagactac	aaaaacatca	4380
agactcccaa	tcattgatgt	tgctcctctc	gatgtggcg	ctcctgatca	agagttcggt	4440
tttgatgtgg	gccccagttt	tttcctc				4467

<210> 10

<211> 4167

<212> DNA

<213> Homo sapiens

<400> 10

atggctcacg	ctcgtttct	cctcctcgct	ctcgctgttt	tggcaacagc	tgctgtggct	60
------------	-----------	------------	------------	------------	------------	----

PCTIL2018050627-seql-000001-EN.txt

gtggcttcaa gttctagtt tgctgattcc aacccaattc gtccagttac tgatagagca	120
gcttccactt tggctcaatt gcttcaagaa gaaactgtga ggaaggccc tgctggcgat	180
aggggccccta gggcgaaag gggccacca ggacctccag gcagggatgg cgaagatggt	240
ccaactggcc ctcctggacc tcctggccct ccagggccac ccggcttggg cgaaacttc	300
gcagctcaat acgatggcaa gggtgttggt cttggcctg gtcctatggg cttgatggga	360
cctagaggcc cacctggtgc tgctggtgct cctggaccac agggtttca gggaccagct	420
ggcgagccag gagagccagg ccaaacagga ccagctggtg caaggggacc tgctggacct	480
cctggaaaag ctggtaaga tggtcaccca ggcaaaccag gacgtcctgg cgaaagaggt	540
tttgggac cacaaggcgc tagggattt ccaggtacac ctggattgcc aggttttaag	600
ggcattcgtg gtcataacgg cctcgatgga ttgaaggac agcctggcgc acctggcggt	660
aagggtgaac ctggagcacc aggtgaaaac ggtactcctg gccagactgg tgcaagagga	720
ctcccaggtg aaagggtag agttggtgct cctggacctg ctggagctag ggtagtgat	780
ggtagtggtg gtcctgtgg ccctgctggt ccaatcggtt ccgctggccc acctggattc	840
ccagggcgtc caggaccta aggagaaatc ggtgctgtgg gtaacgcagg tcctactgg	900
ccagcaggc tcgtggaga agtgggattt ccaggacttt ctggccagt gggccctcca	960
ggcaaccctg gagctaacgg cttgacagga gctaaaggcg cagcaggact ccctggagtg	1020
gctggcgcac caggattgcc tggccaagg ggtatcccag gccctgttgg cgtagctgg	1080
gctactggtg cacgtggact tggcgaa ccaggccctg ctggatcaaa aggcgagtct	1140
ggaaataagg gagaacctgg ttctgctgga cctcaaggc tcctggacc ttctggagaa	1200
gaaggaaaaa gggaccaaa tggcgaggct ggatcagcag gtccaccagg accacctgga	1260
ttcgtggat cccctggtag tagaggactt ccaggcgtc atggtagagc aggctttagt	1320
ggaccaccag gaagtagagg agcatccggt ccagcaggag ttagggtcc taacggagat	1380
gctggtagac caggtgaacc aggtctttagt ggcggagg gcctcccagg tagtccagga	1440
aatatcgccc ctgctggaaa agaaggccct gttggacttc caggtattga tggacgtcct	1500
ggccctattt gcccaggcagg tgcaagagga gaacctggca atattggatt tccaggacca	1560
aagggtccaa caggcgatcc tggaaaaat ggagataagg gtcatgctgg attggcaggc	1620

PCTIL2018050627-seql-000001-EN.txt

gcaagggcg ctcctggtcc agatggaaac aacggcgac agggtccacc tggccctcag	1680
ggtgttcaag gcggaaaagg cgaacaaggc ccagctggac caccaggctt tcaaggcttgc	1740
ccaggaccaa gtggtccagc aggtgaagtt ggcaagccag gcgagcgtgg acttcatggc	1800
gagtttggac tccctggacc agcaggacca aggggtgaaa gaggccctcc tggagagagt	1860
ggcgctgctg gaccaacagg cccaatcggt agtagaggtc ctagtggacc tccaggccca	1920
gatggaaata agggtgaacc aggagttgtg ggcgctgttg gaacagctgg tccttcagga	1980
ccatcaggac tcccaggcga gagaggcgct gctggcattc ctggaggaaa aggtgaaaaaa	2040
ggcgaacctg gcctccgtgg cgaatcgga aatcctggac gtgatggtgc tcgtggtgca	2100
cacggcgctg tggcgctcc agggcctgct ggtgctactg gtgatagagg agaggctggc	2160
cgagctggcc cagcagggtcc tgctggccca aggggtagtc ctggtaaaag aggcaagtt	2220
ggacctgctg gccctaacgg cttgctggc cctgctggag cagcaggtaa acctggcgct	2280
aaaggtaaaa gggcgaaaa gggccaaaaa ggtgaaaatg gcgttgggg accaactgg	2340
ccagtggcg cagctggacc tgctggtcca aatggaccac caggaccagc aggttagtaga	2400
ggagatggtg gacctccagg aatgacaggt tttccaggtg ctgctggtag aacaggac	2460
cctggccta gtggtatttc tggccacca ggaccaccag gtcctgctgg aaaagaagga	2520
ttgaggggtc cacgtggtaa tcaaggacca gtggcagaa ctggtaagt tggcgcagt	2580
ggaccacctg gtttgctgg agaaaaggc cttctggag aggcaggaac agctggcct	2640
cctggtacac ctggaccta aggactttg ggtcacctg gtattctcg attgccagga	2700
agtagggcg aacgtggact tcctggcgtg gcaggagcag ttggagaacc tggcccttc	2760
ggaatcgcag gcccaccagg cgcaagagga ccaccaggag ctgttggatc accaggcgt	2820
aatggtgac ctggcgaggc tggcgtgat gaaatgtgg cccaccagga	2880
agagatggtc aacctggaca caaaggcgag aggggctacc cagggaaat tggcccgat	2940
ggtgctgctg ggcgaccagg cccacacgg ccagttggac cagcaggaaa acacggtaat	3000
cgtggcgaaa caggcccttc aggcccagtgg gacactgctg gtgctgttgg cccaagagga	3060
ccatctggac ctcaaggcat tagaggcgat aaggagagc ctggcgaaaa aggacctaga	3120
ggcttgcctg gtttaaagg acacaacggt ctccaaggac ttccaggtat cgctggcat	3180

PCTIL2018050627-seql-000001-EN.txt

catggagatc	agggtgctcc	tggatcagtg	ggtccagcag	gtcctagagg	cccagcaggc	3240
ccttccggtc	cagcagggaaa	ggatggacgt	actggccacc	ctggaactgt	gggcctgct	3300
ggaatttagag	gtcctaagg	tcatcagggc	cctgctggcc	ctccaggtcc	accaggtcct	3360
ccaggcccac	caggagtttc	aggtggtggt	tacgatttg	gttacgatgg	tgattttac	3420
cgtgctgatc	aacctagaag	tgctccttct	ctccgtccta	aagattatga	agttgatgct	3480
actttgaaat	cacttaacaa	ccagattgag	actcttctca	cacctgaggg	atcaagaaag	3540
aatccagcac	gtacatgccg	tgatctcaga	cttagtcacc	cagagtggtc	aagtggctat	3600
tattggattg	atcctaatac	gggttgtaca	atggaggct	tcaaagttt	ctgtgatttt	3660
ccaaactggag	agacatgtat	tagggcacaa	cctgagaaca	ttccagctaa	aaattggtat	3720
cgttcctcta	aagataagaa	acatgtttgg	ctcggagaga	ctattaacgc	tggttctcag	3780
ttcgagtata	atgttgaggg	cgttacttct	aaagagatgg	caactcagct	cgctttatg	3840
agattgctcg	ctaactacgc	atccaaaac	atcacttatac	actgcaaaaa	ttccattgca	3900
tatatggatg	aggagacagg	aaatttgaag	aaagcagtta	ttctccaagg	tagtaacgat	3960
gttgagctt	tggctgaggg	aaatagtaga	ttcacttaca	cagttttgg	ggatggatgc	4020
tcaaagaaaa	ctaatgagt	gggcaagaca	atcattgagt	acaagacaaa	taagccttct	4080
aggctccat	ttctcgat	tgcaccttt	gatatcgag	gagctgatca	cgagttttt	4140
gttgatatcg	gacctgttt	ttttaag				4167

<210> 11
 <211> 1633
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic sequence containing the coding regions of the vascular
 signal sequence of barley gene for Thiol protease aleurain
 precursor fused to the human Prolyl 4-hydroxylase beta subunit
 and flanking regions

<400> 11	ctcgagtaaa	ccatggctca	tgcttagggtt	ttgctttgg	ctcttgctgt	tcttgctact	60
	gctgctgttg	ctgtggcttc	ttcttcatct	ttcgctgatt	ctaaccat	taggcccagt	120

PCTIL2018050627-seql-000001-EN.txt

actgatagag	ctgcttctac	tcttgctcaa	ttgggtcgaca	tggatgctcc	agaagaggag	180
gatcacgttc	ttgtgcttag	gaagtctaac	ttcgctgaag	ctcttgctgc	tcacaagtac	240
cttcttgtgg	agttttatgc	tccttggtgc	ggacattgca	aagctttgc	tccagagtat	300
gctaaggctg	ctggaaagtt	gaaggctgag	ggatctgaaa	ttaggcttc	taaagtggat	360
gctactgagg	agtctgatct	tgctcaacag	tacggagtt	ggggatacc	aactattaag	420
ttcttcagga	acggagatac	tgcttctcca	aaggagtata	ctgctggaag	ggaggctgat	480
gatattgtga	actggcttaa	gaagagaact	ggaccagctg	ctactactct	tccagatgga	540
gctgctgctg	aatctcttgt	ggagtcatct	gaggtggcag	tgattggatt	cttcaaggat	600
gtggagtctg	attctgctaa	gcagttcctt	caagctgctg	aggctattga	tgatattcca	660
ttcggaaatta	cttctaactc	tgatgtgttc	tctaagtacc	agcttgataa	ggatggagtg	720
tgcttttca	agaaattcga	tgagggagg	aacaatttcg	agggagaggt	gacaaaggag	780
aacttcttg	atttcataa	gcacaaccag	cttccacttg	tgattgagtt	cactgagcag	840
actgctccaa	agattttcgg	aggagagatt	aagactcaca	ttcttctttt	cttccaaag	900
tctgtgtctg	attacgatgg	aaagttgtct	aactcaaga	ctgctgctga	gtctttcaag	960
ggaaagattc	ttttcatttt	cattgattct	gatcacactg	ataaccagag	gattcttgag	1020
ttcttcggac	ttaagaagga	agagtgc	gctgttaggc	ttattactct	tgaggaggag	1080
atgactaagt	acaagccaga	gtctgaagaa	cttactgctg	agaggattac	tgagttctgc	1140
cacagattcc	ttgagggaaa	gattaagcca	cacttatgt	ctcaagagct	tccagaggat	1200
tgggataagc	agccagttaa	ggtgtggtg	ggtaaaaact	tcgaggatgt	ggcttcgat	1260
gagaagaaga	acgtgtcgt	ggagttctac	gcaccttgg	gtggtcactg	taagcagctt	1320
gctccaattt	gggataagtt	gggagagact	tacaaggatc	acgagaacat	tgtgattgct	1380
aagatggatt	ctactgctaa	cgaggtggag	gctgttaagg	ttcactcttt	cccaactttg	1440
aagttcttcc	cagcttctgc	tgataggact	gtgattgatt	acaacggaga	aaggactctt	1500
gatggattca	agaagttcct	tgagtctgga	ggacaagatg	gagctggaga	tgatgtatgt	1560
cttggaggatt	tggaagaagc	tgaggagcca	gatatggagg	aggatgtga	tcagaaggct	1620
gtgtgatgag	ctc					1633

<210> 12
 <211> 1723
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Synthetic sequence containing the coding regions of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Prolyl 4-hydroxylase alpha-1 subunit and flanking regions

 <400> 12

ctcgagtaaa	ccatggctca	tgcttagggtt	ttgctttgg	ctcttgctgt	tcttgctact	60
gctgctgttg	ctgtggcttc	ttcttcatct	ttcgctgatt	ctaaccatat	taggcccagg	120
actgatagag	ctgcttctac	tcttgctcaa	ttgggtcgaca	tgcacccagg	attcttcact	180
tctattggac	agatgactga	tcttattcac	actgagaagg	atcttgcgtac	ttctcttaag	240
gattacatta	aggctgagga	ggataagttt	gagcagatata	agaagtgggc	tgagaagttt	300
gataggctta	cttctactgc	tacaaaagat	ccagagggat	tcgttggtca	tccagtgaac	360
gctttcaagt	tgtatgaagag	gcttaacact	gagtggagtg	agcttgagaa	ccttgcgttt	420
aaggatatgt	ctgatggatt	catttctaac	cttactattc	agaggcagta	cttccaaat	480
gatgaggatc	aagtgggagc	tgctaaggct	cttcttaggc	ttcaggatata	ttacaacctt	540
gatactgata	caatttctaa	ggaaacctt	ccaggatata	agcacaagtc	tttccttact	600
gctgaggatt	gcttcgagct	tggaaagggtt	gcatacactg	aggctgatta	ctaccacact	660
gagctttgga	tggaacaagc	tcttaggcaa	cttgatgagg	gagagatttc	tactattgtat	720
aagggttcag	tgcttgatta	ccttcttac	gctgtgtacc	agcagggtga	tcttgataag	780
gctctttgc	ttactaagaa	gttgcttgag	cttgatccag	aacatcagag	ggctaacggaa	840
aaccttaagt	acttcgagta	cattatggct	aaggaaaagg	atgtgaacaa	gtctgcttct	900
gatgatcagt	ctgatcaaaa	gactactcca	aagaagaagg	gagtggctgt	tgattatctt	960
cctgagagggc	agaagtatga	gatgtgtgt	agggggagagg	gtattaagat	gactccaagg	1020
aggcagaaga	agttgttctg	caggtatcac	gatggaaaca	ggaacccaaa	gttcattctt	1080
gctccagcta	agcaagaaga	tgagtggat	aagccaagga	ttattaggtt	ccacgatatt	1140
atttctgatg	ctgagattga	gattgtgaag	gatcttgcta	agccaagact	taggaggct	1200

PCTIL2018050627-seql-000001-EN.txt

actatttcta accctattac tggtgatctt gagactgtgc actacaggat ttctaagtct	1260
gcttggcttt ctggatacga gaaccaggat gtgtcttagga ttaacatgag gattcaggat	1320
cttactggac ttgatgtgtc tactgctgag gagcttcaag ttgctaacta cggagttgga	1380
ggacaatatg agccacactt cgatttcgct aggaaggatg agccagatgc ttttaaggag	1440
cttggaaactg gaaacaggat tgctacttgg cttttctaca tgtctgatgt ttctgctgga	1500
ggagctactg ttttcccaga agtgggagct tctgtttggc caaagaaggg aactgctgtg	1560
ttctggtaca acctttcgc ttctggagag ggagattact ctactaggca tgctgcttgc	1620
ccagttcttg ttggaaacaa gtgggtgtca aacaagtggc ttcatgagag gggacaagag	1680
tttagaaggc catgcactct ttctgagctt gagtgatgag ctc	1723

<210> 13
<211> 2888
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence containing the coding regions of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Lysyl hydroxylase 3 and flanking regions

gCGAATTCGC tagtatcac tgaaaagaca gcaagacaat ggtgtctcgA tgcaccagaa	60
ccacatcttt gcagcagatg tgaagcagcc agagtggtcc acaagacgca ctcagaaaag	120
gcATCTTCTA ccgacacaga aaaagacaac cacagctcat catccaacat gtagactgtc	180
gttatgcgtc ggctgaagat aagactgacc ccaggccagc actaaagaag aaataatgca	240
agtggccta gctccacttt agcttaata attatgtttc attattattc tctgctttg	300
ctctctatat aaagagctt tattttcatt tgaaggcaga ggcgaacaca cacacagaac	360
ctccctgctt acaaaccaga tcttaaacca tggctcacgc tagggtttg cttctgctc	420
ttgctgttct tgctactgct gctgttgctg tggcttcttc aagtttttc gctgattcta	480
acccaattag gccagtgact gatagagctg cttctactct tgctcaattg agatctatgt	540
ctgatagacc aaggggaagg gatccagttt atccagagaa gttgcttgg attactgtgg	600

PCTIL2018050627-seql-000001-EN.txt

ctactgctga gactgaagga taccttagat tccttaggag tgctgagttc ttcaactaca	660
ctgtgaggac tcttggactt ggagaagaat ggaggggagg agatgttgc agaactgttgc	720
gaggaggaca gaaagtgaga tggcttaaga aagagatgga gaagtacgct gatagggagg	780
atatgattat tatgttcgtg gattcttacg atgtgattct tgctggatct ccaactgagc	840
ttttgaagaa attcggttcag tctggatcta ggcttcttt ctctgctgag tcttttgc	900
ggccagaatg gggacttgct gagcaatatac cagaagtggg aactggaaag agattccta	960
actctggagg attcatttgc ttgcgtacta ctattcacca gattgtgagg cagtggaaat	1020
acaaggatga cgatgtatc cagctttct acactaggct ttaccttgc ccaggactta	1080
gggagaagtt gtctcttaac cttgatcaca agtctaggat tttccagaac cttaacggtg	1140
ctcttgcgtt ggttgcgtt aagttcgata ggaacagagt gaggattagg aacgtggctt	1200
acgatactct tcctattgtg gtgcgttgc acggaccaac aaaactccag cttaactacc	1260
ttggaaacta cgttccaaac ggatggactc cagaaggagg atgtggattc tgcaatcagg	1320
ataggagaac tcttccagga ggacaaccac caccaagagt tttccttgc gtgttgcgtt	1380
aacagccaaac tccattcctt ccaagattcc ttcaaggct tcttctttt gattaccac	1440
cagatagggt gacactttc cttcacaaca acgaggttt ccacgagcca cacattgctg	1500
attcttggcc acagtttcag gatcatttct ctgctgttgc gttgggttgtt ccagaagaag	1560
ctcttctcc aggagaagct agggatatgg ctatggattt gtgcaggcag gatccagagt	1620
gcgagttcta cttctctttt gatgctgttgc ctgtgttgc taaccttgc actcttagga	1680
ttcttattga ggagaacagg aaagtgttgc ctccaaatgct ttctaggcgc ggaaagttgt	1740
ggcttaattt ctgggggtgt cttctcttgc atgagttacta cgcttagatca gaggactacg	1800
tggagcttgt tcagagaaag agagtgggag tttggaaacgt tccttatatt tctcaggctt	1860
acgtgatttgc gggagatact cttaggatgg agcttccaca gagggatgtt ttctctggat	1920
ctgatactga tccagatatg gctttcttgc agtcttcag ggataaggaa attttccttc	1980
acctttctaa ccagcatgag ttggaaagat tgcttgcgttac ttcaagatac gataactgagc	2040
accttcatcc tcatctttgg cagatttcg ataaccaggat ggatttggaaag gagcgttaca	2100
ttcacgagaa ctactcttgc gctcttgcgtt gagaaggaaat tttggagcaaa ccatgcccag	2160

PCTIL2018050627-seql-000001-EN.txt

atgtttactg gttcccactt ctttctgagc aaatgtgcga tgagcttgg	2220
agcattacgg acaatggagt ggaggttagac atgaggattc taggcttgct ggaggatacg	2280
agaacgttcc aactgtggat attcacatga agcaagtggg atacgaggat caatggcttc	2340
agcttcttag gacttatgtg ggaccaatga ctgagtcctt tttcccagga taccacacta	2400
aggctagggc tgttatgaac ttcgttgtga ggtatcgtcc agatgagcaa ccatctctta	2460
ggccacacca cgattcttct actttcactc ttaacgtggc tcttaaccac aaggacttg	2520
attatgaggg aggaggatgc cgtttcctta gatacgattt cgtgatttct tcaccaagaa	2580
aggatgggc tcttcttcat ccaggaaggc ttactcatta ccacgaggga cttccaacta	2640
cttggggAAC tagatatatt atggtgtctt tcgtggatcc atgactgctt taatgagata	2700
tgcgagacgc ctatgatcgc atgatattt cttcaattt tgggtgcac gttgtaaaaa	2760
acctgagcat gtgttagctca gatccttacc gcccgtttcg gttcattcta atgaatataat	2820
cacccgttac tattgttattt ttatgaataa tattctccgt tcaatttact gattgtccag	2880
aattcgcg	2888

<210> 14

<211> 45

<212> PRT

<213> Artificial Sequence

<220>

<223> Vacuolar targeting sequence of the thiol protease aleurain precursor (NCBI accession P05167 GI:113603)

<400> 14

Met Ala His Ala Arg Val Leu Leu Leu Ala Leu Ala Val Leu Ala Thr			
1	5	10	15

Ala Ala Val Ala Val Ala Ser Ser Ser Ser Phe Ala Asp Ser Asn Pro		
20	25	30

Ile Arg Pro Val Thr Asp Arg Ala Ala Ser Thr Leu Ala		
35	40	45

<210> 15

<211> 1469

PCTIL2018050627-seql-000001-EN.txt

<212> PRT

<213> Homo sapiens

<400> 15

Met Ala His Ala Arg Val Leu Leu Leu Ala Leu Ala Val Leu Ala Thr
1 5 10 15

Ala Ala Val Ala Val Ala Ser Ser Ser Ser Phe Ala Asp Ser Asn Pro
20 25 30

Ile Arg Pro Val Thr Asp Arg Ala Ala Ser Thr Leu Ala Gln Leu Gln
35 40 45

Glu Glu Gly Gln Val Glu Gly Gln Asp Glu Asp Ile Pro Pro Ile Thr
50 55 60

Cys Val Gln Asn Gly Leu Arg Tyr His Asp Arg Asp Val Trp Lys Pro
65 70 75 80

Glu Pro Cys Arg Ile Cys Val Cys Asp Asn Gly Lys Val Leu Cys Asp
85 90 95

Asp Val Ile Cys Asp Glu Thr Lys Asn Cys Pro Gly Ala Glu Val Pro
100 105 110

Glu Gly Glu Cys Cys Pro Val Cys Pro Asp Gly Ser Glu Ser Pro Thr
115 120 125

Asp Gln Glu Thr Thr Gly Val Glu Gly Pro Lys Gly Asp Thr Gly Pro
130 135 140

Arg Gly Pro Arg Gly Pro Ala Gly Pro Pro Gly Arg Asp Gly Ile Pro
145 150 155 160

Gly Gln Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
165 170 175

Pro Pro Gly Leu Gly Gly Asn Phe Ala Pro Gln Leu Ser Tyr Gly Tyr
180 185 190

PCTIL2018050627-seql-000001-EN.txt

Asp Glu Lys Ser Thr Gly Gly Ile Ser Val Pro Gly Pro Met Gly Pro
195 200 205

Ser Gly Pro Arg Gly Leu Pro Gly Pro Pro Gly Ala Pro Gly Pro Gln
210 215 220

Gly Phe Gln Gly Pro Pro Gly Glu Pro Gly Glu Pro Gly Ala Ser Gly
225 230 235 240

Pro Met Gly Pro Arg Gly Pro Pro Gly Pro Pro Gly Lys Asn Gly Asp
245 250 255

Asp Gly Glu Ala Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Pro Pro
260 265 270

Gly Pro Gln Gly Ala Arg Gly Leu Pro Gly Thr Ala Gly Leu Pro Gly
275 280 285

Met Lys Gly His Arg Gly Phe Ser Gly Leu Asp Gly Ala Lys Gly Asp
290 295 300

Ala Gly Pro Ala Gly Pro Lys Gly Glu Pro Gly Ser Pro Gly Glu Asn
305 310 315 320

Gly Ala Pro Gly Gln Met Gly Pro Arg Gly Leu Pro Gly Glu Arg Gly
325 330 335

Arg Pro Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Asn Asp Gly Ala
340 345 350

Thr Gly Ala Ala Gly Pro Pro Gly Pro Thr Gly Pro Ala Gly Pro Pro
355 360 365

Gly Phe Pro Gly Ala Val Gly Ala Lys Gly Glu Ala Gly Pro Gln Gly
370 375 380

Pro Arg Gly Ser Glu Gly Pro Gln Gly Val Arg Gly Glu Pro Gly Pro
385 390 395 400

PCTIL2018050627-seql-000001-EN.txt

Pro Gly Pro Ala Gly Ala Ala Gly Pro Ala Gly Asn Pro Gly Ala Asp
405 410 415

Gly Gln Pro Gly Ala Lys Gly Ala Asn Gly Ala Pro Gly Ile Ala Gly
420 425 430

Ala Pro Gly Phe Pro Gly Ala Arg Gly Pro Ser Gly Pro Gln Gly Pro
435 440 445

Gly Gly Pro Pro Gly Pro Lys Gly Asn Ser Gly Glu Pro Gly Ala Pro
450 455 460

Gly Ser Lys Gly Asp Thr Gly Ala Lys Gly Glu Pro Gly Pro Val Gly
465 470 475 480

Val Gln Gly Pro Pro Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala
485 490 495

Arg Gly Glu Pro Gly Pro Thr Gly Leu Pro Gly Pro Pro Gly Glu Arg
500 505 510

Gly Gly Pro Gly Ser Arg Gly Phe Pro Gly Ala Asp Gly Val Ala Gly
515 520 525

Pro Lys Gly Pro Ala Gly Glu Arg Gly Ser Pro Gly Pro Ala Gly Pro
530 535 540

Lys Gly Ser Pro Gly Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro
545 550 555 560

Gly Ala Lys Gly Leu Thr Gly Ser Pro Gly Ser Pro Gly Pro Asp Gly
565 570 575

Lys Thr Gly Pro Pro Gly Pro Ala Gly Gln Asp Gly Arg Pro Gly Pro
580 585 590

Pro Gly Pro Pro Gly Ala Arg Gly Gln Ala Gly Val Met Gly Phe Pro
595 600 605

PCTIL2018050627-seql-000001-EN.txt

Gly Pro Lys Gly Ala Ala Gly Glu Pro Gly Lys Ala Gly Glu Arg Gly
610 615 620

Val Pro Gly Pro Pro Gly Ala Val Gly Pro Ala Gly Lys Asp Gly Glu
625 630 635 640

Ala Gly Ala Gln Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly Glu Arg
645 650 655

Gly Glu Gln Gly Pro Ala Gly Ser Pro Gly Phe Gln Gly Leu Pro Gly
660 665 670

Pro Ala Gly Pro Pro Gly Glu Ala Gly Lys Pro Gly Glu Gln Gly Val
675 680 685

Pro Gly Asp Leu Gly Ala Pro Gly Pro Ser Gly Ala Arg Gly Glu Arg
690 695 700

Gly Phe Pro Gly Glu Arg Gly Val Gln Gly Pro Pro Gly Pro Ala Gly
705 710 715 720

Pro Arg Gly Ala Asn Gly Ala Pro Gly Asn Asp Gly Ala Lys Gly Asp
725 730 735

Ala Gly Ala Pro Gly Ala Pro Gly Ser Gln Gly Ala Pro Gly Leu Gln
740 745 750

Gly Met Pro Gly Glu Arg Gly Ala Ala Gly Leu Pro Gly Pro Lys Gly
755 760 765

Asp Arg Gly Asp Ala Gly Pro Lys Gly Ala Asp Gly Ser Pro Gly Lys
770 775 780

Asp Gly Val Arg Gly Leu Thr Gly Pro Ile Gly Pro Pro Gly Pro Ala
785 790 795 800

Gly Ala Pro Gly Asp Lys Gly Glu Ser Gly Pro Ser Gly Pro Ala Gly
805 810 815

PCTIL2018050627-seql-000001-EN.txt

Pro Thr Gly Ala Arg Gly Ala Pro Gly Asp Arg Gly Glu Pro Gly Pro
820 825 830

Pro Gly Pro Ala Gly Phe Ala Gly Pro Pro Gly Ala Asp Gly Gln Pro
835 840 845

Gly Ala Lys Gly Glu Pro Gly Asp Ala Gly Ala Lys Gly Asp Ala Gly
850 855 860

Pro Pro Gly Pro Ala Gly Pro Ala Gly Pro Pro Gly Pro Ile Gly Asn
865 870 875 880

Val Gly Ala Pro Gly Ala Lys Gly Ala Arg Gly Ser Ala Gly Pro Pro
885 890 895

Gly Ala Thr Gly Phe Pro Gly Ala Ala Gly Arg Val Gly Pro Pro Gly
900 905 910

Pro Ser Gly Asn Ala Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys
915 920 925

Glu Gly Gly Lys Gly Pro Arg Gly Glu Thr Gly Pro Ala Gly Arg Pro
930 935 940

Gly Glu Val Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Glu Lys Gly
945 950 955 960

Gly Gln Arg Gly Val Val Gly Leu Pro Gly Gln Arg Gly Glu Arg Gly
965 970 975

Phe Pro Gly Leu Pro Gly Pro Ser Gly Glu Pro Gly Lys Gln Gly Pro
980 985 990

Ser Gly Ala Ser Gly Glu Arg Gly Pro Pro Gly Pro Met Gly Pro Pro
995 1000 1005

Gly Leu Ala Gly Pro Pro Gly Glu Ser Gly Arg Glu Gly Ala Pro
1010 1015 1020

PCTIL2018050627-seql-000001-EN.txt

Gly Ala Glu Gly Ser Pro Gly Arg Asp Gly Ser Pro Gly Ala Lys
1025 1030 1035

Gly Asp Arg Gly Glu Thr Gly Pro Ala Gly Pro Pro Gly Ala Pro
1040 1045 1050

Gly Ala Pro Gly Ala Pro Gly Pro Val Gly Pro Ala Gly Lys Ser
1055 1060 1065

Gly Asp Arg Gly Glu Thr Gly Pro Ala Gly Pro Ala Gly Pro Val
1070 1075 1080

Gly Pro Ala Gly Ala Arg Gly Pro Ala Gly Pro Gln Gly Pro Arg
1085 1090 1095

Gly Asp Lys Gly Glu Thr Gly Glu Gln Gly Asp Arg Gly Ile Lys
1100 1105 1110

Gly His Arg Gly Phe Ser Gly Leu Gln Gly Pro Pro Gly Pro Pro
1115 1120 1125

Gly Ser Pro Gly Glu Gln Gly Pro Ser Gly Ala Ser Gly Pro Ala
1130 1135 1140

Gly Pro Arg Gly Pro Pro Gly Ser Ala Gly Ala Pro Gly Lys Asp
1145 1150 1155

Gly Leu Asn Gly Leu Pro Gly Pro Ile Gly Pro Pro Gly Pro Arg
1160 1165 1170

Gly Arg Thr Gly Asp Ala Gly Pro Val Gly Pro Pro Gly Pro Pro
1175 1180 1185

Gly Pro Pro Gly Pro Pro Gly Pro Pro Ser Ala Gly Phe Asp Phe
1190 1195 1200

Ser Phe Leu Pro Gln Pro Pro Gln Glu Lys Ala His Asp Gly Gly
1205 1210 1215

PCTIL2018050627-seql-000001-EN.txt

Arg Tyr Tyr Arg Ala Asp Asp Ala Asn Val Val Arg Asp Arg Asp
1220 1225 1230

Leu Glu Val Asp Thr Thr Leu Lys Ser Leu Ser Gln Gln Ile Glu
1235 1240 1245

Asn Ile Arg Ser Pro Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr
1250 1255 1260

Cys Arg Asp Leu Lys Met Cys His Ser Asp Trp Lys Ser Gly Glu
1265 1270 1275

Tyr Trp Ile Asp Pro Asn Gln Gly Cys Asn Leu Asp Ala Ile Lys
1280 1285 1290

Val Phe Cys Asn Met Glu Thr Gly Glu Thr Cys Val Tyr Pro Thr
1295 1300 1305

Gln Pro Ser Val Ala Gln Lys Asn Trp Tyr Ile Ser Lys Asn Pro
1310 1315 1320

Lys Asp Lys Arg His Val Trp Phe Gly Glu Ser Met Thr Asp Gly
1325 1330 1335

Phe Gln Phe Glu Tyr Gly Gly Gln Gly Ser Asp Pro Ala Asp Val
1340 1345 1350

Ala Ile Gln Leu Thr Phe Leu Arg Leu Met Ser Thr Glu Ala Ser
1355 1360 1365

Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Val Ala Tyr Met Asp
1370 1375 1380

Gln Gln Thr Gly Asn Leu Lys Lys Ala Leu Leu Leu Lys Gly Ser
1385 1390 1395

Asn Glu Ile Glu Ile Arg Ala Glu Gly Asn Ser Arg Phe Thr Tyr
1400 1405 1410

PCTIL2018050627-seql-000001-EN.txt

Ser Val Thr Val Asp Gly Cys Thr Ser His Thr Gly Ala Trp Gly
1415 1420 1425

Lys Thr Val Ile Glu Tyr Lys Thr Thr Lys Thr Ser Arg Leu Pro
1430 1435 1440

Ile Ile Asp Val Ala Pro Leu Asp Val Gly Ala Pro Asp Gln Glu
1445 1450 1455

Phe Gly Phe Asp Val Gly Pro Val Cys Phe Leu
1460 1465

<210> 16
<211> 4416
<212> DNA
<213> Homo sapiens

<400> 16
atggctcacg ctcgtttct cctcctcgct ctcgctgttt tggcaacagc tgctgtggct 60
gtggcttcta gttcttcttt tgctgattca aaccctatttta gacctgttac tgatagagca 120
gcttccactt tggctcaattt gcaagaggag ggccaggttg agggccaaga tgaggatatc 180
cctccaatttta catgcgtgca aaatggcttg cgttaccacg atagggatgt gtggaaacct 240
gaaccttgtc gtatctgtgt gtgtgataac ggcaaggtgc tctgcgtatga ttttatctgc 300
gatgagacaa aaaattgccc tggcgctgaa gttcctgagg gcgagtgttg ccctgtgtgc 360
cctgatggtt ccgagtccttcc aactgatcag gaaactactg gcgtggaggg cccaaaagga 420
gatactggtc cacgtggtcc taggggtcca gcaggtcctc caggttagaga tggatttcca 480
ggccagcctg gattgccagg accaccaggc ccacctggcc caccaggacc tcctggtctt 540
ggtgaaatt tcgctccaca actcttttat ggctatgtatg agaagtcaac aggtggattt 600
tccgttccag gtcctatggg accatccgga ccaagaggc tcccaagggtcc tccagggtct 660
cctggacctc aaggcttca aggacctcca ggcgaaccag gagaaccagg cgcttctgg 720
ccaatgggcc caaggggacc acctggccca ccagaaaaaa atggcgatga tggcgaagct 780
ggaaaggctg gtcgtcctgg agagagaggt ctcctggcc cacagggtgc aagaggctt 840
ccaggaactg ctggcttgcc tggaaatgaag ggacataggg gcttctccgg ctcgtatggc 900

PCTIL2018050627-seql-000001-EN.txt

gctaagggtg atgctggccc tgctggacca aagggcgagc caggttcccc tggagaaaac	960
ggtgctcctg gacaaatggg tcctcgtgga cttccaggag aaaggggtcg tccaggcgct	1020
ccaggaccag caggtgctag gggaaacgat ggtgcaacag gcgctgctgg ccctcctggc	1080
ccaactggtc ctgctggccc tccaggattc ccaggcgcag ttggagctaa aggagaagca	1140
ggaccacagg gcccttagggg ttctgaagga cctcagggtg ttagaggtga accaggtcct	1200
ccaggcccag ctggagcagc tggccagca ggaaatccag gtgctgatgg tcaacctgga	1260
gctaaggcg ctaatggcg accaggtatc gcaggcgcac caggtttcc tggcgctaga	1320
ggcccaagtg gtcctcaagg accaggtgga ccaccaggtc caaaaggcaa ttctggcgaa	1380
cctggcgctc caggttctaa aggagatact ggtgctaaag gcgaaccagg acctgttggt	1440
gttcagggtc ctcctggtcc tgctggagaa gaaggaaaaa gaggtgctcg tggagaacca	1500
ggaccaactg gacttcctgg acctcctggt gaacgtggcg gacctggctc aagggtttc	1560
cctggagctg atggagtggc aggtccaaaa ggccctgctg gagagagagg ttcaccaggt	1620
ccagctggtc ctaagggctc ccctggtgaa gcaggtagac caggcgaagc aggattgcca	1680
ggcgcaaagg gattgacagg ctctcctggt agtcctggcc cagatggaaa aacaggccca	1740
ccaggtccag caggacaaga tggacgtcca ggcccaccag gtcctcctgg agcaagggga	1800
caagctggcg ttatgggaaa tccaggacct aaaggtgctg ctggagagcc aggaaaggca	1860
ggtgaaagag gagttcctgg tccaccagga gcagtgggtc ctgctggcaa agatggtaa	1920
gctggagcac agggccctcc agggcctgct ggcccagctg gcgaacgtgg agaacaaggc	1980
ccagctggta gtccaggatt tcaaggattt cctggccctg ctggccctcc aggagaagca	2040
ggaaaacctg gagaacaagg agttcctggt gatttggag cacctggacc ttcaggagca	2100
cgtggtaaaa gaggcttccc tggcgagagg ggtgttcaag gtccaccagg tccagcagga	2160
cctagaggtg ctaatggcg tcctggcaac gatggagcaa aaggtgatgc tggctcct	2220
ggcgcacctg gaagtcaagg tgctcctgga ttgcaaggaa tgcctggaga gaggggtgct	2280
gctggcttgc caggccaaa gggcgatagg ggtgtatgc gacaaaagg tgctgatgga	2340
tccccaggaa aagatggagt tcgtggctt actggccaa tcggacactcc aggcctgct	2400
ggcgctccag gtgataaggg cgaaagtggc ccaagtggac ctgctggacc tactgggtct	2460

PCTIL2018050627-seql-000001-EN.txt

agagggtgcac	ctgggtgatag	gggtgaacct	ggaccacctg	gtccagctgg	ttttgctggt	2520
cctcctggag	ctgatggaca	acctggcgca	aagggtgaac	caggtgatgc	tggcgcaaag	2580
ggagatgctg	gtccacctgg	acctgctggt	ccagcaggcc	cccctgggcc	aatcgtaat	2640
gttggagcac	caggtgctaa	gggagctagg	ggttccgctg	gtccacctgg	agcaacagga	2700
tttccaggcg	ctgctggtag	agttggccca	ccaggcccat	ccggaaacgc	aggccctcct	2760
ggtcctccag	gtcctgctgg	caaggagggt	ggcaaaggac	caaggggcga	aactggccct	2820
gctggtagac	ctggcgaagt	tggccctcct	ggaccaccag	gtccagcagg	agaaaaaggt	2880
ggacagagag	gcgttgtgg	actccctggt	caaaggggag	agagaggatt	tccaggcttg	2940
ccaggaccta	gtggagaacc	tggaaaacaa	ggcccatcag	gcgctagtgg	agagcgtgga	3000
cctcctggcc	ctatgggacc	tcctggattt	gctggcccac	ctggcgaatc	aggtcgtgaa	3060
ggcgcaccag	gcbcagaagg	atcacctgga	agagatggat	cccctggtgc	taaaggcgat	3120
cgtggagaaa	ctggccagc	aggcccacca	ggcgcaccag	gtgcacctgg	cgctccagga	3180
cctgtggac	cagctggaaa	atccggagat	agggcggaga	caggcccagc	aggaccagct	3240
ggacctgttg	gccctgctgg	cgctcgtgga	ccagcaggac	ctcaaggacc	aaggggagat	3300
aagggagaaa	caggcgaaca	aggcgatagg	ggcattaagg	gtcatagggg	tttttagtggc	3360
ctccagggtc	ctcctggccc	acctggatca	ccaggagaac	agggaccatc	tggtgcttcc	3420
ggcccgctg	gtccaagagg	acctccagga	tcagctggtg	cacctggaaa	agatggtctt	3480
aacggtctcc	caggaccaat	cggccctcca	ggacctagag	gaagaacagg	agatgctggc	3540
cctgttggcc	ctccaggacc	tcctggtcca	ccaggtccac	ctggcctcc	atcagctgga	3600
ttcgattttt	catttcttcc	acagccacca	caagagaaag	ctcacgatgg	cgccagatat	3660
taccgtgctg	atgatgctaa	cgttggtagg	gatagagatt	tggaagtgg	tacaactttg	3720
aaatccctct	cccagcaaat	tgaaaacatt	agatctccag	aaggttcacg	taaaaaccca	3780
gctagaacat	gtcgtgattt	gaaaatgtgt	cactccgatt	ggaaaagtgg	tgaatactgg	3840
attgatccaa	atcagggctg	taatctcgat	gctatcaaag	ttttctgtaa	catggaaaca	3900
ggcggaaacat	gcgttatcc	tactcaacct	tccgtggctc	agaaaaattt	gtacatctca	3960
aaaaatccta	aagataagag	gcacgttgg	ttcggtaaa	gtatgactga	tggatttcaa	4020

PCTIL2018050627-seql-000001-EN.txt

tttgagtacg gcggtaagg tagtgatcca gctgatgtgg ctattcaact cacattttg	4080
cgtcttatgt ccacagaggc atcacaaaac atcaattacc actgcaaaaa cagtgtggct	4140
tatatggatc aacaaacagg aaaccttaag aaggctcttc ttttgaaggg ctc当地acgag	4200
attgagatta gagcagaggg caactcaagg tttacttatt cagttactgt tgatggctgc	4260
acttcacata ctggcgcttg gggtaaaaca gttatcgagt ataagactac aaaaacatca	4320
agactcccaa tcattgatgt tgctcctctc gatgtggcg ctc当地gatca agagttcggt	4380
tttgatgtgg gcccagtttgc ttccctctaa tgagct	4416